Document:

<PAGE>

                                                                   EXHIBIT 10.22

                              AMENDED AND RESTATED
                         EXECUTIVE EMPLOYMENT AGREEMENT

         EMPLOYMENT AGREEMENT (the "Agreement") dated as of November 16, 2003,
between Travelers Property Casualty Corp., a Connecticut corporation (the
"Company"), and Robert I. Lipp (the "Executive") shall be effective upon the
closing of the transactions contemplated by that Agreement and Plan of Merger
dated November 16, 2003, by and among the Company, The St. Paul Companies, Inc.
and Travelers Acquisition Corp. (the "Merger").

                               W I T N E S S E T H

         WHEREAS, the Executive currently serves as the Chairman and Chief
Executive Officer of the Company pursuant to the terms of an employment
agreement dated as of March 7, 2002, which became effective upon the
consummation of the initial public offering of the Company (the "Initial
Agreement");

         WHEREAS, in contemplation of the Merger, the Company and the Executive
desire to amend and restate the Initial Agreement and to enter into this
Agreement as to the terms of his continued employment by the Company; and

         WHEREAS, in connection with the Merger, the ultimate parent surviving
corporation following the Merger shall assume and agree to perform this
Agreement and all references to the "Company" herein shall be deemed to refer to
such surviving entity.

         NOW THEREFORE, in consideration of the foregoing, of the mutual
promises contained herein and of other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto
hereby agree as follows:

         1.       POSITION/DUTIES.

         (a)      During the Employment Term (as defined in Section 2 below),
the Executive shall serve as an employee Executive Chairman of the Board of
Directors of the Company (the "Board"). In this capacity the Executive shall
have such duties, authorities and responsibilities required of, and commensurate
with, his status as Chairman of the Board and as provided in the Company's
by-laws. The Executive will consult with the Chief Executive Officer and the
Board on the strategic direction of the Company. The Executive shall report
solely and directly to the Board and will jointly preside with the Chief
Executive Officer at meetings of the Board.

         (b)      During the Employment Term, the Executive shall devote
substantially all of his business time (excluding periods of vacation and other
approved leaves of absence) in the performance of his duties with the Company,
provided the foregoing will not prevent the Executive from (i) participating in
charitable, civic, educational, professional, community or industry affairs or
serving on the board of directors or advisory boards of other companies;
provided, however, that the Executive shall not serve as a director on more than
three boards of directors or advisory boards of other for profit companies or
with regard to any competitive company without the prior written approval of the
Board, and (ii) managing his and his family's

<PAGE>

personal investments so long as such activities in the aggregate do not
materially interfere with his duties hereunder.

         (c)      Upon the consummation of the Merger, the Executive shall be
elected as a director of the Company with a term that extends until at least the
end of the Employment Term. During the Employment Term, the by-laws of the
Company shall provide that the Executive may only be removed from his position
as Chairman of the Board by a vote of at least two-thirds of the members of the
entire Board.

         2.       EMPLOYMENT TERM. The Executive's term of employment under this
Agreement shall be for a term commencing on the Merger Date and ending on
December 31, 2005 (the "Employment Term"), subject to earlier termination as
provided in Section 7, below.

         3.       BASE SALARY. The Company agrees to pay the Executive a base
salary (the "Base Salary") at an annual rate of not less than his current base
salary of $750,000, payable in accordance with the regular payroll practices of
the Company, but not less frequently than monthly. The Executive's Base Salary
shall be subject to annual review by the Board (or a committee thereof) and may
be increased, but not decreased, from time to time by the Board. No increase to
Base Salary shall be used to offset or otherwise reduce any obligations of the
Company to the Executive hereunder or otherwise. The base salary as determined
herein from time to time shall constitute "Base Salary" for purposes of this
Agreement.

         4.       BONUS. During the Employment Term, the Executive shall be
eligible to participate in the Company's bonus and other incentive compensation
plans and programs for the Company's senior executives at a level commensurate
with his position. The Executive shall have the opportunity to earn an annual
bonus measured against objective financial criteria to be determined by the
Board (or a committee thereof) in accordance with the Company's bonus and other
incentive compensation plans and programs under Section 162(m) of the Internal
Revenue Code of 1986, as amended (the "Code").

         5.       STOCK OPTIONS.

         (a)      ASSUMED OPTIONS. The stock option (the "Option") granted to
the Executive by Travelers Property Casualty Corp. on March 22, 2002, shall be
assumed and converted in accordance with the terms and conditions of the Merger
and shall be fully vested upon the consummation of the Merger in accordance with
the terms of the Initial Agreement. The Option shall remain exercisable until
the expiration of the stated 10-year term; provided, however, that in the event
that the Executive becomes an employee or director of any of the five companies
listed on Exhibit A hereto following any termination of employment, the Option
shall remain exercisable for a period of 30 days after the Executive commences
such employment or directorship, but in no event beyond the stated 10-year term,
and thereafter be cancelled. The agreement evidencing the Option shall be
amended to reflect the provisions of this Section 5(a).

         (b)      DISCRETIONARY GRANTS. In addition to the Option, at the sole
discretion of the Committee, the Executive shall be eligible for additional
annual grants of stock options and other equity awards. Any future equity grant
shall provide that such award shall be fully vested and immediately exercisable
in the event that (x) the Executive's employment is

                                      -2-

<PAGE>

terminated by the Company without Cause or the Executive voluntarily terminates
his employment for Good Reason or (y) the Executive dies or becomes Disabled or
a change in control (as defined in the Company's then stock incentive plan)
occurs. Upon the foregoing acceleration events, any future stock option grant
shall remain exercisable for at least two years but in no event beyond the
stated term.

         (c)      TRANSFERABILITY. The Option may be transferred, in whole or in
part, to a Family Member (as defined under the Securities Act of 1933, as
amended or Securities Act Form S-8). A Family Member who is a transferee of the
Option shall not be eligible to receive a reload stock option upon the exercise
of the Option.

         (d)      REGISTRATION. At all times during and after the Employment
Term, the Company shall maintain registrations on Form S-8 and/or another
applicable form.

         6.       EMPLOYEE BENEFITS.

         (a)      BENEFIT PLANS. The Executive shall be entitled to participate
in any employee benefit plan of the Company or its affiliates including, but not
limited to, equity, pension, thrift, profit sharing, medical coverage,
education, or other retirement or welfare benefits that the Company has adopted
or may adopt, maintain or contribute to for the benefit of its senior executives
at a level commensurate with his positions. Except as otherwise provided herein,
the Executive's prior service with Citigroup shall be recognized for eligibility
and vesting purposes under any of the Company's or its affiliates' equity
compensation and benefit plans, including, but not limited to, being classified
as a "retiree." Except as otherwise provided in this Agreement, any vesting
under the Company's or its affiliates equity compensation and benefit plans
shall be subject to and in accordance with the terms of the applicable plan or
program.

         (b)      VACATIONS. The Executive shall be entitled to an annual paid
vacation in accordance with the Company's policy applicable to senior
executives, but in no event less than four weeks per calendar year (as prorated
for partial years and accrued, but not used, with respect to prior years), which
vacation may be taken at such times as the Executive elects with due regard to
the needs of the Company.

         (c)      PERQUISITES. The Company shall provide to the Executive, at
the Company's cost, all perquisites to which other senior executives of the
Company are generally entitled to receive and such other perquisites which are
suitable to the character of the Executive's position with the Company and
adequate for the performance of his duties hereunder. To the extent legally
permissible, the Company shall not treat such amounts as income to the
Executive.

         (d)      BUSINESS AND ENTERTAINMENT EXPENSES. Upon presentation of
appropriate documentation, the Executive shall be reimbursed in accordance with
the Company's expense reimbursement policy for all reasonable and necessary
business and entertainment expenses incurred in connection with the performance
of his duties hereunder.

         (e)      OFFICE SPACE/TRAVEL.

                  (i)      During the Employment Term, the Company shall provide
         the Executive with suitable, furnished offices (and staff) in New York
         and/or Connecticut for use in

                                      -3-

<PAGE>

         connection with the business of the Company. The Executive shall also
         be provided a supplemental office in St. Paul, Minnesota.

                  (ii)     The parties recognize that, for security purposes, it
         will be necessary for the Executive to travel by private aircraft for
         business and personal purposes and shall make appropriate arrangements
         with regard thereto. The Company shall fully gross up for tax purposes
         any deemed income to the Executive arising pursuant to use of such
         aircraft for business purposes, so that the economic benefit is the
         same to the Executive as if such use was provided on a non-taxable
         basis to the Executive.

         7.       TERMINATION. The Executive's employment and the Employment
Term shall terminate on the first of the following to occur:

         (a)      DISABILITY. Upon 30 days written notice by the Company to the
Executive of termination due to Disability, while the Executive remains
Disabled, but only after the Executive has been Disabled and unable to perform
his material duties for at least six consecutive months. For purposes of this
Agreement, "Disability" or "Disabled" shall be determined in accordance with the
terms and procedures of the Company's applicable Long Term Disability Plan,
except with respect to any termination of employment provision contained
therein.

         (b)      DEATH. Automatically on the date of death of the Executive.

         (c)      CAUSE. Immediately upon written notice by the Company to the
Executive of a termination for Cause, provided that such notice is given within
90 days after the discovery of the Cause event by the Chairman of the Audit
Committee of the Board or Chairman of the Compensation and Governance Committee
of the Board. "Cause" shall mean (i) the willful misconduct of the Executive
with regard to the Company that is materially injurious to the Company,
provided, however, that no act or failure to act on the Executive's part shall
be considered "willful" unless done, or omitted to be done, by the Executive not
in good faith and without reasonable belief that his action or omission was in
the best interests of the Company; (ii) the willful and continued failure of the
Executive to attempt to substantially perform the Executive's duties with the
Company (other than any such failure resulting from incapacity due to physical
or mental illness) which failure is not remedied within 15 business days of
written notice from the Company specifying the details thereof; or (iii) the
conviction of the Executive of (or the pleading by the Executive of nolo
contendere to) any felony (other than traffic related offenses or as a result of
vicarious liability).

         Notwithstanding the foregoing, the Executive shall not be deemed to
have been terminated for Cause without (i) advance written notice provided to
the Executive not less than 14 days prior to the date of termination setting
forth the Company's intention to consider terminating the Executive, including a
statement of the date of termination and the specific detailed basis for such
consideration for Cause; (ii) an opportunity of the Executive, together with his
counsel, to be heard before the Board during the 14 day period ending on the
date of termination; (iii) a duly adopted resolution of the Board, after such
opportunity, stating that in accordance with the provisions of the next to the
last sentence of this Section 7(c), that the actions of the Executive
constituted Cause and the basis thereof; and (iv) a written determination
provided by the Board setting forth the acts and omissions that form the basis
of such termination

                                      -4-

<PAGE>

of employment. Any determination by the Board hereunder shall be made by the
affirmative vote of at least a two-thirds majority of the members of the Board
(other than the Executive). Any purported termination of employment of the
Executive by the Company which does not meet each and every substantive and
procedural requirement of this Section 7 shall be treated for all purposes under
this Agreement as a termination of employment without Cause.

         (d)      WITHOUT CAUSE. Upon written notice by the Company to the
Executive of an involuntary termination without Cause, other than for death or
Disability.

         (e)      GOOD REASON. Upon written notice by the Executive to the
Company of a termination for Good Reason. "Good Reason" shall mean, without the
express written consent of the Executive, the occurrence of any of the following
events unless such events are fully corrected in all material respects by the
Company within 30 days following written notification by the Executive to the
Company that he intends to terminate his employment hereunder for one of the
reasons set forth below:

                  (i)      any reduction or diminution (except temporarily
         during any period of Disability) in the Executive's then titles or
         positions, or a material reduction or diminution in the Executive's
         then authorities, duties or responsibilities or reporting requirements
         with the Company, including but not limited to a failure to elect the
         Executive to the Board or removal of the Executive from the Board; or

                  (ii)     a material breach by the Company of any provisions of
         this Agreement, including, but not limited to, any reduction in any
         part of the Executive's then compensation (including Base Salary) or
         benefits or any failure to timely pay any part of Executive's
         compensation (including Base Salary and bonus, if any) or to provide
         the benefits contemplated herein; or

                  (iii)    the failure of the Company to obtain and deliver to
         the Executive a satisfactory written agreement from any successor to
         the Company or pursuant to Section 24(b) hereof to assume and agree to
         perform this Agreement; or

                  (iv)     any termination by the Executive during the 30-day
         period immediately following the six-month anniversary of any change in
         control (as defined in the Company's then stock incentive plan) that
         occurs after the Merger Date.

         (f)      WITHOUT GOOD REASON. Upon written notice by the Executive to
the Company of the Executive's voluntary termination of employment without Good
Reason (which the Company may, in its sole discretion, make effective earlier
than any notice date).

         8.       CONSEQUENCES OF TERMINATION.

         (a)      DISABILITY. Upon such termination, the Company shall pay or
provide the Executive (i) any unpaid Base Salary through the date of termination
and any accrued vacation; (ii) any unpaid bonus as declared or, if not then
declared, as determined by the Board in good faith, with respect to the
performance year ending preceding the date of termination; (iii) reimbursement
for any unreimbursed expenses incurred through the date of termination; (iv) a
pro-rata portion of the Executive's bonus for the performance year in which the
Executive's

                                      -5-

<PAGE>

termination occurs (determined by multiplying the amount the Executive would
have received had employment continued through the end of the performance year,
as determined by the Board in good faith, by a fraction, the numerator of which
is the number of days during the performance year of termination that the
Executive is employed by the Company and the denominator of which is 365); and
(v) all other payments, benefits or fringe benefits to which the Executive may
be entitled under the terms of any applicable compensation arrangement or
benefit, equity or fringe benefit plan or program or grant or this Agreement
(collectively, "Accrued Benefits"). If the Executive's employment should be
terminated pursuant to Section 7(a), the numerator in the calculation of the
pro-rata portion of the Executive's bonus under Section 8(a)(iv) shall exclude
any period during which the Executive is classified by the Company as an
inactive employee.

         (b)      DEATH. In the event the Employment Term ends on account of the
Executive's death, the Executive's estate shall be entitled to any Accrued
Benefits.

         (c)      TERMINATION FOR CAUSE OR WITHOUT GOOD REASON, ETC. If the
Executive's employment should be terminated (v) by the Company for Cause, or (w)
by the Executive without Good Reason, or (x) upon expiration of the Employment
Term on December 31, 2005, or (y) upon Executive's retirement, the Company shall
pay to the Executive any Accrued Benefits (other than those described in
Sections 8(a)(ii) and (iv) if the Executive's employment is terminated by the
Company for Cause).

         (d)      TERMINATION WITHOUT CAUSE OR FOR GOOD REASON. If the
Executive's employment by the Company is terminated prior to December 31, 2005
(x) by the Company other than for Cause or (y) by the Executive for Good Reason,
then the Company shall pay or provide the Executive with (i) Accrued Benefits;
and (ii) shall pay to the Executive a lump sum in cash within 30 days of the
date of termination in an amount equal to the product of (A) the sum of (1) the
Base Salary in effect immediately prior to termination and (2) the highest
annual bonus paid or payable to the Executive for the three performance years
prior to the date of termination (or such lesser number of performance years as
shall actually have been completed prior to the date of termination) multiplied
by (B) three. For purposes of the foregoing, no bonus paid or payable with
respect to performance years beginning before January 1, 2002 shall be taken
into account for purposes of determining the lump sum payment payable pursuant
to this Section 8(d).

         (e)      Any termination payments made and benefits provided under this
Agreement to the Executive shall be in lieu of any termination or severance
payments or benefits for which the Executive may be eligible under any of the
plans, policies or programs of the Company or its affiliates.

                                      -6-

<PAGE>

         9.       RELEASE. Any and all payments made and benefits provided under
this Agreement to the Executive upon termination of employment including but not
limited to, those referenced in paragraph 8 shall be contingent upon the full
execution of a general release of all claims by the Executive against the
Company and its affiliates in a form substantially in the form of Exhibit B
hereto and mutually agreed upon by the Executive and the Company. Accrued
Benefits other than those described in Sections 8(a)(ii) and (iv) shall not be
contingent on the execution of such release.

         10.      EXCISE TAX. In the event that the Executive becomes or has
already become entitled to payments and/or benefits which would constitute
"parachute payments" within the meaning of Section 280G(b)(2) of the Code
(including without limitation as a result of this Agreement, the Initial
Agreement or any other plan, arrangement or agreement with the Company or any
affiliate (including Travelers Property Casualty Corp.), or payments and/or
benefits from any person whose actions result in a change of ownership or
effective control of the Company or Travelers Property Casualty Corp. covered by
Section 280G(b)(2) of the Code or any person affiliated with the Company or
Travelers Property Casualty Corp. or such person), the provisions of Exhibit C
shall apply. For purposes of Exhibit C, the term "Change in Control" shall mean
a change of ownership or effective control (as such terms are used in Section
280G and the regulations thereunder) heretofore or hereafter of the Company or
Travelers Property Casualty Corp.

         11.      NO ASSIGNMENTS.

         (a)      This Agreement is personal to each of the parties hereto.
Except as provided in Section 11(b) below, no party may assign or delegate any
rights or obligations hereunder without first obtaining the written consent of
the other party hereto.

         (b)      The Company shall require any successor (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or
substantially all of the business and/or assets of the Company to expressly
assume and agree to perform this Agreement in the same manner and to the same
extent that the Company would be required to perform it if no such succession
had taken place. As used in this Agreement, "Company" shall mean the Company and
any successor to its business and/or assets, which assumes and agrees to perform
this Agreement by operation of law, or otherwise.

         (c)      This Agreement shall inure to the benefit of and be
enforceable by the Executive and his personal or legal representatives,
executors, administrators, successors, heirs, distributees, devisees and
legatees. If the Executive should die while any amount would still be payable to
him hereunder had he continued to live, all such amounts, unless otherwise
provided herein, shall be paid in accordance with the terms of this Agreement to
his devisee, legatee or other designee or, if there is no such designee, to his
estate.

         12.      NOTICE. For the purpose of this Agreement, notices and all
other communications provided for in this Agreement shall be in writing and
shall be deemed to have been duly given (i) on the date of delivery if delivered
by hand, (ii) on the date of transmission, if delivered by confirmed facsimile,
(iii) on the first business day following the date of deposit if delivered by
guaranteed overnight delivery service, or (iv) on the fourth business day
following

                                      -7-

<PAGE>
the date delivered or mailed by United States registered or certified mail,
return receipt requested, postage prepaid, addressed as follows:

                  If to the Executive:

                  At the address (or to the facsimile number) shown on the
                  records of the Company

                  If to the Company:

                  At the address (or to the facsimile number) of the Company's
                  principal executive office
                  Attention: General Counsel

or to such other address as either party may have furnished to the other in
writing in accordance herewith, except that notices of change of address shall
be effective only upon receipt.

         13.      (a) CONFIDENTIALITY. The Executive acknowledges that in his
employment hereunder he will occupy a position of trust and confidence. The
Executive shall not, except as in good faith deemed necessary or desirable by
the Executive to perform his duties hereunder, or as required by applicable law
or legal process, without limitation in time or until such information shall
have become public or known in the Company's industry other than by the
Executive's unauthorized disclosure, disclose to others or use, whether directly
or indirectly, any Confidential Information regarding the Company. "Confidential
Information" shall mean information about the Company, its subsidiaries and
affiliates, and their respective employees, clients and customers that is not
disclosed by the Company for financial reporting purposes and that was learned
by the Executive in the course of his employment by the Company, including
(without limitation) any proprietary knowledge, trade secrets, data, formulae,
information and client and customer lists and all papers, resumes, and records
(including computer records) of the documents containing such Confidential
Information.

         (b)      NON-SOLICITATION OF EMPLOYEES. The Executive recognizes that
he possesses and will possess confidential information about other employees of
the Company relating to their education, experience, skills, abilities,
compensation and benefits, and inter-personal relationships with customers of
the Company. The Executive recognizes that the information he possesses and will
possess about these other employees is not generally known, is of substantial
value to the Company in developing its business and in securing and retaining
customers, and has been and will be acquired by him because of his business
position with the Company. The Executive agrees that, during the Employment Term
and for the one year period thereafter, he will not, directly or indirectly,
solicit or recruit any non-administrative or non-clerical employee of the
Company whose W-2 earnings for the immediately preceding calendar year were
$200,000 or above for the purpose of being employed by him or by any competitor
of the Company on whose behalf he is acting as an agent, representative or
employee.

         (c)      NON-SOLICITATION OF CUSTOMERS. The Executive recognizes that
he possesses and will possess confidential and proprietary business information
about customers of the Company and that the customer information he possesses
and will possess is not generally known, is of substantial value to the Company
in developing its business and securing and

                                      -8-

<PAGE>

retaining customers, and will be acquired by him because of his business
position with the Company. The Executive agrees that, during the Employment Term
and for the one-year period thereafter, he will not personally solicit or induce
any customers of the Company with whom he had contact during his employment with
the Company to divert any portion of its business with the Company to another
person or entity or direct that such customers be targeted for diversion as a
result of (i) his prior relationship with them on behalf of the Company or (ii)
an effort targeted primarily at customers of the Company.

         (d)      EQUITABLE RELIEF AND OTHER REMEDIES. The Executive
acknowledges and agrees that the Company's remedies at law for a breach or
threatened breach of any of the provisions of this Section would be inadequate
and, in recognition of this fact, the Executive agrees that, in the event of
such a breach or threatened breach, in addition to any remedies at law, the
Company, without posting any bond, shall be entitled to obtain equitable relief
in the form of specific performance, temporary restraining order, a temporary or
permanent injunction or any other equitable remedy which may then be available.

         (e)      REFORMATION. If it is determined by a court of competent
jurisdiction in any state that any restriction in this Section 13 is excessive
in duration or scope or is unreasonable or unenforceable under the laws of that
state, it is the intention of the parties that such restriction may be modified
or amended by the court to render it enforceable to the maximum extent permitted
by the law of that state.

         (f)      SURVIVAL OF PROVISIONS. Without effect as to the survival of
other provisions of this Agreement intended to survive the termination or
expiration of the Executive's employment, the obligations contained in this
Section 13 shall survive the termination or expiration of the Executive's
employment with the Company and shall be fully enforceable thereafter.

         14.      COORDINATION. With regard to the equity grants, payments and
benefits described in this Agreement (the "Contract Rights") the provisions of
this Agreement, to the extent that they are more favorable to the Executive,
shall control over any provisions to the contrary in any plan, program, or
equity grant applicable to the Executive. The Company shall not impose any
restrictions not contained in this Agreement on the Contract Rights, and shall
not condition any future equity grants, payments, or benefits not contemplated
by this Agreement upon the Executive's agreement to any additional restrictions
on the Contract Rights. However, nothing shall limit the Company's discretion to
include any new or different terms, conditions, or restrictions in any future
equity grant, payment or benefit to the Executive not contemplated by this
Agreement.

         15.      ATTORNEY'S FEES.

         (a)      In the event of any dispute arising out of or under this
Agreement or the Executive's employment with the Company and the arbitrator
determines that the Executive has prevailed on the issues in the arbitration,
the Company shall, upon presentment of appropriate documentation, promptly, at
the Executive's election, pay or reimburse the Executive for all reasonable
legal and other professional fees, costs of arbitration and other expenses
incurred in connection therewith by the Executive.

                                      -9-

<PAGE>

         (b)      The Company shall promptly pay the Executive's reasonable
costs of entering into this Agreement, including the reasonable fees and
expenses of his counsel.

         (c)      The Company shall gross up for tax purposes any deemed income
to the Executive arising pursuant to the payments provided under this Section
15, so that the economic benefit is the same to the Executive as if such
payments were provided on a non-taxable basis to the Executive. Payments
pursuant to this Section 15 shall be made on a current ongoing basis.

         16.      SECTION HEADINGS. The section headings used in this Agreement
are included solely for convenience and shall not affect, or be used in
connection with, the interpretation of this Agreement.

         17.      SEVERABILITY. The provisions of this Agreement shall be deemed
severable and the invalidity or unenforceability of any provision shall not
affect the validity or enforceability of the other provisions hereof.

         18.      COUNTERPARTS. This Agreement may be executed in several
counterparts, each of which shall be deemed to be an original but all of which
together will constitute one and the same instrument.

         19.      ARBITRATION. Any dispute or controversy arising under or in
connection with this Agreement, other than injunctive relief under Section 13(d)
hereof, shall be settled exclusively by arbitration, conducted before a single
arbitrator in New York, New York in accordance with the National Rules for the
Resolution of Employment Disputes of the American Arbitration Association then
in effect. The decision of the arbitrator will be final and binding upon the
parties hereto. Judgment may be entered on the arbitrator's award in any court
having jurisdiction. Nothing herein shall limit either the right of the Company
or the Executive to seek injunctive relief in a court of applicable
jurisdiction.

         20.      INDEMNIFICATION. In addition to any other rights of
indemnification of the Executive, the Company hereby covenants and agrees to
promptly indemnify the Executive (or, in the event of his death, his heirs,
executors, administrators or legal representatives) and hold him harmless to the
fullest extent permitted by law against and in respect to any and all actions,
suits, proceedings, claims, demands, judgments, costs, expenses (including
attorney's fees), penalties, fines, settlements, losses, and damages resulting
from, or in connection with, the Executive's employment with, and serving as a
director of, the Company, including but not limited to as an officer and
director of any subsidiary or as a fiduciary of any employee benefit plan. The
Company, within 10 days of presentation of invoices, shall advance to the
Executive reimbursement of all legal fees and disbursements reasonably incurred
by the Executive in connection with any potentially indemnifiable matter;
provided, however, that to the extent required by applicable law, in order to
receive such advanced fees and disbursements, the Executive must first sign an
undertaking reasonably satisfactory to the Company that he will promptly repay
the Company all advanced fees and disbursements in the event it is finally
determined in accordance with law that the Executive cannot be indemnified for
the matter at issue under applicable law. The burden of proving that
indemnification of the Executive is not permissible at law shall be on the
Company.

                                      -10-

<PAGE>

         21.      LIABILITY INSURANCE. The Company shall cover the Executive
under directors and officers liability insurance both during and, while
potential liability exists (but no less than six years), after the term of this
Agreement in the same amount and to the same extent, if any, as the Company
covers its other officers and directors.

         22.      MISCELLANEOUS. No provision of this Agreement may be modified,
waived or discharged unless such waiver, modification or discharge is agreed to
in writing and signed by the Executive and such officer or director as may be
designated by the Board. No waiver by either party hereto at any time of any
breach by the other party hereto of, or compliance with, any condition or
provision of this Agreement to be performed by such other party shall be deemed
a waiver of similar or dissimilar provisions or conditions at the same or at any
prior or subsequent time. This Agreement together with all exhibits hereto sets
forth the entire agreement of the parties hereto in respect of the subject
matter contained herein. No agreements or representations, oral or otherwise,
express or implied, with respect to the subject matter hereof have been made by
either party which are not expressly set forth in this Agreement. The validity,
interpretation, construction and performance of this Agreement shall be governed
by the laws of the State of New York without regard to its conflicts of law
principles.

         23.      FULL SETTLEMENT. Except as set forth in this Agreement, the
Company's obligation to make the payments provided for in this Agreement and
otherwise to perform its obligations hereunder shall not be affected by any
circumstances, including without limitation, set-off, counterclaim, recoupment,
defense or other claim, right or action which the Company may have against the
Executive or others. In no event shall the Executive be obliged to seek other
employment or take any other action by way of mitigation of the amounts payable
to the Executive under any of the provisions of this Agreement, nor shall the
amount of any payment hereunder be reduced by any compensation earned by the
Executive as a result of employment by another employer.

         24.      REPRESENTATIONS, ETC.

         (a)      The Company represents and warrants that there is no legal or
other impediment or limitation to the Company's performance of its obligations.

         (b)      On the Merger Date, the Company shall deliver to the Executive
a satisfactory written agreement from the ultimate parent surviving corporation
following the Merger assuming and agreeing to perform this Agreement.

         (c)      The Executive represents and warrants to the Company that he
has the legal right to enter into this Agreement and to perform all of the
obligations on his part to be performed hereunder in accordance with its terms
and that he is not a party to any agreement or understanding, written or oral,
which could prevent him from entering into this Agreement or performing all of
his obligations hereunder.

         (d)      To the extent that after the Merger any separate prior
employee benefit plan or incentive plan continues for the senior executives
previously employed by the separate prior entities, the Executive shall continue
in the former Travelers Property Casualty Corp. plan. To the extent that senior
executives are moved from one plan to another, (i) if all continuing senior

                                      -11-

<PAGE>

executives are moved, the Executive also shall be moved, and (ii) if only some
senior executives are moved, the Executive shall be moved if, and only if, such
other plan is more beneficial to the Executive. The parties may vary the
foregoing by written agreement.

                                      -12-

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first written above.

TRAVELERS PROPERTY CASUALTY CORP.

By: /s/ Jay S. Benet
Title: Chief Financial Officer

ROBERT I. LIPP

/s/ Robert I. Lipp

                                      -13-

<PAGE>

                                    EXHIBIT A

                               LIST OF COMPETITORS

1.       American International Group

2.       The Hartford Financial Services, Inc.

3.       Chubb Corporation

4.       Allstate Corporation

5.       Progressive Corporation

<PAGE>

                                    EXHIBIT B

                                 FORM OF RELEASE

         Agreement and General Release ("Release"), by and between Robert I.
Lipp ( "your" or "you") [INSERT NAME] (the "Company").

         1.       Pursuant to your Employment Agreement with the Company dated
as of _______, 2003 ("Employment Agreement"), your [termination/retirement] will
be effective at the close of business on ___________, 200_ ("Termination or
Retirement Date").

         2.       You agree that as of the Effective Date of this Agreement
(defined in Paragraph 15) you will resign as an officer, director, or member of
any internal and any outside directorships, memberships, or other affiliations
in which you participate as a representative of the Company [to the extent not
remaining in such capacity].

         3.       Following your Termination or Retirement Date you will receive
information as to COBRA elections from the COBRA administrator for certain
benefits (i.e., medical and dental) that you may wish to continue.

         4.       In consideration for the payments and benefits provided under
the Employment Agreement upon your [termination/retirement] pursuant to Section
8 of the Employment Agreement, you, on your behalf, and on behalf of your
agents, assignees, attorneys, heirs, executors, and administrators (collectively
referred to as "Releasors"), covenant not to sue and release the Company, its
past and present parents, affiliates, successors, assigns, subsidiaries,
divisions, and related business entities (collectively referred to as the
"Company") and its or their current or former officers, directors, shareholders,
employees, agents and representatives (collectively referred to as "Releasees")
from any and all liability, claims, demands, actions, causes of action, suits,
grievances, debts, sums of money, controversies, agreements, promises, damages,
pay, bonus, stock, stock options, costs, expenses, attorneys' fees, and remedies
of any type that Releasors may have by reason of any matter, cause, act or
omission including, but not limited to, those arising out of or in connection
with your employment with or separation from the Company. This covenant not to
sue and general release shall apply to all disputes, claims, liens, injuries and
damages, whether known or unknown, occurring at any time on or before the
Effective Date of this Agreement and includes, but is not limited to, a full
release of:

         -    any claims under Title VII of the Civil Rights Act of 1964, the
              Age Discrimination in employment Act of 1967, the Rehabilitation
              Act of 1973, the Civil Rights Act of 1866, the Americans with
              Disabilities Act of 1990, the Employee Retirement Income Security
              Act of 1974, the Civil Rights Act of 1991, the Equal Pay Act of
              1963, the Family and Medical Leave Act of 1993, the Fair Labor
              Standards Act of 1938, the Older Workers Benefit Protection Act of
              1990, the Occupational Safety and Health Act of 1970, the Worker
              Adjustment and Retraining Notification Act of 1989, the New York
              State Human Rights Law, the New York City Human Rights Ordinance,
              and the Connecticut Human Rights and Opportunities Law, and

<PAGE>

         -    any other federal, state, or local statute or regulation regarding
              employment, employment discrimination, termination of employment,
              retaliation, equal opportunity, and wage and hour.

You specifically understand that you are releasing, among other claims, claims
based on age, race, color, sex, sexual orientation or preference, marital
status, religion, national origin, citizenship, veteran status, disability, and
any other legally protected categories as well as other compensation-related
claims. This also includes a release of any claims for breach of contract, any
tortious act or other civil wrong, attorneys' fees, and all compensation and
benefit claims including without limitation claims concerning salary, bonus, and
any awards, grants or purchases under any equity and incentive compensation plan
or program, and any separation pay plan maintained by the Company or any of its
affiliates or subsidiaries. You acknowledge that this release is intended to
include, without limitation, all claims known or unknown that you have or may
have against the Company and Releasees through the Effective Date of this
Agreement, including but not limited to those which arise out of or relate to
your employment with or separation from the Company. Notwithstanding anything
herein, you expressly reserve and do not release (a) your rights under any
applicable pension plan or any other employee benefit plan (other than any
equity compensation plan), under any vacation or sick leave policy or under
COBRA, (b) your vested rights to any equity under any equity compensation plan,
(c) claims arising after the Effective Date of this Agreement, or with respect
to the enforcement of this Agreement, (d) your rights of indemnification or
contribution to which you were entitled immediately prior to the Termination or
Retirement Date under the Company's By-laws, the Company's Certificate of
Incorporation or otherwise with regard to your service as an officer or director
of the Company or your service as a fiduciary with regard to any employee
benefit plan, including, without limitation, pursuant to Section 20 of the
Employment Agreement, (e) your rights as a stockholder or (f) your rights under
Sections 10 and 21 of the Employment Agreement.

         5.       In consideration of the covenants and undertakings set forth
herein, the Company hereby covenants not to sue and releases you from liability
for any and all acts or omissions including but not limited to, those occurring
during or in connection with your employment with or separation from the Company
or as a stockholder of the Company. This covenant not to sue and general release
shall apply to all disputes, claims, liens, injuries and damages, whether known
or unknown, occurring at any time on or before the Effective Date of this
Agreement. This release and covenant not to sue shall not apply to any breach of
this Agreement or any claims against you by the Company for any debt or credit
obligations including but not limited to any insurance, loan, mortgage, or
credit card debt owed by you to the Company.

         6.       (a)      You represent that you have not and will not file,
                           directly or indirectly, any claims against the
                           Company or the Releasees in any court, administrative
                           agency, or arbitration, concerning any claims
                           released herein.

                  (b)      In the event that you have filed, directly or
                           indirectly, claims against the Company or Releasees
                           in any forum which are released herein, you agree to
                           notify [INSERT TITLE AND ADDRESS], and to withdraw
                           with

                                      -2-

<PAGE>

                           prejudice any such claims before signing this
                           Agreement. You acknowledge and agree that you are not
                           eligible to receive the payments and benefits set
                           forth in Section 8 of the Employment Agreement prior
                           to such withdrawal.

         7.       To the extent permitted by applicable law, you agree not to
participate or assist in any action, complaint, charge, claim, or proceeding
against the Company or the Releasees of any kind on behalf of any other person
or entity (except pursuant to a court order, in response to a valid subpoena, or
as requested by the Company or its attorneys) with regard to matters relating to
your period of employment with the Company. You further agree that you will not
seek or accept any award, judgment or settlement from any source or proceeding
against the Company or the Releasees with respect to any claim or right arising
from any act, omission, transaction, or occurrence through the Effective Date of
this Agreement released herein.

         8.       Nothing contained in this Agreement is intended to prohibit or
restrict you from providing truthful information concerning your employment or
the Company's business activities to any government, regulatory or
self-regulatory agency.

         9.       Subject to your reasonable business commitments, you agree to
reasonably cooperate with the Company and its counsel with regard to any past,
present, or future legal matters which relate to or arise out of the business
you conducted on behalf of the Company. You will be entitled to your reasonable
actual out-of-pocket expenses incurred in connection with providing such
cooperation, including reasonable travel and reasonable attorneys' fees,
following submission of appropriate documentation.

         10.      The terms of this Agreement are not an admission of liability
or wrongdoing by either you or the Company.

         11.      You agree to return to the Company all documents,
correspondence, memoranda, disks, audio or video tapes, written and other files,
notes, manuals, handbooks, and account records (whether stored electronically or
otherwise) in your possession, including but not limited to Confidential
Information as defined in your Employment Agreement, upon the execution of this
Agreement. Your "possession" includes any person or entity to whom you may have
given such information other than in connection with the performance of your
duties for the Company.

         12.      Except with respect to Paragraph 4 above, the invalidity or
unenforceability of any provision of this Agreement shall have no effect upon
and shall not impair the validity or enforceability of any other provision of
this Agreement.

         13.      This Agreement shall be governed by the laws of the State of
New York (regardless of conflict of laws principles) as to all matters including
without limitation validity, construction, effect, performance, and remedies.

         14.      You acknowledge that: (i) you have read and understand each of
the provisions of this Agreement; (ii) you have consulted with an attorney prior
to executing this Agreement; (iii) you have been given twenty-one (21) days from
your receipt of this Agreement to review it and

                                      -3-

<PAGE>

to consider your decision to sign it; (iv) you are entering into this Agreement
of your own free will; and (v) this Agreement is not intended to be a
prospective waiver of claims arising after the Effective Date of this Agreement.

         15.      This Agreement shall not become effective or enforceable until
eight (8) days following its execution by you ("Effective Date") during which
time you or the Company may revoke this Agreement by notifying [INSERT TITLE],
at the address above, in writing.

         16.      Notwithstanding anything in this Agreement, the provisions in
your Employment Agreement which are intended to survive termination of your
Employment Agreement, including but not limited to those contained in Section 13
thereof, shall survive and continue in full force and effect.

[COMPANY NAME]                             Agreed to and accepted by:

_____________________________              _______________________________
By: [Name]                                 Robert I. Lipp

_____________________________              _______________________________
Date                                       Date

                                      -4-

<PAGE>

                                    EXHIBIT C

                               GROSS-UP PROVISIONS

         (a)      Anything in this Agreement to the contrary notwithstanding, in
the event it shall be determined that the Executive shall become entitled to
payments and/or benefits provided by this Agreement or any other amounts in the
"nature of compensation" (whether pursuant to the terms of this Agreement or any
other plan, arrangement or agreement with the Company or any affiliate, any
person whose actions result in a change of ownership or effective control of the
Company covered by Section 280G(b)(2) of the Code or any person affiliated with
the Company or such person) as a result of such change in ownership or effective
control of the Company (a "Payment") would be subject to the excise tax imposed
by Section 4999 of the Code or any interest or penalties are incurred by the
Executive with respect to such excise tax (such excise tax, together with any
such interest and penalties, are hereinafter collectively referred to as the
"Excise Tax"), then the Executive shall be entitled to receive an additional
payment (a "Gross-Up Payment") in an amount such that after payment by the
Executive of all taxes (including any interest or penalties imposed with respect
to such taxes), including, without limitation, any income taxes (and any
interest and penalties imposed with respect thereto) and Excise Tax imposed upon
the Gross-Up Payment, the Executive retains an amount of the Gross-Up Payment
equal to the Excise Tax imposed upon the Payments.

         (b)      Subject to the provisions of paragraph (c), all determinations
required to be made under this Exhibit C, including whether and when a Gross-Up
Payment is required and the amount of such Gross-Up Payment and the assumptions
to be utilized in arriving at such determination, shall be made by a nationally
recognized accounting firm (the "Accounting Firm") which shall provide detailed
supporting calculations both to the Company and the Executive within 15 business
days of the receipt of notice from the Executive that there has been a Payment,
or such earlier time as is requested by the Company. The Accounting Firm shall
be jointly selected by the Company and the Executive and shall not, during the
two years preceding the date of its selection, have acted in any way on behalf
of the Company or its affiliated companies. If the Company and the Executive
cannot agree on the firm to serve as the Accounting Firm, then the Company and
the Executive shall each select a nationally recognized accounting firm and
those two firms shall jointly select a nationally recognized accounting firm to
serve as the Accounting Firm. All fees and expenses of the Accounting Firm shall
be borne solely by the Company. Any Gross-Up Payment, as determined pursuant to
this Exhibit C, shall be paid by the Company to the Executive within five days
of the receipt of the Accounting Firm's determination. If the Accounting Firm
determines that no Excise Tax is payable by the Executive, it shall furnish the
Executive with a written opinion that failure to report the Excise Tax on the
Executive's applicable federal income tax return would not result in the
imposition of a negligence or similar penalty. Any determination by the
Accounting Firm shall be binding upon the Company and the Executive. As a result
of the uncertainty in the application of Section 4999 of the Code at the time of
the initial determination by the Accounting Firm hereunder, it is possible that
Gross-Up Payments which will not have been made by the Company should have been
made ("Underpayment"), consistent with the calculations required to be made
hereunder. In the event that the Company exhausts its remedies pursuant to
paragraph (c) hereof and the Executive thereafter is required to make a payment
of any Excise Tax, the Accounting Firm shall

<PAGE>

determine the amount of the Underpayment that has occurred and any such
Underpayment shall be promptly paid by the Company to or for the benefit of the
Executive.

         (c)      The Executive shall notify the company in writing of any claim
by the Internal Revenue Service that, if successful, would require the payment
by the Company of a Gross-Up Payment. Such notification shall be given as soon
as practicable but no later than ten business days after the Executive is
informed in writing of such claim and shall apprise the Company of the nature of
such claim and the date on which such claim is requested to be paid. The
Executive shall not pay such claim prior to the expiration of the 30-day period
following the date on which he or she gives such notice to the Company (or such
shorter period ending on the date that any payment of taxes with respect to such
claim is due). If the Company notifies the Executive in writing prior to the
expiration of such period that it desires to contest such claim, the Executive
shall:

         (i)      give the Company any information reasonably requested by the
                  Company relating to such claim,

         (ii)     take such action in connection with contesting such claim as
                  the Company shall reasonably request in writing from time to
                  time, including, without limitation, accepting legal
                  representation with respect to such claim by an attorney
                  reasonably selected by the Company,

         (iii)    cooperate with the Company in good faith in order effectively
                  to contest such claim, and

         (iv)     permit the Company to participate in any proceedings relating
                  to such claim; provided, however, that the Company shall bear
                  and pay directly all costs and expenses (including additional
                  interest and penalties) incurred in connection with such
                  contest and shall indemnify and hold the Executive harmless,
                  on an after-tax basis, for any Excise Tax or income tax
                  (including interest and penalties with respect thereto)
                  imposed as a result of such representation and payment of
                  costs and expenses. Without limitation on the foregoing
                  provisions of this paragraph (c), the Company shall control
                  all proceedings taken in connection with such contest and, at
                  its sole option, may pursue or forego any and all
                  administrative appeals, proceedings, hearings and conferences
                  with the taxing authority in respect of such claim and may, at
                  its sole option, either direct the Executive to pay the tax
                  claimed and sue for a refund or contest the claim in any
                  permissible manner, and the Executive agrees to prosecute such
                  contest to a determination before any administrative tribunal,
                  in a court of initial jurisdiction and in one or more
                  appellate courts, as the Company shall determine; provided,
                  however, that if the Company directs the Executive to pay such
                  claim and sue for a refund, the Company shall advance the
                  amount of such payment to the Executive, on an interest-free
                  basis and shall indemnify and hold the Executive harmless, on
                  an after-tax basis, from any Excise Tax or income tax
                  (including interest or penalties with respect thereto) imposed
                  with respect to such advance or with respect to any imputed
                  income with respect to such advance; and further provided the
                  Executive

                                      -2-
<PAGE>

                  shall not be required by the Company to agree to any extension
                  of the statute of limitations relating to the payment of taxes
                  for the taxable year of the Executive with respect to which
                  such contested amount is claimed to be due unless such
                  extension is limited solely to such contested amount.
                  Furthermore, the Company's control of the contest shall be
                  limited to issues with respect to which a Gross-Up Payment
                  would be payable hereunder and the Executive shall be entitled
                  to settle or contest, as the case may be, any other issue
                  raised by the Internal Revenue Service or any other taxing
                  authority.

         (d)      If, after the receipt by the Executive of an amount advanced
by the Company pursuant to paragraph (c) hereof, the Executive becomes entitled
to receive any refund with respect to such claim, the Executive shall (subject
to the Company's complying with the requirements of paragraph (c) hereof)
promptly pay to the Company the amount of such refund (together with any
interest paid or credited thereon after taxes applicable thereto). If, after the
receipt by the Executive of an amount advanced by the Company pursuant to
paragraph (c) hereof, a determination is made that the Executive shall not be
entitled to any refund with respect to such claim and the Company does not
notify the Executive in writing of its intent to contest such denial of refund
prior to the expiration of 30 days after such determination, then such advance
shall be forgiven and shall not be required to be repaid and the amount of such
advance shall offset, to the extent thereof, the amount of Gross-Up Payment
required to be paid.

         (e)      If, pursuant to regulations issued under Section 280G or 4999
of the Code, the Company and the Executive were required to make a preliminary
determination of the amount of an excess parachute payment and thereafter a
redetermination of the Excise Tax is required under the applicable regulations,
the parties shall request the Accounting Firm to make such redetermination. If
as a result of such redetermination an additional Gross-Up Payment is required,
the amount thereof shall be paid by the Company to the Executive within five
days of the receipt of the Accounting Firm's determination. If the
redetermination of the Excise Tax results in a reduction of the Excise Tax, the
Executive shall take such steps as the Company may reasonably direct in order to
obtain a refund of the excess Excise Tax paid. If the Company determines that
any suit or proceeding is necessary or advisable in order to obtain such refund,
the provisions of paragraph (c) hereof relating to the contesting of a claim
shall apply to the claim for such refund, including, without limitation, the
provisions concerning legal representation, cooperation by the Executive,
participation by the Company in the proceedings and indemnification by the
Company. Upon receipt of any such refund, the Executive shall promptly pay the
amount of such refund to the Company. If the amount of the income taxes
otherwise payable by the Executive in respect of the year in which the Executive
makes such payment to the Company is reduced as a result of such payment, the
Executive shall, no later than the filing of his income tax return in respect of
such year, pay the amount of such tax benefit to the Company. In the event there
is a subsequent redetermination of the Executive's income taxes resulting in a
reduction of such tax benefit, the Company shall, promptly after receipt of
notice of such reduction, pay to the Executive the amount of such reduction. If
the Company objects to the calculation or recalculation of the tax benefit, as
described in the preceding two sentences, the Accounting Firm shall make the
final determination of the appropriate amount. The Executive shall not be
obligated to pay to the Company the amount of any further tax

                                      -3-

<PAGE>

benefits that may be realized by him or her as a result of paying to the Company
the amount of the initial tax benefit.

         (f)      Nothing in this Exhibit C is intended to violate the
Sarbanes-Oxley Act and to the extent that any advance or repayment obligation
hereunder would do so, such obligation shall be modified so as to make the
advance a nonrefundable payment to the Executive and the repayment obligation
null and void.

                                      -4-<PAGE>

                                                                    EXHIBIT 10.1

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                          SECURITIES PURCHASE AGREEMENT

                  SECURITIES PURCHASE AGREEMENT (the "AGREEMENT"), dated as of
February 27, 2004, by and among DUSA Pharmaceuticals, Inc., a New Jersey
corporation, with headquarters located at 25 Upton Drive, Wilmington,
Massachusetts 01887 (the "COMPANY"), and the investors listed on the Schedule of
Buyers attached hereto as Exhibit A (individually, a "BUYER" and collectively,
the "BUYERS").

                  WHEREAS:

                  A.       The Company and each Buyer is executing and
delivering this Agreement in reliance upon the exemption from securities
registration afforded by Section 4(2) of the Securities Act of 1933, as amended
(the "1933 ACT"), and Rule 506 of Regulation D ("REGULATION D") as promulgated
by the United States Securities and Exchange Commission (the "SEC") under the
1933 Act.

                  B.       Each Buyer wishes to purchase, and the Company wishes
to sell, upon the terms and conditions stated in this Agreement, (i) that
aggregate number of shares of the common stock, no par value, of the Company
(the "COMMON STOCK"), set forth opposite such Buyer's name in column (3) on the
Schedule of Buyers (which aggregate amount for all Buyers together shall be
2,250,000 shares of Common Stock and shall collectively be referred to herein as
the "COMMON SHARES") and (ii) a right to acquire up to that number of additional
shares of Common Stock set forth opposite such Buyer's name in column (4) on the
Schedule of Buyers (the "ADDITIONAL INVESTMENT RIGHTS"), in substantially the
form attached hereto as Exhibit B (as exercised, collectively, the "ADDITIONAL
INVESTMENT RIGHT SHARES").

                  C.       Contemporaneously with the execution and delivery of
this Agreement, the parties hereto are executing and delivering a Registration
Rights Agreement, substantially in the form attached hereto as Exhibit C (the
"REGISTRATION RIGHTS AGREEMENT"), pursuant to which the Company has agreed to
provide certain registration rights with respect to the Common Shares and the
Additional Investment Right Shares under the 1933 Act and the rules and
regulations promulgated thereunder and applicable state securities laws.

                  D.       The Common Shares, the Additional Investment Rights
and the Additional Investment Right Shares collectively are referred to herein
as the "SECURITIES".

                  NOW, THEREFORE, the Company and each Buyer hereby agree as
follows:

                  1. PURCHASE AND SALE OF COMMON SHARES AND ADDITIONAL
INVESTMENT RIGHTS.

                           a. Purchase of Common Shares and Additional
Investment Rights.

                           Subject to the satisfaction (or waiver) of the
conditions set forth in Sections 6 and 7 below, the Company shall issue and sell
to each Buyer, and each Buyer severally, but not jointly, agrees to purchase
from the Company on the Closing Date (as defined in Section 1(c) below), the
number of Common Shares as is set forth opposite such Buyer's name

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

in column (3) on the Schedule of Buyers, along with the Additional Investment
Rights to acquire up to that number of Additional Investment Right Shares as is
set forth opposite such Buyer's name in column (4) on the Schedule of Buyers
(the "CLOSING"). The Closing shall occur on the Closing Date at the offices of
Schulte Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022.

                           b. Purchase Price. The purchase price for the Common
Shares and related Additional Investment Rights to be purchased by each Buyer at
the Closing shall be the amount set forth opposite such Buyer's name in column
(5) of the Schedule of Buyers (the "PURCHASE PRICE"), which shall be equal to
the amount of $11.00 per Common Share.

                           c. Closing Date. The date and time of the Closing
(the "CLOSING DATE") shall be 10:00 a.m., New York City Time, on March 1, 2004
(or such later date as is mutually agreed to by the Company and each Buyer)
after notification of satisfaction (or waiver) of the conditions to the Closing
set forth in Sections 6 and 7 below.

                           d. Form of Payment. On the Closing Date, (i) each
Buyer shall pay its Purchase Price to the Company for the Common Shares and the
Additional Investment Rights to be issued and sold to such Buyer at the Closing,
by wire transfer of immediately available funds in accordance with the Company's
written wire instructions, and (ii) the Company shall deliver to each Buyer (A)
one or more stock certificates, free and clear of all restrictive and other
legends (except as expressly provided in Section 2(g) hereof), evidencing the
number of Common Shares such Buyer is purchasing as is set forth opposite such
Buyer's name in column (3) of the Schedule of Buyers, duly executed on behalf of
the Company and registered on the transfer books of the Company in the name of
such Buyer and (B) an Additional Investment Right pursuant to which such Buyer
shall have the right to acquire such number of Additional Investment Right
Shares as is set forth opposite such Buyer's name in column (4) of the Schedule
of Buyers, in all cases duly executed on behalf of the Company and registered in
the name of such Buyer.

                  2. BUYER'S REPRESENTATIONS AND WARRANTIES.

                           Each Buyer represents and warrants with respect to
only itself that:

                           a. No Public Sale or Distribution. Such Buyer is (i)
acquiring the Common Shares and the Additional Investment Rights and (ii) upon
exercise of the Additional Investment Rights will acquire the Additional
Investment Right Shares issuable upon exercise thereof, in the ordinary course
of business for its own account and not with a view towards, or for resale in
connection with, the public sale or distribution thereof, except pursuant to
sales registered or exempted under the 1933 Act and such Buyer does not have a
present arrangement to effect any distribution of the Securities to or through
any person or entity; provided, however, that by making the representations
herein, such Buyer does not agree to hold any of the Securities for any minimum
or other specific term and reserves the right to dispose of the Securities at
any time in accordance with or pursuant to a registration statement or an
exemption under the 1933 Act.

                                       2

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           b. Accredited Investor Status. Such Buyer is an
"accredited investor" as that term is defined in Rule 501(a) of Regulation D.
Specifically such Buyer is either (i) a corporation, Massachusetts or similar
business trust, or partnership, not formed for the specific purpose of acquiring
the Common Shares, with total assets in excess of $5,000,000 or (ii) if an
individual, a natural person whose individual net worth, or joint net worth with
that person's spouse, at the time of his or her purchase exceeds $1,000,000 or a
natural person who had an individual income (not including his or her spouse's
income) in excess of $200,000 in 2002 and 2003 or joint income with his or her
spouse in excess of $300,000 in each of those years and has a reasonable
expectation of reaching such income level in 2004.

                           c. Reliance on Exemptions. Such Buyer understands
that the Securities are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state
securities laws and that the Company is relying in part upon the truth and
accuracy of, and such Buyer's compliance with, the representations, warranties,
agreements, acknowledgments and understandings of such Buyer set forth herein in
order to determine the availability of such exemptions and the eligibility of
such Buyer to acquire the Securities.

                           d. Information. Such Buyer and its advisors, if any,
have been furnished with all materials relating to the business, finances and
operations of the Company and materials relating to the offer and sale of the
Securities which have been requested by such Buyer including: (i) the SEC
Documents (as defined in Section 3(j) below); and (ii) the Company's proxy
statement dated April 28, 2003 (the "Proxy Statement"). Such Buyer and its
advisors, if any, have been afforded the opportunity to ask questions of the
Company. Neither such inquiries nor any other due diligence investigations
conducted by such Buyer or its advisors, if any, or its representatives shall
modify, amend or affect such Buyer's right to rely on the Company's
representations and warranties contained herein. Such Buyer understands that its
investment in the Securities involves a high degree of risk including, without
limitation, the risks set forth in the SEC Documents under the captions "Factors
Affecting Future Operating Results" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations", and is able to afford a complete
loss of such investment. Such Buyer has sought such accounting, legal and tax
advice as it has considered necessary to make an informed investment decision
with respect to its acquisition of the Securities.

                           e. No Governmental Review. Such Buyer understands
that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of
the Securities or the fairness or suitability of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the
offering of the Securities.

                           f. Transfer or Resale. Such Buyer understands that
except as provided in the Registration Rights Agreement: (i) the Securities have
not been and are not being registered under the 1933 Act or any state securities
laws, and may not be offered for sale, sold, assigned or transferred unless (A)
subsequently registered thereunder, (B) such Buyer shall have delivered to the
Company an opinion of counsel, in a form reasonably acceptable to the Company,
to the effect that such Securities to be sold, assigned or transferred may be
sold, assigned or transferred pursuant to an exemption from such registration;
(ii) any sale of the Securities made in reliance

                                       3

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

on Rule 144 or Rule 144A promulgated under the 1933 Act, as amended, (or a
successor rule thereto) (collectively, "RULE 144") may be made only in
accordance with the terms of Rule 144 and further, if Rule 144 is not
applicable, any resale of the Securities under circumstances in which the seller
(or the Person (as defined in Section 3(r)) through whom the sale is made) may
be deemed to be an underwriter (as that term is defined in the 1933 Act) may
require compliance with some other exemption under the 1933 Act or the rules and
regulations of the SEC thereunder; and (iii) neither the Company nor any other
Person is under any obligation to register the Securities under the 1933 Act or
any state securities laws or to comply with the terms and conditions of any
exemption thereunder. Notwithstanding the foregoing, the Securities may be
pledged in connection with a bona fide margin account or other loan secured by
the Securities and such pledge of Securities shall not be deemed to be a
transfer, sale or assignment of the Securities hereunder, and no Buyer effecting
a pledge of Securities shall be required to provide the Company with any notice
thereof or otherwise make any delivery to the Company pursuant to this Agreement
or any other Transaction Document, including, without limitation, this Section
2(f).

                           g. Legends. Such Buyer understands that (i) the
Additional Investment Rights and (ii) the certificates or other instruments
representing the Common Shares and the Additional Investment Right Shares, until
such time as the resale of the Common Shares and the Additional Investment Right
Shares have been registered under the 1933 Act as contemplated by the
Registration Rights Agreement or such legend is not otherwise required pursuant
to applicable law, shall bear any legend as required by the "Blue Sky" laws of
any state and a restrictive legend in substantially the following form (and a
stop-transfer order may be placed against transfer of such stock certificates):

         [NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS
         CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE
         EXERCISABLE HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE
         HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
         OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
         FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN
         EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE
         SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL, IN A
         FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT
         REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER
         SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED
         IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR
         FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

                                       4

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           h. Validity; Enforcement. This Agreement and the
Registration Rights Agreement have been duly and validly authorized, executed
and delivered on behalf of such Buyer and shall constitute the legal, valid and
binding obligations of such Buyer enforceable against such Buyer in accordance
with their respective terms, except as such enforceability may be limited by
general principles of equity or to applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or
affecting generally, the enforcement of applicable creditors' rights and
remedies. Such Buyer, if an individual, has reached the age of majority in the
jurisdiction in which he resides, is legally competent to execute this
Securities Purchase Agreement, and does not intend to change residence to
another jurisdiction.

                           i. No Conflicts. The execution, delivery and
performance by such Buyer of this Agreement and the Registration Rights
Agreement and the consummation by such Buyer of the transactions contemplated
hereby and thereby will not (i) result in a violation of the organizational
documents of such Buyer or (ii) conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Buyer is a
party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws) applicable to
such Buyer, except in the case of clauses (ii) and (iii) above, for such
conflicts, defaults, rights or violations which would not, individually or in
the aggregate, reasonably be expected to have a material adverse effect on the
ability of such Buyer to perform its obligations hereunder.

                           j. Residency. Such Buyer is a resident of that
jurisdiction specified below its address on the Schedule of Buyers.

                           k. Commission Fees. Such Buyer has not entered into
any agreement to pay commissions to any Person with respect to the purchase or
sale of the Securities, except commissions for which such Buyer will be
responsible.

                           l. Reliance. Such Buyer has, in connection with its
decision to purchase the Securities, relied solely upon the SEC Documents, the
Proxy Statement and the Transaction Documents. Such Buyer has not relied upon
any representations or other information (whether oral or written) from the
Company, the Placement Agent (as defined in Section 3(a) below) or any of their
respective agents other than as set forth in the SEC Documents, the Proxy
Statement and the Transaction Documents.

                           m. Placement Agent Participation. Each Buyer
acknowledges that the Placement Agent and its affiliates are purchasing 275,000
of the Common Shares and the related Additional Investment Rights pursuant to
this Agreement.

                  3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

                           The Company represents and warrants to each of the
Buyers that:

                           a. Organization and Qualification. As of the date
hereof and the Closing Date, each of the Company and its "SUBSIDIARIES" (which
for purposes of this Agreement means any "Significant Subsidiary" as defined in
Regulation S-X) are corporations duly organized and

                                       5

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

validly existing in good standing under the laws of the jurisdiction in which
they are incorporated, and have the requisite corporate power and authorization
to own their properties and to carry on their business as now being conducted;
provided, however, that the Company is not in good standing in New Jersey on the
date hereof but shall be in good standing as of the Closing. As of the date
hereof and the Closing Date, each of the Company and its Subsidiaries is duly
qualified as a foreign corporation to do business and is in good standing in
every jurisdiction in which its ownership of property or the nature of the
business conducted by it makes such qualification necessary, except to the
extent that the failure to be so qualified or be in good standing would not have
a Material Adverse Effect. As used in this Agreement, "MATERIAL ADVERSE EFFECT"
means any material adverse effect on the business, properties, assets,
operations, results of operations, condition (financial or otherwise) or
prospects of the Company and its Subsidiaries, taken as a whole, or on the
transactions contemplated hereby and the other Transaction Documents (as defined
in Section 3(b) below) or by the agreements and instruments to be entered into
in connection herewith or therewith, or on the authority or ability of the
Company to perform its obligations under the Transaction Documents. The Company
has no Subsidiaries except as set forth on Schedule 3(a).

                           b. Authorization; Enforcement; Validity. The Company
has the requisite corporate power and authority to enter into and perform its
obligations under this Agreement, the Registration Rights Agreement, the
Irrevocable Transfer Agent Instructions (as defined in Section 5(b)), the
Additional Investment Rights and each of the other agreements entered into by
the parties hereto in connection with the transactions contemplated by this
Agreement (collectively, the "TRANSACTION DOCUMENTS") and to issue the
Securities in accordance with the terms hereof and thereof. The execution and
delivery of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby, including, without
limitation, the issuance of the Common Shares and the Additional Investment
Rights and the reservation for issuance and the issuance of the Additional
Investment Right Shares issuable upon exercise thereof, have been duly
authorized by the Company's board of directors and no further consent or
authorization is required by the Company, its board of directors or its
shareholders. This Agreement and the other Transaction Documents have been duly
executed and delivered by the Company, and, assuming due and effective
authorization, execution and delivery by the Buyers, constitute the legal, valid
and binding obligations of the Company, enforceable against the Company in
accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or
affecting generally, the enforcement of applicable creditors' rights and
remedies.

                           c. Issuance of Securities. The Common Shares and the
Additional Investment Rights are duly authorized and, upon issuance in
accordance with the terms hereof, shall be validly issued and free from all
taxes, liens and charges with respect to the issue thereof, and the Common
Shares are fully paid and nonassessable with the holders being entitled to all
rights accorded to a holder of the Common Stock. As of the Closing Date, the
Company shall have duly authorized and reserved for issuance a number of shares
of Common Stock which equals the number of Additional Investment Right Shares.
The Company shall, so long as any of the Additional Investment Rights are
outstanding, take all action necessary to reserve and keep available out of its
authorized and unissued Common Stock, solely for the purpose of effecting the
exercise of the Additional Investment Rights, 100% of the number of shares of
Common

                                       6

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

Stock issuable upon exercise of the Additional Investment Rights. Upon exercise
in accordance with the Additional Investment Rights, the Additional Investment
Right Shares will be validly issued, fully paid and nonassessable and free from
all taxes, liens and charges with respect to the issue thereof, with the holders
being entitled to all rights accorded to a holder of Common Stock. Based in part
on the representations of each Buyer in Section 2 hereof, the issuance by the
Company of the Securities is exempt from registration under the 1933 Act.

                           d. No Conflicts. The execution, delivery and
performance of the Transaction Documents by the Company and the consummation by
the Company of the transactions contemplated hereby and thereby (including,
without limitation, the issuance of the Common Shares and Additional Investment
Rights and reservation for issuance and issuance of the Additional Investment
Right Shares) will not: (i) result in a violation of the Certificate of
Incorporation or Bylaws (as each is defined in Section 3(q) below) of the
Company or any of its Subsidiaries, or (ii) conflict with, or constitute a
default (or an event which with notice or lapse of time or both would become a
default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any material agreement, indenture or instrument
to which the Company or any of its Subsidiaries is a party, or (iii) result in a
violation of any law, rule, regulation, order, judgment or decree (including
federal and state securities laws and regulations and the rules and regulations
of the Nasdaq National Market (the "PRINCIPAL MARKET")) applicable to the
Company or any of its Subsidiaries or by which any property or asset of the
Company or any of its Subsidiaries is bound or affected.

                           e. Consents. Based in part on the representations of
each Buyer in Section 2 hereof, no consent, authorization or order of, or make
any filing or registration with, any court, governmental agency or any
regulatory or self-regulatory agency or any other Person in order for it to
execute, deliver or perform any of its obligations under or contemplated by the
Transaction Documents, in each case in accordance with the terms hereof or
thereof, other than: (i) the filing of a Form D pursuant to Regulation D, (ii)
the filing, if required, of any notice with any state whose laws require such
filing, (iii) the qualification of the Common Stock, if required, under other
applicable state laws, and (iv) the listing of the Common Shares and the
Additional Investment Right Shares on the Principal Market. All consents,
authorizations, orders, filings and registrations which the Company is required
to obtain pursuant to the preceding sentence have been obtained or effected on
or prior to the Closing Date. The Company and its Subsidiaries are unaware of
any facts or circumstances that might prevent the Company from obtaining or
effecting any of the registration, application or filings pursuant to the
preceding sentence. The Company is not in violation of the listing requirements
of the Principal Market and has no knowledge of any facts that would reasonably
lead to delisting or suspension of the Common Stock in the foreseeable future.

                           f. Acknowledgment Regarding Buyer's Purchase of
Securities. The Company acknowledges and agrees that each Buyer, other than any
affiliate of the Placement Agent, is acting solely in the capacity of arm's
length purchaser with respect to the Transaction Documents and the transactions
contemplated hereby and thereby and that no Buyer is: (i) an officer or director
of the Company, (ii) an "affiliate" of the Company (as defined in Rule 144), or
(iii) to the knowledge of the Company, a "beneficial owner" of more than 10% of
the Common Stock (as defined for purposes of Rule 13d-3 of the Securities
Exchange Act of 1934, as amended (the "1934 ACT")). The Company further
acknowledges that no Buyer is acting as a

                                       7

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated hereby
and thereby, and any advice given by a Buyer or any of its representatives or
agents in connection with the Transaction Documents and the transactions
contemplated hereby and thereby is merely incidental to such Buyer's purchase of
the Securities. The Company further represents to each Buyer that the Company's
decision to enter into the Transaction Documents has been based solely on the
independent evaluation by the Company and its representatives.

                           g. No General Solicitation; Placement Agent. Neither
the Company, nor any of its affiliates, nor any Person acting on its or their
behalf, has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D) in connection with the offer or sale of the
Securities. The Company acknowledges that it has engaged Sunrise Securities
Corp. as placement agent (the "PLACEMENT AGENT") in connection with the sale of
the Securities. Other than the Placement Agent, the Company has not engaged any
placement agent or other agent in connection with the sale of the Securities.

                           h. No Integrated Offering. None of the Company, its
Subsidiaries, any of their affiliates, and any Person acting on their behalf
has, directly or indirectly, made any offers or sales of any security or
solicited any offers to buy any security, under circumstances that would require
registration of any of the Securities under the 1933 Act or cause this offering
of the Securities to be integrated with prior offerings by the Company for
purposes of the 1933 Act or any applicable stockholder approval provisions,
including, without limitation, under the rules and regulations of any exchange
or automated quotation system on which any of the securities of the Company are
listed or designated. None of the Company, its Subsidiaries, their affiliates
and any Person acting on their behalf will take any action or steps referred to
in the preceding sentence that would require registration of any of the
Securities under the 1933 Act or cause the offering of the Securities to be
integrated with other offerings.

                           i. Application of Takeover Protections. The Company
and its board of directors have taken all necessary action, if any, in order to
render inapplicable any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Certificate of Incorporation or the laws of
the state of its incorporation which is or could become applicable to any Buyer
as a result of the transactions contemplated by this Agreement, including,
without limitation, the Company's issuance of the Securities and any Buyer's
ownership of the Securities.

                           j. SEC Documents; Financial Statements. Since January
1, 2001, the Company has timely filed all reports, schedules, forms, statements
and other documents required to be filed by it with the SEC pursuant to the
reporting requirements of the 1934 Act (all of the foregoing filed prior to the
date hereof or prior to the date of the Closing, and all exhibits included
therein and financial statements and schedules thereto and documents
incorporated by reference therein being hereinafter referred to as the "SEC
DOCUMENTS"). The Company has delivered to the Buyers or their respective
representatives true, correct and complete copies of the SEC Documents not
available on the EDGAR system except for redactions pursuant to confidential
treatment applications. As of their respective dates, the SEC Documents complied
in all material respects with the requirements of the 1934 Act and the rules and
regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC

                                       8

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

Documents, at the time they were filed with the SEC, contained any untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. As of
their respective dates, the financial statements of the Company included in the
SEC Documents complied as to form in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC with
respect thereto. Such financial statements have been prepared in accordance with
generally accepted accounting principles, consistently applied, during the
periods involved (except (i) as may be otherwise indicated in such financial
statements or the notes thereto, or (ii) in the case of unaudited interim
statements, to the extent they may exclude footnotes or may be condensed or
summary statements) and fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of its
operations and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal year-end audit adjustments). After giving effect
to the 8-K Filing (as defined in Section 4(i) below), no other information
provided by or on behalf of the Company to the Buyers which is not included in
the SEC Documents, including, without limitation, information referred to in
Section 2(d) of this Agreement, contains any untrue statement of a material fact
or omits to state any material fact necessary in order to make the statements
therein, in the light of the circumstance under which they are or were made, not
misleading.

                           k. Absence of Certain Changes. Since January 1, 2003,
except as disclosed in Schedule 3(l), there has been no material adverse change
and no material adverse development in the business, properties, operations,
condition (financial or otherwise), results of operations or prospects of the
Company or its Subsidiaries. Since January 1, 2003, the Company has not: (i)
declared or paid any dividends, (ii) sold any assets, individually or in the
aggregate, in excess of $250,000 outside of the ordinary course of business, or
(iii) had capital expenditures, individually or in the aggregate, in excess of
$1,000,000. The Company has not taken any steps to seek protection pursuant to
any bankruptcy law nor does the Company have any knowledge or reason to believe
that its creditors intend to initiate involuntary bankruptcy proceedings or any
actual knowledge of any fact which would reasonably lead a creditor to do so.
The Company is not as of the date hereof, and after giving effect to the
transactions contemplated hereby to occur at the Closing, will not be Insolvent
(as defined below). For purposes of this Section 3(k), "INSOLVENT" means: (i)
the present fair saleable value of the Company's assets is less than the amount
required to pay the Company's total Indebtedness (as defined in Section 3(r)
below), (ii) the Company is unable to pay its debts and liabilities,
subordinated, contingent or otherwise, as such debts and liabilities become
absolute and matured, (iii) the Company intends to incur or believes that it
will incur debts that would be beyond its ability to pay as such debts mature,
or (iv) the Company has unreasonably small capital with which to conduct the
business in which it is engaged as such business is now conducted and is
proposed to be conducted.

                           l. No Undisclosed Events, Liabilities, Developments
or Circumstances. No event, liability, development or circumstance has occurred
or exists, or is contemplated to occur, with respect to the Company or its
Subsidiaries or their respective business, properties, prospects, operations or
financial condition, that would be required to be disclosed by the Company under
applicable securities laws on a registration statement on Form S-1 filed with
the SEC relating to an issuance and sale by the Company of its Common Stock and
which has not been publicly announced.

                                       9

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           m. Conduct of Business; Regulatory Permits. Neither
the Company nor its Subsidiaries is in violation of any term of or in default
under the Certificate of Incorporation or Bylaws or their organizational charter
or bylaws, respectively. Neither the Company nor any Subsidiary is in violation
of any judgment, decree or order or any statute, ordinance, rule or regulation
applicable to the Company or its Subsidiaries, and neither the Company nor any
of its Subsidiaries will conduct its business in violation of any of the
foregoing, except for possible violations which would not, individually or in
the aggregate, have a Material Adverse Effect. Without limiting the generality
of the foregoing, the Company is not in violation of any of the rules,
regulations or requirements of the Principal Market and has no knowledge of any
facts or circumstances that would reasonably lead to delisting or suspension of
the Common Stock by the Principal Market in the foreseeable future. Since
January 1, 2003: (i) the Common Stock has been designated for quotation or
listed on the Principal Market, (ii) trading in the Common Stock has not been
suspended by the SEC or the Principal Market and (iii) the Company has received
no communication, written or oral, from the SEC or the Principal Market
regarding the suspension or delisting of the Common Stock from the Principal
Market. The Company and its Subsidiaries possess all certificates,
authorizations and permits issued by the appropriate federal, state or foreign
regulatory authorities necessary to conduct their respective businesses, except
where the failure to possess such certificates, authorizations or permits would
not have, individually or in the aggregate, a Material Adverse Effect, and
neither the Company nor any such Subsidiary has received any notice of
proceedings relating to the revocation or modification of any such certificate,
authorization or permit.

                           n. Foreign Corrupt Practices. Neither the Company,
nor any of its Subsidiaries, nor, to the knowledge of the Company, any director,
officer, agent, employee or other Person acting on behalf of the Company or any
of its Subsidiaries has, in the course of its actions for, or on behalf of, the
Company: (i) used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expenses relating to political activity; (ii)
made any direct or indirect unlawful payment to any foreign or domestic
government official or employee from corporate funds; (iii) violated or is in
violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as
amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment,
kickback or other unlawful payment to any foreign or domestic government
official or employee.

                           o. Sarbanes-Oxley Act. The Company is in compliance
with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that
are effective as of the date hereof, and any and all applicable rules and
regulations promulgated by the SEC thereunder that are effective as of the date
hereof, except where such noncompliance would not have, individually or in the
aggregate, a Material Adverse Effect.

                           p. Transactions With Affiliates. Except as set forth
in the Company's Annual Report on Form 10-K for the year ended December 31,
2002, none of the officers, directors or employees of the Company is presently a
party to any transaction with the Company or any of its Subsidiaries (other than
for ordinary course services as employees, officers or directors), including any
contract, agreement or other arrangement providing for the furnishing of
services to or by, providing for rental of real or personal property to or from,
or otherwise requiring payments to or from any such officer, director or
employee or, to the knowledge of the

                                       10

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

Company, any corporation, partnership, trust or other entity in which any such
officer, director, or employee has a substantial interest or is an officer,
director, trustee or partner.

                           q. Equity Capitalization. As of the date hereof, the
authorized capital stock of the Company consists of: (i) 100,000,000 shares of
capital stock, 40,000,000 of which are of Common Stock, of which as of the date
hereof, 14,001,372 shares are issued and outstanding, prior to any option grant
on February 26, 2004, 2,709,825 shares are subject to issuance pursuant to the
Company's employee incentive plan and other warrants outstanding exercisable or
exchangeable for, or convertible into, shares of Common Stock, and (ii)
60,000,000 shares of capital stock, with terms and provisions to be determined,
of which as of the date hereof, none are issued and outstanding. All of such
outstanding shares of Common Stock have been, or upon issuance will be, validly
issued and are fully paid and nonassessable. Except as set forth on Schedule
3(q): (A) no shares of the Company's capital stock are subject to preemptive
rights or any other similar rights or any liens or encumbrances suffered or
permitted by the Company; (B) there are no outstanding options, warrants, scrip,
rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, or exercisable or
exchangeable for, any shares of capital stock of the Company or any of its
Subsidiaries, or contracts, commitments, understandings or arrangements by which
the Company or any of its Subsidiaries is or may become bound to issue
additional shares of capital stock of the Company or any of its Subsidiaries or
options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, or
exercisable or exchangeable for, any shares of capital stock of the Company or
any of its Subsidiaries; (C) there are no outstanding debt securities, notes,
credit agreements, credit facilities or other agreements, documents or
instruments evidencing Indebtedness (as defined in Section 3(r)) of the Company
or any of its Subsidiaries or by which the Company or any of its Subsidiaries is
or may become bound; (D) there are no financing statements securing obligations
in any material amounts, either singly or in the aggregate, filed in connection
with the Company; (E) there are no agreements or arrangements under which the
Company or any of its Subsidiaries is obligated to register the sale of any of
their securities under the 1933 Act (except the Registration Rights Agreement);
(F) there are no outstanding securities or instruments of the Company or any of
its Subsidiaries which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the
Company or any of its Subsidiaries is or may become bound to redeem a security
of the Company or any of its Subsidiaries; (G) there are no securities or
instruments containing anti-dilution or similar provisions that will be
triggered by the issuance of the Securities; (H) the Company does not have any
stock appreciation rights or "phantom stock" plans or agreements or any similar
plan or agreement; and (I) the Company and its Subsidiaries have no liabilities
or obligations required to be disclosed in the SEC Documents but not so
disclosed in the SEC Documents, other than those incurred in the ordinary course
of the Company's or any Subsidiary's respective businesses and which,
individually or in the aggregate, do not or would not have a Material Adverse
Effect. The Company has furnished or made available to the Buyer true, correct
and complete copies of the Company's Certificate of Incorporation, as amended
and as in effect on the date hereof (the "CERTIFICATE OF INCORPORATION"), and
the Company's Bylaws, as amended and as in effect on the date hereof (the
"BYLAWS"), and the terms of all securities convertible into, or exercisable or
exchangeable for, Common Stock and the material rights of the holders thereof in
respect thereto.

                                       11

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           r. Indebtedness and Other Contracts. Except as
disclosed in Schedule 3(r), neither the Company nor any of its Subsidiaries: (i)
has any outstanding Indebtedness (as defined below), or (ii) is in violation of
any term of or in default under any contract, agreement or instrument relating
to any Indebtedness, except where such violations and defaults would not result,
individually or in the aggregate, in a Material Adverse Effect, or (iii) is a
party to any contract, agreement or instrument relating to any Indebtedness, the
performance of which, in the judgment of the Company's officers, has or is
expected to have a Material Adverse Effect. Schedule 3(r) provides a detailed
description of the material terms of any such outstanding Indebtedness, none of
which is secured. The SEC Documents set forth each of the Company's "material
contracts," as such term is used in Item 601 of Regulation S-K promulgated by
the SEC. For purposes of this Agreement: (A) "INDEBTEDNESS" of any Person means,
without duplication (1) all indebtedness for borrowed money, (2) all obligations
issued, undertaken or assumed as the deferred purchase price of property or
services (other than trade payables entered into in the ordinary course of
business), (3) all reimbursement or payment obligations with respect to letters
of credit, surety bonds and other similar instruments, (4) all obligations
evidenced by notes, bonds, debentures or similar instruments, including
obligations so evidenced incurred in connection with the acquisition of
property, assets or businesses, (5) all indebtedness created or arising under
any conditional sale or other title retention agreement, or incurred as
financing, in either case with respect to any property or assets acquired with
the proceeds of such indebtedness (even though the rights and remedies of the
seller or bank under such agreement in the event of default are limited to
repossession or sale of such property), (6) all monetary obligations under any
leasing or similar arrangement which, in connection with generally accepted
accounting principles, consistently applied for the periods covered thereby, is
classified as a capital lease, (7) all indebtedness referred to in clauses (1)
through (6) above secured by (or for which the holder of such Indebtedness has
an existing right, contingent or otherwise, to be secured by) any mortgage,
lien, pledge, charge, security interest or other encumbrance upon or in any
property or assets (including accounts and contract rights) owned by any Person,
even though the Person which owns such assets or property has not assumed or
become liable for the payment of such indebtedness, and (8) all Contingent
Obligations in respect of indebtedness or obligations of others of the kinds
referred to in clauses (1) through (7) above; (B) "CONTINGENT OBLIGATION" means,
as to any Person, any direct or indirect liability, contingent or otherwise, of
that Person with respect to any indebtedness, lease, dividend or other
obligation of another Person if the primary purpose or intent of the Person
incurring such liability, or the primary effect thereof, is to provide assurance
to the obligee of such liability that such liability will be paid or discharged,
or that any agreements relating thereto will be complied with, or that the
holders of such liability will be protected (in whole or in part) against loss
with respect thereto; and (C) "PERSON" means an individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization and a government or any department or agency
thereof.

                           s. Absence of Litigation. Except as set forth on
Schedule 3(s), there is no action, suit, proceeding, inquiry or investigation
before or by the Principal Market, any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the
Company, threatened against or affecting the Company, the Common Stock or any of
its Subsidiaries or any of the Company's or the Company's Subsidiary's officers
or directors in their capacities as such.

                                       12

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           t. Insurance. The Company and each of its
Subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as management of the Company
believes to be prudent and customary in the businesses in which the Company and
its Subsidiaries are engaged. Neither the Company nor any Subsidiary has been
refused any insurance coverage sought or applied for and neither the Company nor
any Subsidiary has any reason to believe that it will not be able to renew its
existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its
business at a cost that would not have a Material Adverse Effect.

                           u. Employee Relations.

                           (i)      Neither the Company nor any of its
Subsidiaries is a party to any collective bargaining agreement or employs any
member of a union. The Company and its Subsidiaries believe that their relations
with their employees are good. No executive officer of the Company (as defined
in Rule 501(f) of the 1933 Act) has notified the Company that such officer
intends to leave the Company or otherwise terminate such officer's employment
with the Company. No executive officer of the Company, to the knowledge of the
Company, is, or is now expected to be, in violation of any material term of any
employment contract, confidentiality, disclosure or proprietary information
agreement, non-competition agreement, or any other contract or agreement or any
restrictive covenant, and the continued employment of each such executive
officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters.

                           (ii)     The Company and its Subsidiaries, to its
knowledge, are in compliance with all federal, state, local and foreign laws and
regulations respecting employment and employment practices, terms and conditions
of employment and wages and hours, except where failure to be in compliance
would not, either individually or in the aggregate, reasonably be expected to
result in a Material Adverse Effect.

                           v. Title. The Company and its Subsidiaries do not own
any real property. The Company and its Subsidiaries have good and marketable
title to all personal property owned by them which is material to the business
of the Company and its Subsidiaries, in each case free and clear of all liens,
encumbrances and defects except such as do not interfere with the use made and
proposed to be made of such property by the Company and any of its Subsidiaries.
Any real property and facilities held under lease by the Company and any of its
Subsidiaries are held by them under valid, subsisting and enforceable leases
with such exceptions as are not material and do not interfere with the use made
and proposed to be made of such property and buildings by the Company and its
Subsidiaries.

                           w. Intellectual Property Rights. The Company and its
Subsidiaries own or possess adequate rights or licenses to use all trademarks,
trade names, service marks, service mark registrations, service names, patents,
patent rights, copyrights, inventions, licenses, approvals, governmental
authorizations, trade secrets and other intellectual property rights
("INTELLECTUAL PROPERTY RIGHTS") necessary to conduct their respective
businesses as now conducted. Except as set forth in the SEC Documents, none of
the Company's Intellectual Property Rights have expired or terminated, or are
expected to expire or terminate within three

                                       13

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

years from the date of this Agreement. The Company does not have any knowledge
of any infringement by the Company or its Subsidiaries of Intellectual Property
Rights of others. Except as set forth in the SEC Documents and on Schedule 3(w),
there is no claim, action or proceeding being made or brought, or to the
knowledge of the Company, being threatened, against the Company or any of its
Subsidiaries regarding its Intellectual Property Rights. Except as set forth on
Schedule 3(s), the Company is unaware of any facts or circumstances which might
give rise to any of the foregoing infringements or claims, actions or
proceedings. The Company and its Subsidiaries have taken reasonable security
measures to protect the secrecy, confidentiality and value of all of their
Intellectual Property Rights.

                           x. Environmental Laws. To the knowledge of the
Company, the Company and its Subsidiaries: (i) are in compliance with any and
all Environmental Laws (as hereinafter defined), (ii) have received all permits,
licenses or other approvals required of them under applicable Environmental Laws
to conduct their respective businesses, and (iii) are in compliance with all
terms and conditions of any such permit, license or approval where, in each of
the foregoing clauses (i), (ii) and (iii), the failure to so comply could be
reasonably expected to have, individually or in the aggregate, a Material
Adverse Effect. The term "ENVIRONMENTAL LAWS" means all federal, state, local or
foreign laws relating to pollution or protection of human health or the
environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata), including, without limitation,
laws relating to emissions, discharges, releases or threatened releases of
chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes
(collectively, "HAZARDOUS MATERIALS") into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage,
disposal, transport or handling of Hazardous Materials, as well as all
authorizations, codes, decrees, demands or demand letters, injunctions,
judgments, licenses, notices or notice letters, orders, permits, plans or
regulations issued, entered, promulgated or approved thereunder.

                           y. Subsidiary Rights. The Company has the
unrestricted right to vote, and (subject to limitations imposed by applicable
law) to receive dividends and distributions on, all capital securities of its
Subsidiaries.

                           z. Tax Status. The Company and each of its
Subsidiaries (i) has made or filed all federal and state income and all other
tax returns, reports and declarations required by any jurisdiction to which it
is subject, (ii) has paid all taxes and other governmental assessments and
charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith
and (iii) has set aside on its books provision reasonably adequate for the
payment of all taxes for periods subsequent to the periods to which such
returns, reports or declarations apply. To the knowledge of the Company, there
are no unpaid taxes in any material amount claimed to be due by the taxing
authority of any jurisdiction, and the officers of the Company know of no basis
for any such claim.

                           aa.      Internal Accounting and Disclosure Controls.
The Company and each of its Subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurance that: (i)
transactions are executed in accordance with management's general or specific
authorizations, (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset and liability accountability, (iii)
access to assets or incurrence of liabilities is permitted only

                                       14

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

in accordance with management's general or specific authorization, and (iv) the
recorded accountability for assets and liabilities is compared with the existing
assets and liabilities at reasonable intervals and appropriate action is taken
with respect to any difference. The Company maintains disclosure controls and
procedures (as such term is defined in Rule 13a-14 under the 1934 Act) that are
effective in ensuring that information required to be disclosed by the Company
in the reports that it files or submits under the 1934 Act is recorded,
processed, summarized and reported, within the time periods specified in the
rules and forms of the SEC, including, without limitation, controls and
procedures designed in to ensure that information required to be disclosed by
the Company in the reports that it files or submits under the 1934 Act is
accumulated and communicated to the Company's management, including its
principal executive officer or officers and its principal financial officer or
officers, as appropriate, to allow timely decisions regarding required
disclosure.

                           bb.      Disclosure. The Company confirms that
neither it nor any other Person acting on its behalf has provided any of the
Buyers or their respective agents or counsel with any information that
constitutes or might constitute material, nonpublic information other than with
respect to this Agreement. The Company understands and confirms that each of the
Buyers will rely on the foregoing representations in effecting transactions in
securities of the Company. All disclosure provided to the Buyers regarding the
Company, its business and the transactions contemplated hereby, including the
Schedules to this Agreement, furnished by or on behalf of the Company are true
and correct and do not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not
misleading. No event or circumstance has occurred or information exists with
respect to the Company or any Subsidiary or either of its or their respective
business, properties, prospects, operations or financial conditions, which,
under applicable law, rule or regulation, requires public disclosure or
announcement by the Company but which has not been so publicly announced or
disclosed (assuming for this purpose that the Company's reports filed under the
Exchange Act of 1934, as amended, are being incorporated into an effective
registration statement filed by the Company under the 1933 Act). The Company
acknowledges and agrees that no Buyer makes or has made any representations or
warranties with respect to the transactions contemplated hereby other than those
specifically set forth in Section 2.

                  4. COVENANTS.

                           a. Best Efforts. Each party shall use its best
efforts timely to satisfy each of the covenants and the conditions to be
satisfied by it as provided in Sections 5, 6 and 7 of this Agreement.

                           b. Form D and Blue Sky. The Company agrees to file a
Form D with respect to the Securities as required under Regulation D and to
provide a copy thereof to each Buyer promptly after such filing. The Company, on
or before the Closing Date, shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for or to
qualify the Securities for sale to the Buyers at the Closing pursuant to this
Agreement under applicable securities or "Blue Sky" laws of the states of the
United States (or to obtain an exemption from such qualification), and shall
provide evidence of any such action so taken to the Buyers on or prior to the
Closing Date. The Company shall make all filings and reports relating

                                       15

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

to the offer and sale of the Securities required under applicable securities or
"Blue Sky" laws of the states of the United States following the Closing Date.

                           c. Reporting Status. Until the date on which the
Investors (as defined in the Registration Rights Agreement) shall have sold all
the Common Shares and Additional Investment Right Shares and none of the
Additional Investment Rights is outstanding (the "REPORTING PERIOD"), the
Company shall timely file all reports required to be filed with the SEC pursuant
to the 1934 Act, and the Company shall not terminate its status as an issuer
required to file reports under the 1934 Act even if the 1934 Act or the rules
and regulations thereunder would otherwise permit such termination.

                           d. Use of Proceeds. The Company will use the proceeds
from the sale of the Securities to expand its sales force, for possible product
acquisitions and for general working capital purposes, including research and
development opportunities, and not for the redemption or repurchase of any of
its equity securities.

                           e. Financial Information. The Company agrees to send
the following to each Investor during the Reporting Period: (i) unless the
following are filed with the SEC through EDGAR and are available to the public
through the EDGAR system: (A) within one (1) Business Day after the filing
thereof with the SEC, a copy of its Annual Reports on Form 10-K, its Quarterly
Reports on Form 10-Q, any Current Reports on Form 8-K and any registration
statements (other than on Form S-8) or amendments filed pursuant to the 1933
Act, and (B) on the same day as the release thereof, facsimile copies of all
press releases issued by the Company or any of its Subsidiaries, and (ii) copies
of any notices and other information made available or given to the shareholders
of the Company generally, contemporaneously with the making available or giving
thereof to the shareholders. As used herein, "BUSINESS DAY" means any day other
than Saturday, Sunday or other day on which commercial banks in The City of New
York are authorized or required by law to remain closed.

                           f. Listing. The Company shall promptly secure the
listing of all of the Registrable Securities (as defined in the Registration
Rights Agreement) upon each national securities exchange and automated quotation
system, if any, upon which shares of Common Stock are then listed (subject to
official notice of issuance) and shall maintain, so long as any other shares of
Common Stock shall be so listed, such listing of all Registrable Securities from
time to time issuable under the terms of the Transaction Documents. The Company
shall maintain the Common Stock's authorization for listing on the Principal
Market. Neither the Company nor any of its Subsidiaries shall take any action
which would be reasonably expected to result in the delisting or suspension of
the Common Stock on the Principal Market. The Company shall pay all fees and
expenses in connection with satisfying its obligations under this Section 4(f).

                           g. Fees. At the Closing, the Company shall pay an
expense allowance of $25,000 to Smithfield Fiduciary LLC (a Buyer) or its
designee(s), which amount shall be withheld by such Buyer from its Purchase
Price at the Closing. The Company shall be responsible for the payment of the
Placement Agent's fees. The Company shall pay, and hold each Buyer harmless
against, any liability, loss or expense (including, without limitation,
reasonable attorney's fees and out-of-pocket expenses) arising in connection
with any claim

                                       16

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

relating to any such payment. Except as otherwise set forth in this Agreement or
in the Transaction Documents, each party to this Agreement shall bear its own
expenses in connection with the sale of the Securities to the Buyers.

                           h. Pledge of the Securities. The Company acknowledges
and agrees that the Securities may be pledged by an Investor (as defined in the
Registration Rights Agreement) in connection with a bona fide margin agreement
or other loan or financing arrangement that is secured by the Securities. The
pledge of Securities shall not be deemed to be a transfer, sale or assignment of
the Securities hereunder, and no Investor effecting a pledge of Securities shall
be required to provide the Company with any notice thereof or otherwise make any
delivery to the Company pursuant to this Agreement or any other Transaction
Document, including, without limitation, Section 2(f) of this Agreement;
provided that an Investor and its pledgee shall be required to comply with the
provisions of Section 2(f) of this Agreement in order to effect a sale, transfer
or assignment of Securities to such pledgee. The Company hereby agrees to
execute and deliver such documentation as a pledgee of any Securities may
reasonably request in connection with a pledge of any Securities to such pledgee
by an Investor.

                           i. Disclosure of Transactions and Other Material
Information. The Company shall, on or before 8:30 a.m., New York City Time, on
the date hereof, issue a press release reasonably acceptable to the Buyers
disclosing all material terms of the transactions contemplated hereby. On or
before 8:30 a.m., New York City Time, on the second Business Day following the
date of execution of this Agreement by all parties, the Company shall file a
Current Report on Form 8-K describing the terms of the transactions contemplated
by the Transaction Documents in the form required by the 1934 Act, and attaching
the material Transaction Documents (including, without limitation, this
Agreement (and all schedules to this Agreement), the form of Additional
Investment Right and the Registration Rights Agreement) as exhibits to such
filing (such filing including all attachments, the "8-K FILING"). The Company
shall not, and shall cause each of its Subsidiaries and each of their respective
officers, directors, employees and agents, not to, provide any Buyer with any
material, nonpublic information regarding the Company or any of its Subsidiaries
from and after the filing of the press release referred to in the first sentence
of this Section without the express written consent of such Buyer. Subject to
the foregoing, neither the Company nor any Buyer shall issue any press releases
or any other public statements with respect to the transactions contemplated
hereby; provided, however, that the Company shall be entitled, without the prior
approval of any Buyer, to make any press release or other public disclosure with
respect to such transactions: (i) in substantial conformity with the 8-K Filing
and contemporaneously therewith, and (ii) as is required by applicable law and
regulations, including the applicable rules and regulations of the Principal
Market (provided that in the case of clause (i) Legal Counsel (as defined in the
Registration Rights Agreement) shall be consulted by the Company in connection
with any such press release or other public disclosure prior to its release).

                           j. Additional Registration Statements. Until the date
that the Registration Statement (as defined in the Registration Rights
Agreement) is first declared effective by the SEC (the "EFFECTIVE DATE"), the
Company will not file a registration statement under the 1933 Act relating to
securities that are not the Securities other than in connection with an Approved
Stock Plan.

                                       17

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           k. Reservation of Shares. The Company shall take all
action necessary to at all times have authorized, and reserved for the purpose
of issuance, from and after the Closing Date, the number of shares of Common
Stock issuable upon exercise of the Additional Investment Rights being issued at
the Closing in conformity with Section 3(c).

                           l. Additional Issuances of Securities.

                           (i)      For purposes of this Section 4(l), the
following definitions shall apply.

                                    (1) "APPROVED STOCK PLAN" means any employee
benefit plan or other stock option agreement which has been approved by the
board of directors of the Company, pursuant to which the Company's securities
may be issued to any employee, officer, director or consultant for services
provided to the Company or any of its Subsidiaries, or pursuant to the exercise
of any securities of the Company issued thereunder.

                                    (2) "COMMON STOCK EQUIVALENTS" means,
collectively, Options and Convertible Securities.

                                    (3) "CONVERTIBLE SECURITIES" means any stock
or securities (other than Options) convertible into or exercisable or
exchangeable for Common Stock.

                                    (4) "OPTIONS" means any rights, warrants or
options to subscribe for or purchase Common Stock or Convertible Securities.

                                    (5) "TRADING DAY" means any day on which the
         Common Stock is traded on the Principal Market, or, if the Principal
         Market is not the principal trading market for the Common Stock, then
         on the principal securities exchange or securities market on which the
         Common Stock is then traded; provided that "Trading Day" shall not
         include any day on which the Common Stock is scheduled to trade on such
         exchange or market for less than 4.5 hours or any day that the Common
         Stock is suspended from trading during the final hour of trading on
         such exchange or market (or if such exchange or market does not
         designate in advance the closing time of trading on such exchange or
         market, then during the hour ending at 4:00 p.m., New York City Time).

                           (ii)     From the date hereof until the date that is
30 Trading Days following the Effective Date, other than in connection with an
Approved Stock Plan, the Company will not, directly or indirectly, offer, sell,
grant any option to purchase, or otherwise dispose of (or announce any offer,
sale, grant or any option to purchase or other disposition of) any of its or its
Subsidiaries' equity or equity equivalent securities, including without
limitation any debt, preferred stock or other instrument or security that is, at
any time during its life and under any circumstances, convertible into or
exchangeable or exercisable for Common Stock or Common Stock Equivalents.

                                       18

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                  5. TRANSFER RESTRICTIONS; TRANSFER AGENT INSTRUCTIONS.

                           a. Transfer Restrictions. The legend set forth in
Section 2(g) shall be removed and the Company shall issue a certificate without
such legend or any other similar legend to the holder of the applicable
Securities upon which it is stamped, if: (i) such Securities are registered for
resale under the 1933 Act, (ii) in connection with a sale, assignment or other
transfer, such holder provides the Company with an opinion of counsel, in a form
reasonably acceptable to the Company, to the effect that such sale, assignment
or transfer of such Securities may be made without registration under the
applicable requirements of the 1933 Act, or (iii) such holder provides the
Company with reasonable assurance that such Securities can be sold, assigned or
transferred pursuant to Rule 144. The Company shall cause Company Counsel (as
defined below) to issue the legal opinion included as Exhibit A to the
Registration Rights Agreement to the Company's transfer agent on the Effective
Date. Following the Effective Date or at such earlier time as a legend is no
longer required for certain Securities, the Company will no later than three
Business Days following the delivery by a Buyer to the Company or the Company's
transfer agent of a legended certificate representing such Securities, deliver
or cause to be delivered to such Buyer a certificate representing such
Securities that is free from all restrictive legends. Following the Effective
Date and upon the delivery to any Buyer of any certificate representing
Securities that is free from all restrictive and other legends, such Buyer
agrees that any sale of such Securities shall be made pursuant to the
Registration Statement and in accordance with the plan of distribution described
therein or pursuant to an available exemption from the registration requirements
of the 1933 Act. The Company may not make any notation on its records or give
instructions to any transfer agent of the Company that enlarge the restrictions
on transfer set forth in Section 2(g). The Company will not effect or publicly
announce its intention to effect any exchange, recapitalization or other
transaction that effectively requires or rewards physical delivery of
certificates evidencing the Common Stock.

                           b. Transfer Agent Instructions. The Company shall
issue irrevocable instructions to its transfer agent, and any subsequent
transfer agent, to issue certificates or credit shares to the applicable balance
accounts at The Depository Trust Company ("DTC"), registered in the name of each
Buyer or its respective nominee(s), for the Additional Investment Right Shares
in such amounts as specified from time to time by each Buyer to the Company upon
exercise of the Additional Investment Rights in the form of Exhibit D attached
hereto (the "IRREVOCABLE TRANSFER AGENT INSTRUCTIONS"). The Company represents
and warrants that no instruction other than the Irrevocable Transfer Agent
Instructions referred to in this Section 5, and stop transfer instructions to
give effect to Section 2(f) hereof, will be given by the Company to its transfer
agent with respect to the Securities, and that the Securities shall otherwise be
freely transferable on the books and records of the Company as and to the extent
provided in this Agreement and the other Transaction Documents.

                           c. Breach. The Company acknowledges that a breach by
it of its obligations hereunder will cause irreparable harm to a Buyer.
Accordingly, the Company acknowledges that the remedy at law for a breach of its
obligations under this Section 5 will be inadequate and agrees, in the event of
a breach or threatened breach by the Company of the provisions of this Section
5, that a Buyer shall be entitled, in addition to all other available remedies,
to seek an order and/or injunction restraining any breach and requiring
immediate

                                       19

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

issuance and transfer, without the necessity of showing economic loss and
without any bond or other security being required.

                  6. CONDITIONS TO THE COMPANY'S OBLIGATION TO SELL.

                           The obligation of the Company hereunder to issue and
sell the Common Shares and the related Additional Investment Rights to each
Buyer at the Closing is subject to the satisfaction, at or before the Closing
Date, of each of the following conditions, provided that these conditions are
for the Company's sole benefit and may be waived by the Company at any time in
its sole discretion by providing each Buyer with prior written notice thereof:

                           (i)      Such Buyer shall have executed each of the
Transaction Documents to which it is a party and delivered the same to the
Company.

                           (ii)     Such Buyer shall have delivered to the
Company the Purchase Price for the Common Shares and the related Additional
Investment Rights being purchased by such Buyer at the Closing by wire transfer
of immediately available funds pursuant to the wire instructions provided by the
Company.

                           (iii)    The representations and warranties of such
Buyer shall be true and correct in all material respects as of the date when
made and as of the Closing Date as though made at that time (except for
representations and warranties that speak as of a specific date), and such Buyer
shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required by this Agreement to be performed,
satisfied or complied with by such Buyer at or prior to the Closing Date.

                  7. CONDITIONS TO EACH BUYER'S OBLIGATION TO PURCHASE.

                           The obligation of each Buyer hereunder to purchase
the Common Shares and the related Additional Investment Rights at the Closing is
subject to the satisfaction, at or before the Closing Date, of each of the
following conditions, provided that these conditions are for each Buyer's sole
benefit and may be waived by such Buyer at any time in its sole discretion by
providing the Company with prior written notice thereof:

                           (i)      The Company shall have executed and
delivered to such Buyer (i) each of the Transaction Documents and (ii) the
Common Shares (in such amounts as such Buyer shall request) and the related
Additional Investment Rights (in such amounts as such Buyer shall request) being
purchased by such Buyer at the Closing pursuant to this Agreement.

                           (ii)     Such Buyer shall have received the opinion
of Reed Smith, LLP, the Company's outside counsel ("COMPANY COUNSEL"), dated as
of the Closing Date, in substantially the form of Exhibit E attached hereto.

                           (iii)    The Company shall have delivered to such
Buyer a copy of the Irrevocable Transfer Agent Instructions, in the form of
Exhibit D attached hereto, which instructions shall have been delivered to and
acknowledged in writing by the Company's transfer agent.

                                       20

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           (iv)     The Company shall have delivered to such
Buyer a certificate evidencing the incorporation and good standing of the
Company and each of its Subsidiaries in such corporation's state of
incorporation issued by the Secretary of State of such state of incorporation as
of a date within 10 days of the Closing Date.

                           (v)      The Common Stock: (i) shall be listed on the
Principal Market and (ii) shall not have been suspended, as of the Closing Date,
by the SEC or the Principal Market from trading on the Principal Market nor
shall suspension by the SEC or the Principal Market have been threatened, as of
the Closing Date, either: (A) in writing by the SEC or the Principal Market, or
(B) by falling below the minimum listing maintenance requirements of the
Principal Market.

                           (vi)     The Company shall have delivered to such
Buyer a certified copy of the Certificate of Incorporation as certified by the
Secretary of State of the State of New Jersey within 10 days of the Closing
Date.

                           (vii)    The Company shall have delivered to such
Buyer a certificate, executed by the Secretary of the Company and dated as of
the Closing Date, as to (i) the resolutions consistent with Section 3(b) as
adopted by the Company's Board of Directors in a form reasonably acceptable to
such Buyer, (ii) the Certificate of Incorporation and (iii) the Bylaws, each as
in effect at the Closing, in the form attached hereto as Exhibit F.

                           (viii)   The representations and warranties of the
Company shall be true and correct as of the date when made and as of the Closing
Date as though made at that time (except for representations and warranties that
speak as of a specific date) and the Company shall have performed, satisfied and
complied in all material respects with the covenants, agreements and conditions
required by this Agreement to be performed, satisfied or complied with by the
Company at or prior to the Closing Date. Such Buyer shall have received a
certificate, executed by the Chief Executive Officer of the Company, dated as of
the Closing Date, to the foregoing effect and as to such other matters as may be
reasonably requested by such Buyer in the form attached hereto as Exhibit G.

                           (ix)     The Company shall have delivered to such
Buyer a letter from the Company's transfer agent certifying the number of shares
of Common Stock outstanding as of a date within 5 days of the Closing Date.

                           (x)      The Company shall have obtained all
governmental, regulatory or third party consents and approvals, if any,
necessary for the sale of the Common Shares and the Additional Investment
Rights.

                           (xi)     The Company shall have delivered to such
Buyer such other documents relating to the transactions contemplated by this
Agreement as such Buyer or its counsel may reasonably request.

                  8. TERMINATION. In the event that the Closing shall not have
occurred with respect to a Buyer on or before ten (10) days from the date hereof
due to the Company's or such Buyer's failure to satisfy the conditions set forth
in Sections 6 and 7 above (and the nonbreaching party's failure to waive such
unsatisfied condition(s)), the nonbreaching party shall have the

                                       21

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

option to terminate this Agreement with respect to such breaching party at the
close of business on such date without liability of any party to any other
party.

                  9. MISCELLANEOUS.

                           a. Governing Law; Jurisdiction; Jury Trial. All
questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New
York, without giving effect to any choice of law or conflict of law provision or
rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of
New York. Each party hereby irrevocably submits to the non-exclusive
jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such suit, action or proceeding is brought
in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by
mailing a copy thereof to such party at the address for such notices to it under
this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO
REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED
HEREBY.

                           b. Counterparts. This Agreement may be executed in
two or more identical counterparts, all of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party; provided that a facsimile signature
shall be considered due execution and shall be binding upon the signatory
thereto with the same force and effect as if the signature were an original, not
a facsimile signature.

                           c. Headings. The headings of this Agreement are for
convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.

                           d. Severability. If any provision of this Agreement
shall be invalid or unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement in that jurisdiction or the validity or
enforceability of any provision of this Agreement in any other jurisdiction.

                           e. Entire Agreement; Amendments. This Agreement
supersedes all other prior oral or written agreements between the Buyers, the
Company, their affiliates and Persons acting on their behalf with respect to the
matters discussed herein, and this Agreement and the instruments referenced
herein contain the entire understanding of the parties with respect to the
matters covered herein and therein and, except as specifically set forth herein
or therein, neither

                                       22

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

the Company nor any Buyer makes any representation, warranty, covenant or
undertaking with respect to such matters. No provision of this Agreement may be
amended other than by an instrument in writing signed by the Company and the
holders of Common Shares representing at least a majority of the amount of the
Common Shares, or, if prior to the Closing Date, the Buyers listed on the
Schedule of Buyers as being obligated to purchase at least a majority of the
amount of the Common Shares. No provision hereof may be waived other than by an
instrument in writing signed by the party against whom enforcement is sought. No
such amendment shall be effective to the extent that it applies to less than all
of the holders of the Common Shares then outstanding. No consideration shall be
offered or paid to any Person to amend or consent to a waiver or modification of
any provision of any of the Transaction Documents unless the same consideration
also is offered to all of the parties to the Transaction Documents, holders of
Common Shares or holders of the Additional Investment Rights, as the case may
be. The Company has not, directly or indirectly, made any agreements with any
Buyers relating to the terms or conditions of the transactions contemplated by
the Transaction Documents except as set forth in the Transaction Documents.

                           f. Notices. Any notices, consents, waivers or other
communications required or permitted to be given under the terms of this
Agreement must be in writing and will be deemed to have been delivered: (i) upon
receipt, when delivered personally; (ii) upon receipt, when sent by facsimile
(provided confirmation of transmission is mechanically or electronically
generated and kept on file by the sending party); or (iii) one Business Day
after deposit with an overnight courier service, in each case properly addressed
to the party to receive the same. The addresses and facsimile numbers for such
communications shall be:

                           If  to   the Company:

                           DUSA Pharmaceuticals, Inc.
                           25 Upton Drive
                           Wilmington, Massachusetts 01887
                           Telephone: (978) 657-7500
                           Facsimile: (978) 657-9193
                           Attention: President and CEO

                           with  a copy to:

                           Reed Smith LLP
                           Princeton Forrestal Village
                           136 Main Street
                           Princeton, New Jersey 08543
                           Telephone: (609) 514-8543
                           Facsimile: (609) 951-0824
                           Attention: Nanette W. Mantell, Esq.

                           If  to   the Transfer Agent:

                           American Stock Transfer and Trust
                           59 Maiden Lane

                                       23

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           New York, NY 10038
                           Telephone:       (212) 936-5100
                           Facsimile:       (718) 236-4588
                           Attention:       Donna Ansbro

If to a Buyer, to its address and facsimile number set forth on the Schedule of
Buyers, with copies to such Buyer's representatives as set forth on the Schedule
of Buyers, or to such other address and/or facsimile number and/or to the
attention of such other Person as the recipient party has specified by written
notice given to each other party 5 days prior to the effectiveness of such
change. Written confirmation of receipt: (A) given by the recipient of such
notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the sender's facsimile machine containing the time,
date, recipient facsimile number and an image of the first page of such
transmission, or (C) provided by an overnight courier service shall be
rebuttable evidence of personal service, receipt by facsimile or receipt from an
overnight courier service in accordance with clause (i), (ii) or (iii) above,
respectively.

                           g. Successors and Assigns. This Agreement shall be
binding upon and inure to the benefit of the parties and their respective
successors and assigns. Neither the Company, nor any Buyer, shall assign this
Agreement or any rights or obligations hereunder without the prior written
consent of: (i) in the case of the Company, the holders of Common Shares
representing at least a majority of the number of the Common Shares, and (ii) in
the case of any Buyer, the Company; provided, however, that a Buyer may assign
to an affiliate without any such consent.

                           h. No Third Party Beneficiaries. This Agreement is
intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision
hereof be enforced by, any other Person.

                           i. Survival. Unless this Agreement is terminated
under Section 8, the representations and warranties of the Company and the
Buyers contained in Sections 2 and 3, the agreements and covenants set forth in
Sections 4, 5 and 9 shall survive the Closing and the delivery and exercise of
Securities, as applicable. Each Buyer shall be responsible only for its own
representations, warranties, agreements and covenants hereunder.

                           j. Further Assurances. Each party shall do and
perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates,
instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the
consummation of the transactions contemplated hereby.

                           k. Indemnification. In consideration of each Buyer's
execution and delivery of this Agreement and acquiring the Securities hereunder
and in addition to any other obligations under the Transaction Documents, the
Company shall defend, protect, indemnify and hold harmless each Buyer and each
other holder of the Securities and all of their stockholders, partners, members,
officers, directors, employees and direct or indirect investors and any of the
foregoing Persons' agents or other representatives (including, without
limitation, those retained in connection with the transactions contemplated by
this Agreement) (collectively, the

                                       24

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

"INDEMNITEES") from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in
connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including
reasonable attorneys' fees and disbursements (the "INDEMNIFIED LIABILITIES"),
incurred by any Indemnitee as a result of, or arising out of, or relating to:
(i) any misrepresentation or breach of any representation or warranty made by
the Company in the Agreement or any other certificate, instrument or document
contemplated hereby, (ii) any breach of any covenant, agreement or obligation of
the Company contained in the Agreement or any other certificate, instrument or
document contemplated hereby, or (iii) any cause of action, suit or claim
brought or made against such Indemnitee by a third party (including for these
purposes a derivative action brought on behalf of the Company) and arising out
of or resulting from: (A) the execution, delivery, performance or enforcement of
the Agreement or any other certificate, instrument or document contemplated
hereby, (B) any transaction financed or to be financed in whole or in part,
directly or indirectly, with the proceeds of the issuance of the Securities, or
(C) the status of such Buyer or holder of the Securities as an investor in the
Company. To the extent that the foregoing undertaking by the Company may be
unenforceable for any reason, the Company shall make the maximum contribution to
the payment and satisfaction of each of the Indemnified Liabilities which is
permissible under applicable law. Except as otherwise set forth herein, the
mechanics and procedures with respect to the rights and obligations under this
Section 9(k) shall be the same as those set forth in Section 6 of the
Registration Rights Agreement.

                           l. No Strict Construction. The language used in this
Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against
any party.

                           m. Remedies. Each party to this Agreement shall have
all rights and remedies set forth herein. Any Person having any rights under any
provision of this Agreement shall be entitled to enforce such rights
specifically (without posting a bond or other security), to recover damages by
reason of any breach of any provision of this Agreement and to exercise all
other rights granted by law. Furthermore, the Company recognizes that in the
event that it fails to perform, observe, or discharge any or all of its
obligations under the Transaction Documents, any remedy at law may prove to be
inadequate relief to the Buyers. The Company therefore agrees that the Buyers
shall be entitled to seek temporary and permanent injunctive relief in any such
case without the necessity of proving actual damages and without posting a bond
or other security.

                           n. Rescission and Withdrawal Right. Notwithstanding
anything to the contrary contained in (and without limiting any similar
provisions of) the Transaction Documents, whenever any Buyer exercises a right,
election, demand or option under a Transaction Document and the Company does not
timely perform its related obligations within the periods therein provided, then
such Buyer may rescind or withdraw, in its sole discretion from time to time
upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights.

                           o. Payment Set Aside. To the extent that the Company
makes a payment or payments to the Buyers hereunder or pursuant to any of the
other Transaction Documents or

                                       25

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

the Buyers enforce or exercise their rights hereunder or thereunder, and such
payment or payments or the proceeds of such enforcement or exercise or any part
thereof are subsequently invalidated, declared to be fraudulent or preferential,
set aside, recovered from, disgorged by or are required to be refunded, repaid
or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the extent of any
such restoration the obligation or part thereof originally intended to be
satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.

                           p. Independent Nature of Buyers' Obligations and
Rights. The obligations of each Buyer under any Transaction Document are several
and not joint with the obligations of any other Buyer, and no Buyer shall be
responsible in any way for the performance of the obligations of any other Buyer
under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Buyer pursuant hereto or
thereto, shall be deemed to constitute the Buyers as a partnership, an
association, a joint venture or any other kind of entity, or create a
presumption that the Buyers are in any way acting in concert or as a group with
respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Buyer confirms that it has independently participated in the
negotiation of the transaction contemplated hereby with the advice of its own
counsel and advisors. Each Buyer shall be entitled to independently protect and
enforce its rights, including, without limitation, the rights arising out of
this Agreement or out of any other Transaction Documents, and it shall not be
necessary for any other Buyer to be joined as an additional party in any
proceeding for such purpose.

                            [SIGNATURE PAGE FOLLOWS]

                                       26

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

COMPANY:

DUSA PHARMACEUTICALS, INC.

By:  /s/ D. Geoffrey Shulman
     ---------------------------
     Name:  D. Geoffrey Shulman
     Title: President and CEO

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

SMITHFIELD FIDUCIARY LLC

By:  /s/ Adam J. Chill
     ----------------------------
Name:    Adam J. Chill
Title:   Authorized Signatory

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

MAINFIELD ENTERPRISES INC.

By:  /s/ Avi Vigder
     ----------------------------
     Name:  Avi Vigder
     Title: Authorized Signatory

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

CRANSHIRE CAPITAL L.P.

By:  /s/ Mitchell P. Kopin
     -------------------------
     Name:  Mitchell P. Kopin
     Title: President-Downsview Capital, Inc., The General Partner

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

VERTICAL VENTURES, LLC

By:  /s/ Richard K. Abbe
     --------------------------
     Name:  Richard K. Abbe
     Title: Partner

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

OMICRON MASTER TRUST

By:  /s/ Bruce Bernstein
     ------------------------------
     Name:  Bruce Bernstein
     Title: Managing Partner

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

PORTSIDE GROWTH AND OPPORTUNITY FUND

By:  /s/ Jeffrey Smith
     -----------------------------------
     Name:  Jeffrey Smith
     Title: Authorized Signatory

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

SUNRISE EQUITY PARTNERS, LP
ITS GENERAL PARTNER LEVELCOUNTER LLC

By:  /s/ Marilyn S. Adler
     ---------------------------
     Name:  Marilyn S. Adler
     Title:  Manager

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

SUNRISE SECURITIES CORP.

By:  /s/ Nathan Low
     -----------------------------------
     Name:  N. Low
     Title: Partner

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

LANGLEY PARTNERS, L.P.

By:  /s/ Jeffrey Thorp
     ----------------------------------
     Name:  Jeffrey Thorp
     Title: Managing Member of Langley Capital, LLC, its General Partner

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

BUYER:

/s/ Paul Scharfer
-------------------------------------
     PAUL SCHARFER

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                    EXHIBITS

Exhibit A         Schedule of Buyers
Exhibit B         Form of Additional Investment Rights
Exhibit C         Form of Registration Rights Agreement
Exhibit D         Form of Irrevocable Transfer Agent Instructions
Exhibit E         Form of Company Counsel Opinion
Exhibit F         Form of Secretary's Certificate
Exhibit G         Form of Officer's Certificate

                                    SCHEDULES

Schedule 3(a)              Subsidiaries
Schedule 3(l)              Absence of Certain Changes
Schedule 3(q)              Capitalization
Schedule 3(r)(i)           Indebtedness and Other Contracts
Schedule 3(r)(ii)          Material Contracts
Schedule 3(s)              Litigation
Schedule 3(w)              Intellectual Property

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT A

                               SCHEDULE OF BUYERS

<TABLE>
<CAPTION>
      (1)                    (2)                   (3)             (4)            (5)                     (6)
                                                                NUMBER OF
                                                NUMBER OF       ADDITIONAL                      LEGAL REPRESENTATIVE'S
                     ADDRESS AND FACSIMILE       COMMON         INVESTMENT                       ADDRESS AND FACSIMILE
     BUYER                  NUMBER               SHARES        RIGHT SHARES   PURCHASE PRICE             NUMBER
-------------------------------------------------------------------------------------------------------------------------
<S>             <C>                             <C>            <C>            <C>              <C>
SMITHFIELD      c/o Highbridge Capital           780,000         117,000        $8,580,000     Schulte Roth & Zabel LLP
FIDUCIARY LLC   Management, LLC                                                                919 Third Avenue
                9 West 57th Street, 27th                                                       New York, New York 10022
                Floor                                                                          Attn: Eleazer Klein, Esq.
                New York, New York  10019                                                      Facsimile: (212) 593-5955
                Attention: Ari J. Storch                                                       Telephone: (212) 756-2000
                           Adam J. Chill
                Facsimile: (212) 751-0755
                Telephone: (212) 287-4720
                Residence: Cayman Islands

MAINFIELD       c/o Sage Capital Growth, Inc.    650,000          97,500        $7,150,000
ENTERPRISES     660 Madison Avenue, 18th
INC.            Floor
                New York, New York  10021
                Attention:  Eldad Gal
                Facsimile:  (212) 651-9010
                Telephone:  (212) 651-9008
                Residence:  British Virgin
                Islands

CRANSHIRE       c/o Downsview Capital, Inc.      100,000          15,000        $1,100,000
CAPITAL L.P.    The General Partner
                666 Dundee Road, Suite 1901
                Northbrook, IL  60062
                Attention:  Mitchell P.
                Kopin
                Facsimile:  (847)
                562-9031
                Telephone:  (847)
                562-9030
                Residence: Illinois

VERTICAL        c/o Vertical Ventures, LLC        50,000           7,500        $  550,000
VENTURES, LLC   900 Third Avenue, 26th Floor
                New York, New York  10022
                Facsimile No.: (646)
                               274-1728

                Telephone No.: (212)
                               974-3070
                Attention: Joshua Silverman
                Residence: New York
</TABLE>

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

<TABLE>
<CAPTION>
      (1)                      (2)                   (3)             (4)            (5)                     (6)
                                                                  NUMBER OF
                                                  NUMBER OF       ADDITIONAL                      LEGAL REPRESENTATIVE'S
                     ADDRESS AND FACSIMILE         COMMON         INVESTMENT                       ADDRESS AND FACSIMILE
     BUYER                  NUMBER                 SHARES        RIGHT SHARES   PURCHASE PRICE             NUMBER
---------------------------------------------------------------------------------------------------------------------------
<S>               <C>                             <C>            <C>            <C>              <C>
OMICRON MASTER    c/o Omicron Capital              100,000          15,000        $1,100,000
TRUST             810 Seventh Avenue
                  39th Floor
                  New York, New York 10019
                  Attention: Brian Daly
                  Facsimile: (212) 803-5263
                  Telephone: (212) 803-5269

PORTSIDE GROWTH   c/o Ramius Capital               200,000          30,000        $2,200,000
AND OPPORTUNITY   Group, L.L.C.
FUND              666 Third Avenue, 26th
                  Floor
                  New York, New York 10006
                  Attention:  Jeffrey Solomon
                              Jeffrey Smith
                  Facsimile: (212) 845-7999
                  Telephone :(212) 845-7917
                  Residence:  Cayman Islands

SUNRISE EQUITY    c/o Sunrise Securities Corp.     175,000          26,250        $1,925,000
PARTNERS, LP      641 Lexington Avenue, 25th
                  Floor
                  New York, NY 10022
                  Attention:  Marilyn Adler
                  Facsimile:  (212) 750-7277
                  Telephone:  (212) 421-1616
                  Residence:  Delaware

SUNRISE           c/o Sunrise Securities Corp.     100,000          15,000        $1,100,000
SECURITIES CORP.  641 Lexington Avenue, 25th
                  Floor
                  New York, NY 10022
                  Attention:  Marcia Kucher
                  Facsimile:  (212) 750-7277
                  Telephone:  (212) 421-1616
                  Residence:  New York

LANGLEY           c/o Langley Capital, LLC          75,000          11,250        $  825,000
PARTNERS, L.P.    535 Madison Avenue, 7th Floor
                  New York, NY 10022
                  Attention:  Jeffrey Thorp
                  Facsimile:  (212) 208-2971
                  Telephone:  (212) 850-7528
                  Residence:  Delaware

PAUL SCHARFER     265 East 66th Street              20,000           3,000        $  220,000
                  New York, NY 10021
                  Facsimile: (212) 772-0255
                  Telephone: (212) 772-0255
                  Residence: New York
</TABLE>

                                       40

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                                                       EXHIBIT B

                       FORM OF ADDITIONAL INVESTMENT RIGHT

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN
REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF WITHOUT EITHER (I) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (II) AN OPINION OF
COUNSEL, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT SUCH TRANSFER MAY
BE MADE WITHOUT REGISTRATION OR QUALIFICATION UNDER SAID ACT OR (III) SUCH
TRANSFER BEING MADE PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE
FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

                           DUSA PHARMACEUTICALS, INC.

                           ADDITIONAL INVESTMENT RIGHT

Additional Investment Right No.: __________
Number of Shares: _____________
Date of Issuance: March 1, 2004 ("ISSUANCE DATE")

DUSA Pharmaceuticals, Inc., a New Jersey corporation (the "COMPANY"), hereby
certifies that, for value received, the receipt and sufficiency of which are
hereby acknowledged, [SMITHFIELD FIDUCIARY LLC][OTHERS] or its permitted assigns
(the "HOLDER"), is entitled, subject to the terms set forth below, to purchase
from the Company, at the Exercise Price (as defined below) then in effect, at
any time or times on or after the date hereof, but not after 11:59 p.m., New
York City time, on the Expiration Date (as defined below), ______________
(_____________)(1) fully paid nonassessable shares of Common Stock (as defined
below) (the "ADDITIONAL INVESTMENT RIGHT SHARES"). Except as otherwise defined
herein, capitalized terms in this Additional Investment Right shall have the
meanings set forth in Section 15. This Additional Investment Right (including
all Additional Investment Rights issued

--------------
(1)      Insert number equal to 15% of the Common Shares purchased by the holder
         on the Closing Date.

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

in exchange, transfer or replacement hereof, the "ADDITIONAL INVESTMENT RIGHTS")
is one of the Additional Investment Rights (the "SPA ADDITIONAL INVESTMENT
RIGHTS") issued pursuant to Section 1 of that certain Securities Purchase
Agreement, dated as of February 27, 2004 (the "INITIAL ISSUANCE DATE"), among
the Company and the purchasers (the "PURCHASERS") referred to therein (the
"SECURITIES PURCHASE AGREEMENT").

                  1. EXERCISE OF ADDITIONAL INVESTMENT RIGHT.

                           a. Mechanics of Exercise. Subject to the terms and
conditions hereof (including, without limitation, the limitations set forth in
Section 1(f)), this Additional Investment Right may be exercised by the Holder
on any day, in whole or in part, by (i) delivery of a written notice, in the
form attached hereto as Exhibit A (the "EXERCISE NOTICE"), of the Holder's
election to exercise this Additional Investment Right, (ii) payment to the
Company of an amount equal to the applicable Exercise Price multiplied by the
number of Additional Investment Right Shares as to which this Additional
Investment Right is being exercised (the "AGGREGATE EXERCISE PRICE") in cash or
wire transfer of immediately available funds. The date the Exercise Notice and
the Aggregate Exercise Price are delivered to the Company (as determined in
accordance with the notice provisions hereof) is an "EXERCISE DATE." The Holder
shall not be required to deliver the original Additional Investment Right in
order to effect an exercise hereunder. Execution and delivery of the Exercise
Notice with respect to less than all of the Additional Investment Right Shares
shall have the same effect as cancellation of the original Additional Investment
Right and issuance of a new Additional Investment Right evidencing the right to
purchase the remaining number of Additional Investment Right Shares. On or
before the first Business Day following the Exercise Date, the Company shall
transmit by facsimile an acknowledgment of confirmation of receipt of the
Exercise Notice and the Aggregate Exercise Price to the Holder and the Company's
transfer agent (the "TRANSFER AGENT"). On or before the third Business Day
following the Exercise Date, the Company shall (X) issue and deliver to the
address as specified in the Exercise Notice, a certificate, registered in the
name of the Holder or its designee, for the number of shares of Common Stock to
which the Holder is entitled pursuant to such exercise, or (Y) provided that the
Transfer Agent is participating in The Depository Trust Company ("DTC") Fast
Automated Securities Transfer Program, upon the request of the Holder, credit
such aggregate number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise to the Holder's or its designee's balance account with
DTC through its Deposit Withdrawal Agent Commission system. On the Exercise
Date, the Holder shall be deemed for all corporate purposes to have become the
holder of record of the Additional Investment Right Shares with respect to which
this Additional Investment Right has been exercised, irrespective of the date of
delivery of the certificates evidencing such Additional Investment Right Shares.
Upon surrender of this Additional Investment Right to the Company following one
or more partial exercises, the Company shall as soon as practicable and in no
event later than three (3) Business Days after receipt of the Additional
Investment Right and at its own expense, issue a new Additional Investment Right
(in accordance with Section 7(d)) representing the right to purchase the number
of Additional Investment Right Shares purchasable immediately prior to such
exercise under this Additional Investment Right, less the number of Additional
Investment Right Shares with respect to which this Additional Investment Right
is exercised. No fractional shares of Common Stock are to be issued upon the
exercise of this Additional Investment Right, but rather the number of shares of
Common Stock to be issued shall be rounded up to the nearest whole number. The
Company shall pay any and all taxes

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

which may be payable with respect to the issuance and delivery of Additional
Investment Right Shares upon exercise of this Additional Investment Right.

                           b. Exercise Price. For purposes of this Additional
Investment Right, "EXERCISE PRICE" means $11.00, subject to adjustment as
provided herein.

                           c. Company's Failure to Timely Deliver Shares Subject
to Section 1(f), if the Company shall fail for any reason or for no reason to
issue to the Holder within ten (10) Business Days of the Exercise Date, a
certificate for the number of shares of Common Stock to which the Holder is
entitled or to credit the Holder's balance account with DTC for such number of
shares of Common Stock to which the Holder is entitled upon the Holder's
exercise of this Additional Investment Right, the Company shall pay as
additional damages in cash to the Holder on each day after such third Business
Day that the issuance of such Common Stock is not timely effected an amount
equal to 1.0% of the product of (A) the sum of the number of shares of Common
Stock not issued to the Holder on a timely basis and to which the Holder is
entitled and (B) the Closing Sale Price of the Common Stock on the Trading Day
(as defined in the Securities Purchase Agreement) immediately preceding the last
possible date which the Company could have issued such Common Stock to the
Holder without violating Section 1(a).

                           d. Absolute and Unconditional Obligation. The
Company's obligations to issue and deliver Additional Investment Right Shares in
accordance with the terms hereof are absolute and unconditional, irrespective of
any action or inaction by the holder to enforce the same, the recovery of any
judgment against any Person or any action to enforce the same, or any setoff,
counterclaim, recoupment, limitation or termination, or any breach or alleged
breach by the holder or any other Person of any obligation to the Company or any
violation or alleged violation of law by the holder or any other Person. Nothing
herein shall limit the Holder's right to pursue any other remedies available to
it hereunder, at law or in equity, including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company's
failure to timely deliver certificates representing Additional Investment Right
Shares upon exercise of the Additional Investment Right as required pursuant to
the terms hereof.

                           e. Disputes. In the case of a dispute as to the
determination of the Exercise Price or the arithmetic calculation of the
Additional Investment Right Shares, the Company shall promptly issue to the
Holder the number of Additional Investment Right Shares that are not disputed
and resolve such dispute in accordance with Section 12.

                           f. Limitations on Exercises. The Company shall not
effect the exercise of this Additional Investment Right, and no Person (as
defined below) who is the Holder shall have the right to exercise this
Additional Investment Right, to the extent that after giving effect to such
exercise, such Person (together with such Person's affiliates) would
beneficially own in excess of 9.99% of the shares of the Common Stock
outstanding immediately after giving effect to such exercise. For purposes of
the foregoing sentence, the aggregate number of shares of Common Stock
beneficially owned by such Person and its affiliates shall include the number of
shares of Common Stock issuable upon exercise of this Additional Investment
Right with respect to which the determination of such sentence is being made,
but shall exclude shares of Common Stock which would be issuable upon (i)
exercise of the remaining, unexercised portion of this Additional Investment
Right beneficially owned by such Person and its affiliates and (ii) exercise

                                       43

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

or conversion of the unexercised or unconverted portion of any other securities
of the Company beneficially owned by such Person and its affiliates (including,
without limitation, any convertible notes or convertible preferred stock or
warrants) subject to a limitation on conversion or exercise analogous to the
limitation contained herein. Except as set forth in the preceding sentence, for
purposes of this paragraph, beneficial ownership shall be calculated in
accordance with Section 13(d) of the Securities Exchange Act of 1934, as
amended. For purposes of this Additional Investment Right, in determining the
number of outstanding shares of Common Stock a holder may rely on the number of
outstanding shares of Common Stock as reflected in (1) the Company's most recent
Form 10-Q, Form 10-K or other public filing with the Securities and Exchange
Commission, as the case may be, (2) a more recent public announcement by the
Company or (3) any other notice by the Company or its Transfer Agent setting
forth the number of shares of Common Stock outstanding. For any reason at any
time, upon the written or oral request of the Holder, the Company shall within
one Business Day confirm orally and in writing to the Holder the number of
shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including the SPA Additional
Investment Rights, by the Holder and its affiliates since the date as of which
such number of outstanding shares of Common Stock was reported.

                  2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF ADDITIONAL
INVESTMENT RIGHT SHARES. The Exercise Price and the number of Additional
Investment Right Shares shall be adjusted from time to time as follows:

                           a. Adjustment upon Subdivision or Combination of
Common Stock. If the Company at any time after the date of issuance of this
Additional Investment Right subdivides (by any stock split, stock dividend,
recapitalization or otherwise) one or more classes of its outstanding shares of
Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision will be proportionately reduced and the
number of Additional Investment Right Shares will be proportionately increased.
If the Company at any time after the date of issuance of this Additional
Investment Right combines (by combination, reverse stock split or otherwise) one
or more classes of its outstanding shares of Common Stock into a smaller number
of shares, the Exercise Price in effect immediately prior to such combination
will be proportionately increased and the number of Additional Investment Right
Shares will be proportionately decreased. Any adjustment under this Section 2(a)
shall become effective at the close of business on the date the subdivision or
combination becomes effective.

                           b. Other Events. If any event occurs of the type
contemplated by the provisions of this Section 2 but not expressly provided for
by such provisions (including, without limitation, the granting of stock
appreciation rights, phantom stock rights or other rights with equity features),
then the Company's Board of Directors will make an appropriate adjustment in the
Exercise Price and the number of Additional Investment Right Shares so as to
protect the rights of the Holder; provided that no such adjustment pursuant to
this Section 2(b) will increase the Exercise Price or decrease the number of
Additional Investment Right Shares as otherwise determined pursuant to this
Section 2.

                  3. RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall
declare or make any dividend or other distribution of its assets (or rights to
acquire its assets) to

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

holders of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification, corporate
rearrangement or other similar transaction) (a "DISTRIBUTION"), at any time
after the issuance of this Additional Investment Right, then, in each such case:

                           a. any Exercise Price in effect immediately prior to
the close of business on the record date fixed for the determination of holders
of Common Stock entitled to receive the Distribution shall be reduced, effective
as of the close of business on such record date, to a price determined by
multiplying such Exercise Price by a fraction of which (i) the numerator shall
be the Closing Bid Price of the Common Stock on the Trading Day immediately
preceding such record date minus the value of the Distribution (as determined in
good faith by the Company's Board of Directors) applicable to one share of
Common Stock, and (ii) the denominator shall be the Closing Bid Price of the
Common Stock on the Trading Day immediately preceding such record date; and

                           b. the number of Additional Investment Right Shares
shall be increased to a number of shares equal to the number of shares of Common
Stock obtainable immediately prior to the close of business on the record date
fixed for the determination of holders of Common Stock entitled to receive the
Distribution multiplied by the reciprocal of the fraction set forth in the
immediately preceding paragraph (a); provided that in the event that the
Distribution is of common stock ("OTHER COMMON STOCK") of a company whose common
stock is traded on a national securities exchange or a national automated
quotation system, then the Holder may elect to receive a warrant to purchase
Other Common Stock in lieu of an increase in the number of Additional Investment
Right Shares, the terms of which shall be identical to those of this Additional
Investment Right, except that such warrant shall be exercisable into the number
of shares of Other Common Stock that would have been payable to the Holder
pursuant to the Distribution had the holder exercised this Additional Investment
Right immediately prior to such record date and with an aggregate exercise price
equal to the product of the amount by which the exercise price of this
Additional Investment Right was decreased with respect to the Distribution
pursuant to the terms of the immediately preceding paragraph (a) and the number
of Additional Investment Right Shares calculated in accordance with the first
part of this paragraph (b).

                  4. PURCHASE RIGHTS; ORGANIC CHANGE.

                           a. Purchase Rights. In addition to any adjustments
pursuant to Section 2 above, if at any time the Company grants, issues or sells
any Options, Convertible Securities or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of
Common Stock (the "PURCHASE RIGHTS"), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate
Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this
Additional Investment Right (without regard to any limitations on the exercise
of this Additional Investment Right) immediately before the date on which a
record is taken for the grant, issuance or sale of such Purchase Rights, or, if
no such record is taken, the date as of which the record holders of Common Stock
are to be determined for the grant, issue or sale of such Purchase Rights.

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           b. Organic Change. Any recapitalization,
reorganization, reclassification, consolidation, merger, sale of all or
substantially all of the Company's assets to another Person or other
transaction, in each case which is effected in such a way that holders of Common
Stock are entitled to receive securities or assets with respect to or in
exchange for Common Stock is referred to herein as an "ORGANIC CHANGE." Prior to
the consummation of any (i) sale of all or substantially all of the Company's
assets to an acquiring Person or (ii) other Organic Change following which the
Company is not a surviving entity, the Company will secure from the Person
purchasing such assets or the Person issuing the securities or providing the
assets in such Organic Change (in each case, the "ACQUIRING ENTITY") a written
agreement (in form and substance reasonably satisfactory to the holders of SPA
Additional Investment Rights representing at least a majority of the shares of
Common Stock obtainable upon exercise of the SPA Additional Investment Rights
then outstanding) to deliver to the Holder in exchange for this Additional
Investment Right, a security of the Acquiring Entity evidenced by a written
instrument substantially similar in form and substance to this Additional
Investment Right and reasonably satisfactory to the Holder (including, an
adjusted exercise price equal to the value for the Common Stock reflected by the
terms of such consolidation, merger or sale, and exercisable for a corresponding
number of shares of Common Stock acquirable and receivable upon exercise of this
Additional Investment Right (without regard to any limitations on the exercise
of this Additional Investment Right), if the value so reflected is less than the
Exercise Price in effect immediately prior to such consolidation, merger or
sale). In the event that an Acquiring Entity is directly or indirectly
controlled by a company or entity whose common stock or similar equity interest
is listed, designated or quoted on a securities exchange or trading market, the
Holder may elect to treat such Person as the Acquiring Entity for purposes of
this Section 4(b). Prior to the consummation of any other Organic Change, the
Company shall make appropriate provision (in form and substance reasonably
satisfactory to the holders of SPA Additional Investment Rights representing at
least a majority of the shares of Common Stock obtainable upon exercise of the
SPA Additional Investment Rights then outstanding) to insure that the Holder
thereafter will have the right to acquire and receive in lieu of or in addition
to (as the case may be) the shares of Common Stock immediately theretofore
acquirable and receivable upon the exercise of this Additional Investment Right
(without regard to any limitations on the exercise of this Additional Investment
Right), such shares of stock, securities or assets that would have been issued
or payable in such Organic Change with respect to or in exchange for the number
of shares of Common Stock which would have been acquirable and receivable upon
the exercise of this Additional Investment Right as of the date of such Organic
Change (without regard to any limitations on the exercise of this Additional
Investment Right).

                  5. NONCIRCUMVENTION. The Company hereby covenants and agrees
that the Company will not, by amendment of the Certificate of Incorporation or
through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities, or any other voluntary action, avoid
or seek to avoid the observance or performance of any of the terms of this
Additional Investment Right, and will at all times in good faith carry out all
the provisions of this Additional Investment Right and take all action as may be
required to protect the rights of the Holder. Without limiting the generality of
the foregoing, the Company (i) will not increase the par value of any shares of
Common Stock receivable upon the exercise of this Additional Investment Right
above the Exercise Price then in effect, (ii) will take all such actions as may
be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable shares of Common Stock upon the exercise of
this Additional Investment

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

Right, and (iii) will, so long as any of the SPA Additional Investment Rights
are outstanding, take all action necessary to reserve and keep available out of
its authorized and unissued Common Stock, solely for the purpose of effecting
the exercise of the SPA Additional Investment Rights, 100% of the number of
shares of Common Stock as shall from time to time be necessary to effect the
exercise of the SPA Additional Investment Rights then outstanding (without
regard to any limitations on exercise).

                  6. HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise
specifically provided herein, the Holder, solely in such Person's capacity as
the Holder, shall not be entitled to vote or receive dividends or be deemed the
holder of shares of Common Stock for any purpose, nor shall anything contained
in this Additional Investment Right be construed to confer upon the Holder,
solely in such Person's capacity as a Holder, any of the rights of a shareholder
of the Company or any right to vote, give or withhold consent to any corporate
action (whether any reorganization, issue of stock, reclassification of stock,
consolidation, merger, conveyance or otherwise), receive notice of meetings,
receive dividends or subscription rights, or otherwise, prior to the issuance to
the Holder of the Additional Investment Right Shares which such Person is then
entitled to receive upon the due exercise of this Additional Investment Right.
In addition, nothing contained in this Additional Investment Right shall be
construed as imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Additional Investment Right or otherwise) or as a
stockholder of the Company, whether such liabilities are asserted by the Company
or by creditors of the Company. Notwithstanding this Section 6, the Company will
provide the Holder with copies of the same notices and other information given
to the stockholders of the Company generally, contemporaneously with the giving
thereof to the stockholders.

                  7. REISSUANCE OF ADDITIONAL INVESTMENT RIGHTS.

                           a. Transfer of Additional Investment Right. If this
Additional Investment Right is to be transferred, the holder shall surrender
this Additional Investment Right to the Company, whereupon the Company will
forthwith issue and deliver upon the order of the Holder a new Additional
Investment Right (in accordance with Section 7(d)), registered as the Holder may
request, representing the right to purchase the number of Additional Investment
Right Shares being transferred by the Holder and, if less then the total number
of Additional Investment Right Shares then underlying this Additional Investment
Right is being transferred, a new Additional Investment Right (in accordance
with Section 7(d)) to the Holder representing the right to purchase the number
of Additional Investment Right Shares not being transferred.

                           b. Lost, Stolen or Mutilated Additional Investment
Right. Upon receipt by the Company of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Additional
Investment Right, and, in the case of loss, theft or destruction, of any
indemnification undertaking by the Holder to the Company in customary form and,
in the case of mutilation, upon surrender and cancellation of this Additional
Investment Right, the Company shall execute and deliver to the Holder a new
Additional Investment Right (in accordance with Section 7(d)) representing the
right to purchase the Additional Investment Right Shares then underlying this
Additional Investment Right.

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           c. Additional Investment Right Exchangeable for
Multiple Additional Investment Rights. This Additional Investment Right is
exchangeable, upon the surrender hereof by the Holder at the principal office of
the Company, for a new Additional Investment Right or Additional Investment
Rights (in accordance with Section 7(d)) representing in the aggregate the right
to purchase the number of Additional Investment Right Shares then underlying
this Additional Investment Right, and each such new Additional Investment Right
will represent the right to purchase such portion of such Additional Investment
Right Shares as is designated by the Holder at the time of such surrender;
provided, however, that no Additional Investment Rights for fractional shares of
Common Stock shall be given.

                           d. Issuance of New Additional Investment Rights.
Whenever the Company is required to issue a new Additional Investment Right
pursuant to the terms of this Additional Investment Right, such new Additional
Investment Right (i) shall be of like tenor with this Additional Investment
Right, (ii) shall represent, as indicated on the face of such new Additional
Investment Right, the right to purchase the Additional Investment Right Shares
then underlying this Additional Investment Right (or in the case of a new
Additional Investment Right being issued pursuant to Section 7(a) or Section
7(c), the Additional Investment Right Shares designated by the Holder which,
when added to the number of shares of Common Stock underlying the other new
Additional Investment Rights issued in connection with such issuance, does not
exceed the number of Additional Investment Right Shares then underlying this
Additional Investment Right), (iii) shall have an issuance date, as indicated on
the face of such new Additional Investment Right which is the same as the
Issuance Date, and (iv) shall have the same rights and conditions as this
Additional Investment Right.

                  8. NOTICES. Whenever notice is required to be given under this
Additional Investment Right, unless otherwise provided herein, such notice shall
be given in accordance with Section 9(f) of the Securities Purchase Agreement.
The Company shall provide the Holder with prompt written notice of all actions
taken pursuant to this Additional Investment Right, including in reasonable
detail a description of such action and the reason therefore. Without limiting
the generality of the foregoing, the Company will give written notice to the
Holder (i) immediately upon any adjustment of the Exercise Price, setting forth
in reasonable detail, and certifying, the calculation of such adjustment and
(ii) at least fifteen days prior to the date on which the Company closes its
books or takes a record (A) with respect to any dividend or distribution upon
the Common Stock, (B) with respect to any grants, issues or sales of any
Options, Convertible Securities or rights to purchase stock, warrants,
securities or other property to holders of Common Stock or (C) for determining
rights to vote with respect to any Organic Change, dissolution or liquidation,
provided in each case that such information shall be made known to the public
prior to or in conjunction with such notice being provided to the Holder.

                  9. AMENDMENT AND WAIVER. Except as otherwise provided herein,
the provisions of this Additional Investment Right may be amended and the
Company may take any action herein prohibited, or omit to perform any act herein
required to be performed by it, only if the Company has obtained the written
consent of the holders of SPA Additional Investment Rights representing at least
a majority of the shares of Common Stock obtainable upon exercise of the SPA
Additional Investment Rights then outstanding; provided that no such action may
increase the exercise price of any SPA Additional Investment Right or decrease
the number of shares or class of stock obtainable upon exercise of any SPA
Additional Investment Right

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

without the written consent of the holder of this Additional Investment Right.
No such amendment shall be effective to the extent that it applies to less than
all of the holders of the SPA Additional Investment Rights then outstanding.

                  10. GOVERNING LAW. This Additional Investment Right shall be
construed and enforced in accordance with, and all questions concerning the
construction, validity, interpretation and performance of this Additional
Investment Right shall be governed by, the internal laws of the State of New
York, without giving effect to any choice of law or conflict of law provision or
rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of
New York.

                  11. CONSTRUCTION; HEADINGS. This Additional Investment Right
shall be deemed to be jointly drafted by the Company and all the Purchasers and
shall not be construed against any person as the drafter hereof. The headings of
this Additional Investment Right are for convenience of reference and shall not
form part of, or affect the interpretation of, this Additional Investment Right.

                  12. DISPUTE RESOLUTION. In the case of a dispute as to the
determination of the Exercise Price or the arithmetic calculation of the
Additional Investment Right Shares, the Company shall submit the disputed
determinations or arithmetic calculations via facsimile within two Business Days
of receipt of the Exercise Notice giving rise to such dispute, as the case may
be, to the Holder. If the Holder and the Company are unable to agree upon such
determination or calculation of the Exercise Price or the Additional Investment
Right Shares within three Business Days of such disputed determination or
arithmetic calculation being submitted to the Holder, then the Company shall,
within two Business Days submit via facsimile (a) the disputed determination of
the Exercise Price to an independent, reputable investment bank selected by the
Company and approved by the Holder or (b) the disputed arithmetic calculation of
the Additional Investment Right Shares to the Company's independent, outside
accountant. The Company shall cause at its expense the investment bank or the
accountant, as the case may be, to perform the determinations or calculations
and notify the Company and the Holder of the results no later than ten Business
Days from the time it receives the disputed determinations or calculations. Such
investment bank's or accountant's determination or calculation, as the case may
be, shall be binding upon all parties absent demonstrable error.

                  13. REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE
RELIEF. The remedies provided in this Additional Investment Right shall be
cumulative and in addition to all other remedies available under this Additional
Investment Right, the Securities Purchase Agreement and the Registration Rights
Agreement, at law or in equity (including a decree of specific performance
and/or other injunctive relief), and nothing herein shall limit the right of the
Holder to pursue actual damages for any failure by the Company to comply with
the terms of this Additional Investment Right. The Company acknowledges that a
breach by it of its obligations hereunder will cause irreparable harm to the
Holder and that the remedy at law for any such breach may be inadequate. The
Company therefore agrees that, in the event of any such breach or threatened
breach, the Holder shall be entitled, in addition to all other available
remedies, to an injunction restraining any breach, without the necessity of
showing economic loss and without any bond or other security being required.

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                  14. TRANSFER. This Additional Investment Right may be offered
for sale, sold, transferred or assigned without the consent of the Company,
except as may otherwise be required by Section 2(f) of the Securities Purchase
Agreement.

                  15. CERTAIN DEFINITIONS. For purposes of this Additional
Investment Right, the following terms shall have the following meanings:

                           a. "BLOOMBERG" means Bloomberg Financial Markets.

                           b. "BUSINESS DAY" means any day other than Saturday,
Sunday or other day on which commercial banks in The City of New York are
authorized or required by law to remain closed.

                           c. "CLOSING BID PRICE" and "CLOSING SALE PRICE"
means, for any security as of any date, the last closing bid price and last
closing trade price, respectively, for such security on the Principal Market, as
reported by Bloomberg, or, if the Principal Market begins to operate on an
extended hours basis and does not designate the closing bid price or the closing
trade price, as the case may be, then the last bid price or last trade price,
respectively, of such security prior to 4:00:00 p.m., New York Time, as reported
by Bloomberg, or, if the Principal Market is not the principal securities
exchange or trading market for such security, the last closing bid price or last
trade price, respectively, of such security on the principal securities exchange
or trading market where such security is listed or traded as reported by
Bloomberg, or if the foregoing do not apply, the last closing bid price or last
trade price, respectively, of such security in the over-the-counter market on
the electronic bulletin board for such security as reported by Bloomberg, or, if
no closing bid price or last trade price, respectively, is reported for such
security by Bloomberg, the average of the bid prices, or the ask prices,
respectively, of any market makers for such security as reported in the "pink
sheets" by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.). If
the Closing Bid Price or the Closing Sale Price cannot be calculated for a
security on a particular date on any of the foregoing bases, the Closing Bid
Price or the Closing Sale Price, as the case may be, of such security on such
date shall be the fair market value as mutually determined by the Company and
the Holder. If the Company and the Holder are unable to agree upon the fair
market value of such security, then such dispute shall be resolved pursuant to
Section 12. All such determinations to be appropriately adjusted for any stock
dividend, stock split, stock combination or other similar transaction during the
applicable calculation period.

                           d. "COMMON STOCK" means (i) the Company's common
stock, no par value and (ii) any capital stock into which such Common Stock
shall have been changed or any capital stock resulting from a reclassification
of such Common Stock.

                           e. "CONVERTIBLE SECURITIES" means any stock or
securities (other than Options) directly or indirectly convertible into or
exercisable or exchangeable for Common Stock.

                           f. "EXPIRATION DATE" means the date that is thirty
(30) Trading Days following, but not including, the Issuance Date.

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                           g. "OPTIONS" means any rights, warrants or options to
subscribe for or purchase Common Stock or Convertible Securities.

                           h. "PERSON" means an individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization, any other entity and a government or any department
or agency thereof.

                           i. "PRINCIPAL MARKET" means the Nasdaq National
Market.

                           j. "REGISTRATION RIGHTS AGREEMENT" means that certain
registration rights agreement dated the Initial Issuance Date by and among the
Company and the Purchasers.

                           k. "TRADING DAY" means any day on which the Common
Stock is traded on the Principal Market, or, if the Principal Market is not the
principal trading market for the Common Stock, then on the principal securities
exchange or securities market on which the Common Stock is then traded; provided
that "Trading Day" shall not include any day on which the Common Stock is
scheduled to trade on such exchange or market for less than 4.5 hours or any day
that the Common Stock is suspended from trading during the final hour of trading
on such exchange or market (or if such exchange or market does not designate in
advance the closing time of trading on such exchange or market, then during the
hour ending at 4:00 p.m., New York City Time).

                            [SIGNATURE PAGE FOLLOWS]

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                  IN WITNESS WHEREOF, the Company has caused this Additional
Investment Right to be duly executed as of the Issuance Date set out above.

                                    DUSA PHARMACEUTICALS, INC.

                                    By:
                                        Name:
                                        Title:

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                                                       EXHIBIT A

                                 EXERCISE NOTICE

            TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS
                           ADDITIONAL INVESTMENT RIGHT

                           DUSA PHARMACEUTICALS, INC.

To:      DUSA Pharmaceuticals, Inc.

         The undersigned is the holder of Additional Investment Right No. _____
(the "ADDITIONAL INVESTMENT RIGHT") issued by DUSA Pharmaceuticals, Inc., a New
Jersey corporation (the "COMPANY"). Capitalized terms used herein and not
otherwise defined shall have the respective meanings set forth in the Additional
Investment Right.

         1.       The Additional Investment Right is currently exercisable to
purchase a total of ____________ Additional Investment Right Shares.

         2.       The undersigned holder hereby exercises its right to purchase
______________ Additional Investment Right Shares pursuant to the Additional
Investment Right.

         3.       The holder shall pay the sum of $___________________ to the
Company in accordance with the terms of the Additional Investment Right.

         4.       Pursuant to this exercise, the Company shall deliver to the
holder __________ Additional Investment Right Shares in accordance with the
terms of the Additional Investment Right.

         5.       Following this exercise, the Additional Investment Right shall
be exercisable to purchase a total of ________________ Additional Investment
Right Shares.

         Please issue the Additional Investment Right Shares in the following
name and to the following address:

         Issue to: _____________________________________________________________
                   _____________________________________________________________
                   _____________________________________________________________

         Account Number: _______________________________________________________
                    (if electronic book entry transfer)

         DTC Participant Number: _______________________________________________
                    (if electronic book entry transfer)

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

Date: _______________ __, ______

________________________________
Name of Registered Holder

By:
     Name:
     Title:

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                 ACKNOWLEDGMENT

         The Company hereby acknowledges this Exercise Notice and hereby directs
American Stock Transfer and Trust to issue the above indicated number of shares
of Common Stock in accordance with the Transfer Agent Instructions dated
February 27, 2004 from the Company and acknowledged and agreed to by American
Stock Transfer and Trust.

                                        DUSA PHARMACEUTICALS, INC.

                                        By:
                                            Name:
                                            Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                               FORM OF ASSIGNMENT

 [To be completed and signed only upon transfer of Additional Investment Right]

                  FOR VALUE RECEIVED, the undersigned hereby sells, assigns and
transfers unto ________________________________ the right represented by the
within Additional Investment Right to purchase ____________ shares of Common
Stock of DUSA Pharmaceuticals, Inc. to which the within Additional Investment
Right relates and appoints ________________ attorney to transfer said right on
the books of DUSA Pharmaceuticals, Inc. with full power of substitution in the
premises.

Dated: __________ , ________

                                    ____________________________________________
                                    (Signature must conform in all respects to
                                    name of holder as specified on the face of
                                    the Additional Investment Right)

                                    ____________________________________________
                                    Address of Transferee

                                    ____________________________________________

                                    ____________________________________________

In the presence of:

_______________________

<PAGE>

[ c.i.] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                                                       EXHIBIT C

                         REGISTRATION RIGHTS AGREEMENT

                  REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), dated as of
February 27, 2004, by and among DUSA Pharmaceuticals, Inc., a New Jersey
corporation, with headquarters located at 25 Upton Drive, Wilmington,
Massachusetts 01887 (the "COMPANY"), and the investors listed on the Schedule of
Buyers attached hereto as Exhibit A (each, a "BUYER" and collectively, the
"BUYERS").

                  WHEREAS:

                  A.       In connection with the Securities Purchase Agreement
by and among the parties hereto of even date herewith (the "SECURITIES PURCHASE
AGREEMENT"), the Company has agreed, upon the terms and subject to the
conditions of the Securities Purchase Agreement, to issue and sell on the date
hereof to each Buyer (i) shares (the "COMMON SHARES") of the Company's common
stock, no par value (the "COMMON STOCK"), and (ii) certain additional investment
rights (the "ADDITIONAL INVESTMENT RIGHTS") which will be exercisable to
purchase additional shares of Common Stock (as exercised, the "ADDITIONAL
INVESTMENT RIGHT SHARES") in accordance with the terms of the Additional
Investment Rights.

                  B.       To induce the Buyers to execute and deliver the
Securities Purchase Agreement, the Company has agreed to provide certain
registration rights under the Securities Act of 1933, as amended, and the rules
and regulations thereunder, or any similar successor statute (collectively, the
"1933 ACT"), and applicable state securities laws.

                  NOW, THEREFORE, in consideration of the premises and the
mutual covenants contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and each
of the Buyers hereby agree as follows:

                  1. Definitions.

                  As used in this Agreement, the following terms shall have the
following meanings:

                           a. "BUSINESS DAY" means any day other than Saturday,
Sunday or any other day on which commercial banks in The City of New York are
authorized or required by law to remain closed.

                           b. "EFFECTIVE DATE" means the date that the
Registration Statement is first declared effective by the SEC.

                           c. "INVESTOR" means: (i) a Buyer, (ii) the Placement
Agent, and (iii) any transferee or assignee thereof to whom a Buyer or the
Placement Agent assigns its rights under this Agreement and who agrees to become
bound by the provisions of this Agreement in accordance with Section 9 and any
transferee or assignee thereof to whom a transferee or assignee assigns its
rights under this Agreement and who agrees to become bound by the provisions of
this Agreement in accordance with Section 9.
<PAGE>
[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                           d. "PERSON" means an individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization and governmental or any department or agency
thereof.

                           e. "REGISTER," "REGISTERED," and "REGISTRATION" refer
to a registration effected by preparing and filing one or more Registration
Statements (as defined below) in compliance with the 1933 Act and pursuant to
Rule 415, and the declaration or ordering of effectiveness of such Registration
Statement(s) by the SEC.

                           f. "REGISTRABLE SECURITIES" means: (i) the Common
Shares, (ii) the Additional Investment Right Shares issued or issuable upon
exercise of the Additional Investment Rights, (iii) the shares of Common Stock
issued to the Placement Agent as commission in accordance with the Placement
Agent Securities Agreement (the "COMMISSION SHARES"), and (iv) any shares of
capital stock issued or issuable with respect to the Common Shares, the
Additional Investment Right Shares, the Additional Investment Rights or
Commission Shares as a result of any stock split, stock dividend,
recapitalization, exchange or similar event or otherwise.

                           g. "REGISTRATION STATEMENT" means a registration
statement or registration statements of the Company filed under the 1933 Act
covering the Registrable Securities.

                           h. "RULE 415" means Rule 415 under the 1933 Act or
any successor rule providing for offering securities on a continuous or delayed
basis.

                           i. "SEC" means the United States Securities and
Exchange Commission.

                  Capitalized terms used herein and not otherwise defined herein
shall have the respective meanings set forth in the Securities Purchase
Agreement.

                  2. Registration.

                           a. Mandatory Registration. The Company shall prepare,
and, as soon as practicable but in no event later than 30 days after the Closing
Date (as defined in the Securities Purchase Agreement) (the "FILING DEADLINE"),
file with the SEC a Registration Statement on Form S-3 covering the resale of
all of the Registrable Securities. In the event that Form S-3 is unavailable for
such a registration, the Company shall use such other form as is available for
such a registration, subject to the provisions of Section 2(d). The Registration
Statement prepared pursuant hereto shall register for resale at least that
number of shares of Common Stock equal to the number of Registrable Securities
as of the trading day immediately preceding the date the Registration Statement
is initially filed with the SEC, subject to adjustment as provided in Section
2(e), and shall contain the "Selling Securityholders" section and "Plan of
Distribution" attached hereto as Annex I. The Company shall use its reasonable
best efforts to have the Registration Statement declared effective by the SEC as
soon as practicable, but in no event later than the date which is (i) in the
event that the Registration Statement is not subject to a full review by the
SEC, 90 days after the Closing Date, or (ii) in the event that the Registration
Statement is subject to a full review by the SEC, 150 days after the Closing
Date (the "EFFECTIVENESS DEADLINE").

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                           b. Allocation of Registrable Securities. The initial
number of Registrable Securities included in any Registration Statement and each
increase in the number of Registrable Securities included therein pursuant to
Section 2(e) shall be allocated pro rata among the Investors based on the number
of Registrable Securities held by each Investor at the time the Registration
Statement covering such initial number of Registrable Securities or increase
thereof is declared effective by the SEC. In the event that an Investor sells or
otherwise transfers any of such Investor's Registrable Securities, each
transferee shall be allocated a pro rata portion of the then remaining number of
Registrable Securities included in such Registration Statement for such
transferor. Any shares of Common Stock included in a Registration Statement and
which remain allocated to any Person which ceases to hold any Registrable
Securities covered by such Registration Statement shall be allocated to the
remaining Investors, pro rata based on the number of Registrable Securities then
held by such Investors which are covered by such Registration Statement. In no
event shall the Company include any securities other than Registrable Securities
on any Registration Statement without the prior written consent of Investors
holding at least a majority of the Registrable Securities.

                           c. Legal Counsel. Subject to Section 5 hereof, the
Buyers holding at least a majority of the Registrable Securities shall have the
right to select one legal counsel to review and oversee any registration
pursuant to this Section 2 ("LEGAL COUNSEL"), which shall be Schulte Roth &
Zabel LLP or such other counsel as thereafter designated by the holders of at
least a majority of the Registrable Securities. The Company and Legal Counsel
shall reasonably cooperate with each other in performing the Company's
obligations under this Agreement.

                           d. Ineligibility for Form S-3. In the event that Form
S-3 is not available for the registration of the resale of Registrable
Securities hereunder, the Company shall (i) register the resale of the
Registrable Securities on another appropriate form reasonably acceptable to the
holders of at least a majority of the Registrable Securities and (ii) undertake
to register the Registrable Securities on Form S-3 as soon as such form is
available, provided that the Company shall maintain the effectiveness of the
Registration Statement then in effect until such time as a Registration
Statement on Form S-3 covering the Registrable Securities has been declared
effective by the SEC.

                           e. Sufficient Number of Shares Registered. In the
event the number of shares available under a Registration Statement filed
pursuant to Section 2(a) is insufficient to cover all of the Registrable
Securities required to be covered by such Registration Statement or an
Investor's allocated portion of the Registrable Securities pursuant to Section
2(b), the Company shall amend the applicable Registration Statement, or file a
new Registration Statement (on the short form available therefor, if
applicable), or both, so as to cover at least 100% of the number of such
Registrable Securities as of the trading day immediately preceding the date of
the filing of such amendment or new Registration Statement, in each case, as
soon as practicable, but in any event not later than fifteen (15) days after the
Company becomes aware of the necessity therefor. The Company shall use its
reasonable best efforts to cause such amendment and/or new Registration
Statement to become effective as soon as practicable following the filing
thereof. For purposes of the foregoing provision, the number of shares available
under a Registration Statement shall be deemed "insufficient to cover all of the
Registrable Securities" if at any time the number of shares of Common Stock
available for resale under such Registration Statement is less than the number
of Registrable Securities. The

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

calculation set forth in the foregoing sentence shall be made without regard to
any limitations on the exercise of the Additional Investment Rights and such
calculation shall assume that the Additional Investment Rights are then
exercisable into shares of Common Stock.

                           f. Effect of Failure to File and Obtain and Maintain
Effectiveness of Registration Statement. If prior to the date as of which the
Investors may sell all of the Registrable Securities covered by a Registration
Statement without restriction pursuant to Rule 144(k) (or the successor thereto)
promulgated under the 1933 Act, (i) a Registration Statement covering all the
Registrable Securities required to be covered thereby and required to be filed
by the Company pursuant to this Agreement is (A) not filed with the SEC on or
before the Filing Deadline (a "FILING FAILURE") or (B) not declared effective by
the SEC on or before the Effectiveness Deadline (an "EFFECTIVENESS FAILURE") or
(ii) on any day after the Effective Date sales of all the Registrable Securities
required to be included on such Registration Statement cannot be made (other
than during an Allowable Grace Period (as defined in Section 3(r) below))
pursuant to such Registration Statement (including, without limitation, because
of a failure: (A) to keep such Registration Statement effective, (B) to disclose
such information as is necessary for sales to be made pursuant to such
Registration Statement, or (C) to register sufficient shares of Common Stock or
to have the Common Stock listed or quoted, or not suspended, on the Principal
Market (as defined in the Securities Purchase Agreement))(a "MAINTENANCE
FAILURE"), or (iii) the exercise rights of the holders pursuant to the
Additional Investment Rights are suspended or not honored for any reason (the
foregoing, an "AIR EXERCISABILITY FAILURE"), then, as partial relief for the
damages to any Investor by reason of any such delay in or reduction of its
ability to sell the underlying shares of Common Stock (which remedy shall not be
exclusive of any other remedies available at law or in equity), the Company
shall pay to each holder of Registrable Securities relating to such Registration
Statement: (1) on each of the day of a Filing Failure, an Effectiveness Failure,
a Maintenance Failure or a AIR Exercisability Failure, as the case may be, an
amount in cash equal to the product of: (i) the aggregate Purchase Price (as
such term is defined in the Securities Purchase Agreement) of such Investor's
Registrable Securities included in such Registration Statement multiplied by
(ii) 0.01, and (2) on the earlier of the last day of each 30 day period after a
Filing Failure, an Effectiveness Failure, a Maintenance Failure or a AIR
Exercisability Failure, as the case may be, or on the third Business Day after
any such Filing Failure, Effectiveness Failure, Maintenance Failure or AIR
Exercisability Failure is cured, an amount in cash equal to the product of (i)
the aggregate Purchase Price of such Investor's Registrable Securities included
in such Registration Statement included in such Registration Statement
multiplied by (ii) 0.01 (prorated for partial months). If the Company fails to
make any payments pursuant to this Section 2(f) in a timely manner, such
payments shall bear interest at the rate of 1.5% per month (prorated for partial
months) until paid in full.

                  3. Related Obligations.

                  At such time as the Company is obligated to file a
Registration Statement with the SEC pursuant to Section 2(a), 2(d) or 2(e), the
Company will use its reasonable best efforts to effect the registration of the
Registrable Securities in accordance with the intended method of disposition
thereof and, pursuant thereto, the Company shall have the following obligations:

                           a. The Company shall submit to the SEC, within two
(2) Business Days after the Company learns that no review of a particular
Registration Statement will be made by

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

the staff of the SEC or that the staff of the SEC has no further comments on a
particular Registration Statement, as the case may be, a request for
acceleration of effectiveness of such Registration Statement to a time and date
not later than 48 hours after the submission of such request. The Company shall
keep each Registration Statement effective pursuant to Rule 415 at all times
until the earlier of (i) the date as of which the Investors may sell all of the
Registrable Securities covered by such Registration Statement without
restriction pursuant to Rule 144(k) (or successor thereto) promulgated under the
1933 Act or (ii) the date on which the Investors shall have sold all the
Registrable Securities covered by such Registration Statement (the "REGISTRATION
PERIOD"). The Company shall ensure that each Registration Statement (including
any amendments or supplements thereto and prospectuses contained therein) shall
not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein, or necessary to make the statements therein
(in the case of prospectuses, in the light of the circumstances in which they
were made) not misleading.

                           b. The Company shall prepare and file with the SEC
such amendments (including post-effective amendments) and supplements to a
Registration Statement and the prospectus used in connection with such
Registration Statement, which prospectus is to be filed pursuant to Rule 424
promulgated under the 1933 Act, as may be necessary to keep such Registration
Statement effective at all times during the Registration Period, and, during
such period, comply with the provisions of the 1933 Act with respect to the
disposition of all Registrable Securities of the Company covered by such
Registration Statement until such time as all of such Registrable Securities
shall have been disposed of in accordance with the intended methods of
disposition by the seller or sellers thereof as set forth in such Registration
Statement. In the case of amendments and supplements to a Registration Statement
which are required to be filed pursuant to this Agreement (including pursuant to
this Section 3(b)) by reason of the Company filing a report on Form 10-K, Form
10-Q or Form 8-K or any analogous report under the Securities Exchange Act of
1934, as amended (the "1934 ACT"), the Company shall have incorporated such
report by reference into such Registration Statement, if applicable, or shall
file such amendments or supplements with the SEC on the same day on which the
1934 Act report is filed which created the requirement for the Company to amend
or supplement such Registration Statement.

                           c. The Company shall: (i) permit Legal Counsel to
review and comment upon: (A) a Registration Statement at least two (2) Business
Days prior to its filing with the SEC, and (B) all amendments and supplements to
all Registration Statements (except for Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K and any similar or
successor reports) within a reasonable number of days prior to their filing with
the SEC, and (ii) not file any Registration Statement or amendment or supplement
thereto in a form to which Legal Counsel reasonably objects. The Company shall
not submit a request for acceleration of the effectiveness of a Registration
Statement or any amendment or supplement thereto without the prior approval of
Legal Counsel, which consent shall not be unreasonably withheld; provided,
however, that in the event such approval is not received by the intended filing
date, the Company shall not be responsible for any penalties accruing pursuant
to Section 2(f) as a result of the failure to give such approval. The Company
shall furnish to Legal Counsel, without charge: (1) copies of any correspondence
from the SEC or the staff of the SEC to the Company or its representatives
relating to any Registration Statement, (2) promptly after the same is prepared
and filed with the SEC, one copy of any Registration Statement and any

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

amendment(s) thereto, including financial statements and schedules, all
documents incorporated therein by reference, if requested by an Investor and not
otherwise available on the EDGAR system, and all exhibits, and (3) upon the
effectiveness of any Registration Statement, one copy of the prospectus included
in such Registration Statement and all amendments and supplements thereto. The
Company shall reasonably cooperate with Legal Counsel in performing the
Company's obligations pursuant to this Section 3.

                           d. The Company shall furnish to each Investor whose
Registrable Securities are included in any Registration Statement, without
charge: (i) promptly after the same is prepared and filed with the SEC, and if
requested by an Investor and not otherwise available on the EDGAR system, at
least one copy of such Registration Statement and any amendment(s) thereto,
including financial statements and schedules, all documents incorporated therein
by reference, all exhibits and each preliminary prospectus, (ii) upon the
effectiveness of any Registration Statement, ten (10) copies of the prospectus
included in such Registration Statement and all amendments and supplements
thereto (or such other number of copies as such Investor may reasonably
request), and (iii) such other documents, including copies of any preliminary or
final prospectus, as such Investor may reasonably request from time to time in
order to facilitate the disposition of the Registrable Securities owned by such
Investor.

                           e. The Company shall use its reasonable best efforts
to: (i) register and qualify, unless an exemption from registration and
qualification applies, the resale by Investors of the Registrable Securities
covered by a Registration Statement under such other securities or "blue sky"
laws of all applicable jurisdictions in the United States, (ii) prepare and file
in those jurisdictions such amendments (including post-effective amendments) and
supplements to such registrations and qualifications as may be necessary to
maintain the effectiveness thereof during the Registration Period, (iii) take
such other actions as may be necessary to maintain such registrations and
qualifications in effect at all times during the Registration Period, and (iv)
take all other actions reasonably necessary or advisable to qualify the
Registrable Securities for sale in such jurisdictions; provided, however, that
the Company shall not be required in connection therewith or as a condition
thereto to: (A) qualify to do business in any jurisdiction where it would not
otherwise be required to qualify but for this Section 3(e), (B) subject itself
to general taxation in any such jurisdiction, or (C) file a general consent to
service of process in any such jurisdiction. The Company shall promptly notify
Legal Counsel and each Investor who holds Registrable Securities of the receipt
by the Company of any notification with respect to the suspension of the
registration or qualification of any of the Registrable Securities for sale
under the securities or "blue sky" laws of any jurisdiction in the United States
or its receipt of actual notice of the initiation or threatening of any
proceeding for such purpose.

                           f. The Company shall notify Legal Counsel and each
Investor in writing of the happening of any event, as promptly as practicable
after becoming aware of such event, as a result of which the prospectus included
in a Registration Statement, as then in effect, includes an untrue statement of
a material fact or omission to state a material fact required to be stated
therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading (provided that in no
event shall such notice contain any material, nonpublic information), and,
subject to Section 3(r), promptly prepare a supplement or amendment to such
Registration Statement to correct such untrue statement or omission, and deliver
ten (10) copies of the prospectus contained in such supplement or amendment to
Legal

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

Counsel and each Investor (or such other number of copies as Legal Counsel or
such Investor may reasonably request). The Company shall also promptly notify
Legal Counsel, and each Investor in writing: (i) when a prospectus or any
prospectus supplement or post-effective amendment has been filed, and when a
Registration Statement or any post-effective amendment has become effective
(notification of such effectiveness shall be delivered to Legal Counsel and each
Investor for whom the Company has current contact information, by facsimile on
the same day of such effectiveness and by regular mail) (ii) of any request by
the SEC for amendments or supplements to a Registration Statement or related
prospectus or related information, and (iii) of the Company's reasonable
determination that a post-effective amendment to a Registration Statement would
be appropriate.

                           g. The Company shall use its reasonable best efforts
to prevent the issuance of any stop order or other suspension of effectiveness
of a Registration Statement, or the suspension of the qualification of any of
the Registrable Securities for sale in any jurisdiction and, if such an order or
suspension is issued, to obtain the withdrawal of such order or suspension at
the earliest possible moment and to notify Legal Counsel and each Investor who
holds Registrable Securities being sold of the issuance of such order and the
resolution thereof or its receipt of actual notice of the initiation or threat
of any proceeding for such purpose.

                           h. If any Investor is required under applicable
securities law to be described in the Registration Statement as an underwriter,
at the reasonable request of such Investor, the Company shall furnish to such
Investor, on the date of the effectiveness of the Registration Statement and
thereafter from time to time on such dates as an Investor may reasonably request
(i) a letter, dated such date, from the Company's independent certified public
accountants in form and substance as is customarily given by independent
certified public accountants to underwriters in an underwritten public offering,
addressed to the Investors, and (ii) an opinion, dated as of such date, of
counsel representing the Company for purposes of such Registration Statement, in
form, scope and substance as is customarily given in an underwritten public
offering, addressed to the Investors.

                           i. Upon the written request of any Investor in
connection with any Investor's due diligence requirements, if any, the Company
shall make available for inspection by: (i) any Investor, (ii) Legal Counsel,
and (iii) one firm of accountants or other agents retained by the Investors
(collectively, the "INSPECTORS"), all pertinent financial and other records, and
pertinent corporate documents and properties of the Company (collectively, the
"RECORDS"), as shall be reasonably deemed necessary by each Inspector, and cause
the Company's officers, directors and employees to supply all information which
any Inspector may reasonably request; provided, however, that each Inspector
shall agree in writing to hold in strict confidence and shall not make any
disclosure (except to an Investor) or use of any Record or other information
which the Company determines in good faith to be confidential, and of which
determination the Inspectors are so notified, unless: (A) the disclosure of such
Records is necessary to avoid or correct a misstatement or omission in any
Registration Statement or is otherwise required under the 1933 Act, (B) the
release of such Records is ordered pursuant to a final, non-appealable subpoena
or order from a court or government body of competent jurisdiction, or (C) the
information in such Records has been made generally available to the public
other than by disclosure in violation of this Agreement or any other agreement
of which the Inspector has knowledge. Each Investor agrees that it shall, upon
learning that disclosure of such Records is

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

required or is sought in or by a court or governmental body of competent
jurisdiction or through other means, give prompt notice to the Company and allow
the Company, at its expense, to undertake appropriate action to prevent
disclosure of, or to obtain a protective order for, the Records deemed
confidential. Nothing herein (or in any other confidentiality agreement between
the Company and any Investor) shall be deemed to limit the Investors' ability to
sell Registrable Securities in a manner which is otherwise consistent with
applicable laws and regulations.

                           j. The Company shall hold in confidence and not make
any disclosure of information concerning an Investor provided to the Company
unless (i) disclosure of such information is necessary to comply with federal or
state securities laws, (ii) the disclosure of such information is necessary to
avoid or correct a misstatement or omission in any Registration Statement, (iii)
the release of such information is ordered pursuant to a subpoena or other
final, non-appealable order from a court or governmental body of competent
jurisdiction, or (iv) such information has been made generally available to the
public other than by disclosure in violation of this Agreement or any other
agreement. The Company agrees that it shall, upon learning that disclosure of
such information concerning an Investor is sought in or by a court or
governmental body of competent jurisdiction or through other means, give prompt
written notice to such Investor and allow such Investor, at the Investor's
expense, to undertake appropriate action to prevent disclosure of, or to obtain
a protective order for, such information.

                           k. The Company shall use its reasonable best efforts
either to (i) cause all the Registrable Securities covered by a Registration
Statement to be listed on each securities exchange on which securities of the
same class or series issued by the Company are then listed, if any, if the
listing of such Registrable Securities is then permitted under the rules of such
exchange, or (ii) secure designation and quotation of all the Registrable
Securities covered by a Registration Statement on the Nasdaq National Market, or
(iii) if, despite the Company's reasonable best efforts to satisfy the preceding
subclause (i) or (ii), the Company is unsuccessful in satisfying the preceding
subclause (i) or (ii), to secure the inclusion for quotation on The Nasdaq
SmallCap Market for such Registrable Securities and, without limiting the
generality of the foregoing, to use its reasonable best efforts to arrange for
at least two market makers to register with the National Association of
Securities Dealers, Inc. as such with respect to such Registrable Securities.
The Company shall pay all fees and expenses in connection with satisfying its
obligation under this Section 3(k).

                           l. The Company shall cooperate with the Investors who
hold Registrable Securities being offered and, to the extent applicable,
facilitate the timely preparation and delivery of certificates (not bearing any
restrictive legend) representing the Registrable Securities to be offered
pursuant to a Registration Statement and enable such certificates to be in such
denominations or amounts, as the case may be, as the Investors may reasonably
request and registered in such names as the Investors may request.

                           m. If requested by an Investor, the Company shall:
(i) as soon as practicable incorporate in a prospectus supplement or
post-effective amendment such information as an Investor reasonably requests to
be included therein relating to the sale and distribution of Registrable
Securities, including, without limitation, information with respect to the
number of Registrable Securities being offered or sold, the purchase price being
paid therefor and any other terms of the offering of the Registrable Securities
to be sold in such offering, (ii)

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

as soon as practicable make all required filings of such prospectus supplement
or post-effective amendment after being notified of the matters to be
incorporated in such prospectus supplement or post-effective amendment, and
(iii) as soon as practicable, supplement or make amendments to any Registration
Statement if reasonably requested by an Investor holding any Registrable
Securities.

                           n. The Company shall use its reasonable best efforts
to cause the Registrable Securities covered by a Registration Statement to be
registered with or approved by such other governmental agencies or authorities
as may be necessary to consummate the disposition of such Registrable
Securities.

                           o. The Company shall make generally available to its
security holders as soon as practical, but not later than ninety (90) days after
the close of the period covered thereby, an earnings statement (in form
complying with, and in the manner provided by, the provisions of Rule 158 under
the 1933 Act) covering a twelve-month period beginning not later than the first
day of the Company's fiscal quarter next following the effective date of a
Registration Statement.

                           p. The Company shall otherwise use its reasonable
best efforts to comply with all applicable rules and regulations of the SEC in
connection with any registration hereunder.

                           q. Within two (2) Business Days after a Registration
Statement which covers Registrable Securities is ordered effective by the SEC,
the Company shall deliver, and shall cause legal counsel for the Company to
deliver, to the transfer agent for such Registrable Securities (with copies to
the Investors whose Registrable Securities are included in such Registration
Statement) confirmation that such Registration Statement has been declared
effective by the SEC in the form attached hereto as Exhibit A.

                           r. Notwithstanding anything to the contrary herein,
at any time after the Registration Statement has been declared effective by the
SEC, the Company may delay the disclosure of material, non-public information
concerning the Company the disclosure of which at the time is not, in the good
faith opinion of the board of directors of the Company and its counsel, in the
best interest of the Company and, in the opinion of counsel to the Company,
otherwise required (a "GRACE PERIOD"); provided, that the Company shall promptly
(i) notify the Investors in writing of the existence of a Grace Period in
conformity with the provisions of this Section 3(r)(provided that in each notice
the Company will not disclose the content of such material, non-public
information to the Investors) and the date on which the Grace Period will begin,
and (ii) notify the Investors in writing of the date on which the Grace Period
ends; and, provided further, that no Grace Period shall exceed ten (10)
consecutive days and during any three hundred sixty five (365) day period such
Grace Periods shall not exceed an aggregate of thirty (30) days and the first
day of any Grace Period must be at least two (2) trading days after the last day
of any prior Grace Period (each, an "ALLOWABLE GRACE PERIOD"). For purposes of
determining the length of a Grace Period above, the Grace Period shall begin on
and include the date the Investors receive the notice referred to in subclause
(i) and shall end on and include the later of: (A) the date the Investors
receive the notice referred to in subclause (ii), or (B) the date referred to in
such notice. The provisions of Section 2(f) hereof shall not be applicable
during the period of any Allowable Grace Period. Upon expiration of the Grace
Period, the Company

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

shall again be bound by the first sentence of Section 3(f) with respect to the
information giving rise thereto unless such material, non-public information is
no longer applicable. Notwithstanding anything to the contrary, the Company
shall cause its transfer agent to deliver unlegended shares of Common Stock to a
transferee of an Investor, so long as such transfer was made in accordance with
the terms of the Securities Purchase Agreement in connection with any sale of
Registrable Securities with respect to which an Investor has entered into a
contract for sale, and delivered a copy of the prospectus included as part of
the applicable Registration Statement, prior to the Investor's receipt of the
notice of a Grace Period and for which the Investor has not yet settled.

                  4. Obligations of the Investors.

                           a. At least seven (7) Business Days prior to the
first anticipated filing date of a Registration Statement, the Company shall
notify each Investor in writing of the information the Company requires from
each such Investor if such Investor elects to have any of such Investor's
Registrable Securities included in such Registration Statement. It shall be a
condition precedent to the obligations of the Company to complete the
registration pursuant to this Agreement with respect to the Registrable
Securities of a particular Investor that such Investor shall furnish to the
Company such information regarding itself, the Registrable Securities held by it
and the intended method of disposition of the Registrable Securities held by it
as shall be reasonably required to effect the filing and effectiveness of the
registration of such Registrable Securities and shall execute such documents in
connection with such registration as the Company may reasonably request.

                           b. Each Investor, by such Investor's acceptance of
the Registrable Securities, agrees to cooperate with the Company as reasonably
requested by the Company in connection with the preparation and filing of any
Registration Statement hereunder, unless such Investor has notified the Company
in writing of such Investor's election to exclude all of such Investor's
Registrable Securities from such Registration Statement.

                           c. Each Investor agrees that, upon receipt of any
notice from the Company of the happening of any event of the kind described in
Section 3(g) or the first sentence of 3(f), such Investor will immediately
discontinue disposition of Registrable Securities pursuant to any Registration
Statement(s) covering such Registrable Securities until such Investor's receipt
of the copies of the supplemented or amended prospectus contemplated by Section
3(g) or the first sentence of 3(f) or receipt of notice that no supplement or
amendment is required. Notwithstanding anything to the contrary, the Company
shall cause its transfer agent to deliver unlegended shares of Common Stock to a
transferee of an Investor, so long as such transfer was made in accordance with
the terms of the Securities Purchase Agreement in connection with any sale of
Registrable Securities with respect to which an Investor has entered into a
contract for sale prior to the Investor's receipt of a notice from the Company
of the happening of any event of the kind described in Section 3(g) or the first
sentence of 3(f) and for which the Investor has not yet settled.

                           d. Each Investor covenants and agrees that it will
comply with any applicable prospectus delivery requirements of the 1933 Act as
applicable to it in connection with sales of Registrable Securities pursuant to
a Registration Statement.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  5. Expenses of Registration.

                  All reasonable expenses, other than underwriting discounts and
selling commissions, incurred in connection with registrations, filings or
qualifications pursuant to Sections 2 and 3, including, without limitation, all
registration, listing and qualifications fees, printers and accounting fees, and
fees and disbursements of counsel for the Company shall be paid by the Company.
The Company also shall reimburse the Investors for fees and disbursements of
Legal Counsel in connection with registration filing or qualification pursuant
to Sections 2 and 3 of this Agreement, provided that the Company shall only be
required to reimburse the Investors for an amount up to or equal to $5,000.

                  6. Indemnification.

                  In the event any Registrable Securities are included in a
Registration Statement under this Agreement:

                           a. To the fullest extent permitted by law, the
Company will, and hereby does, indemnify, hold harmless and defend each
Investor, the directors, officers, partners, members, employees, agents,
representatives of, and each Person, if any, who controls any Investor within
the meaning of the 1933 Act or the 1934 Act (each, an "INDEMNIFIED PERSON"),
against any losses, claims, damages, liabilities, judgments, fines, penalties,
charges, costs, reasonable attorneys' fees, amounts paid in settlement or
expenses, joint or several (collectively, "INDEMNIFIED DAMAGES"), incurred in
investigating, preparing or defending any action, claim, suit, inquiry,
proceeding, investigation or appeal taken from the foregoing by or before any
court or governmental, administrative or other regulatory agency, body or the
SEC, whether pending or threatened, whether or not an indemnified party is or
may be a party thereto (collectively, "CLAIMS"), to which any of them may become
subject insofar as such Claims (or actions or proceedings, whether commenced or
threatened, in respect thereof) arise out of or are based upon: (i) any untrue
statement or alleged untrue statement of a material fact in a Registration
Statement or any post-effective amendment thereto or in any filing made in
connection with the qualification of the offering under the securities or other
"blue sky" laws of any jurisdiction in which Registrable Securities are offered,
or the omission or alleged omission to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, (ii)
any untrue statement or alleged untrue statement of a material fact contained in
any preliminary prospectus if used prior to the effective date of such
Registration Statement, or contained in the final prospectus (as amended or
supplemented, if the Company files any amendment thereof or supplement thereto
with the SEC) or the omission or alleged omission to state therein any material
fact necessary to make the statements made therein, in the light of the
circumstances under which the statements therein were made, not misleading,
(iii) any violation or alleged violation by the Company of the 1933 Act, the
1934 Act, any other law, including, without limitation, any state securities
law, or any rule or regulation thereunder relating to the offer or sale of the
Registrable Securities pursuant to a Registration Statement or (iv) any material
violation of this Agreement (the matters in the foregoing clauses (i) through
(iv) being, collectively, "VIOLATIONS"). Subject to Section 6(c), the Company
shall reimburse the Indemnified Persons, promptly as such expenses are incurred
and are due and payable, for any reasonable legal fees or other reasonable
expenses incurred by them in connection with investigating or defending any such
Claim. Notwithstanding anything to the contrary contained

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

herein, the indemnification agreement contained in this Section 6(a) and the
agreement with respect to contribution contained in Section 7: (i) shall not
apply to a Claim arising out of or based upon a Violation which occurs in
reliance upon and in conformity with information furnished in writing to the
Company by such Indemnified Person for such Indemnified Person expressly for use
in connection with the preparation of the Registration Statement or any such
amendment thereof or supplement thereto, if such prospectus was timely made
available by the Company pursuant to Section 3(d), (ii) with respect to any
preliminary prospectus, shall not inure to the benefit of any such Person from
whom the Person asserting any such Claim purchased the Registrable Securities
that are the subject thereof (or to the benefit of any Person controlling such
Person) if the untrue statement or omission of material fact contained in the
preliminary prospectus was corrected in the prospectus, as then amended or
supplemented, if such prospectus was timely made available by the Company
pursuant to Section 3(d), and the Indemnified Person was promptly advised in
writing not to use the incorrect prospectus prior to the use giving rise to a
violation and such Indemnified Person, notwithstanding such advice, used it or
failed to deliver the correct prospectus as required by the 1933 Act and such
correct prospectus was timely made available pursuant to Section 3(d), (iii)
shall not be available to the extent such Claim is based on a failure of the
Investor to deliver or to cause to be delivered the prospectus made available by
the Company, including a corrected prospectus, if such prospectus or corrected
prospectus was timely made available by the Company pursuant to Section 3(d),
and (iv) shall not apply to amounts paid in settlement of any Claim if such
settlement is effected without the prior written consent of the Company, which
consent shall not be unreasonably withheld or delayed. Such indemnity shall
remain in full force and effect regardless of any investigation made by or on
behalf of the Indemnified Person and shall survive the transfer of the
Registrable Securities by the Investors pursuant to Section 9.

                           b. In connection with any Registration Statement in
which an Investor is participating, each such Investor agrees to severally and
not jointly indemnify, hold harmless and defend, to the same extent and in the
same manner as is set forth in Section 6(a), the Company, each of its directors,
each of its officers who signs the Registration Statement and each Person, if
any, who controls the Company within the meaning of the 1933 Act or the 1934 Act
(each, an "INDEMNIFIED PARTY"), against any Claim for Indemnified Damages to
which any of them may become subject, under the 1933 Act, the 1934 Act or
otherwise, insofar as such Claim or Indemnified Damages arise out of or are
based upon any Violation, in each case to the extent, and only to the extent,
that such Violation occurs in reliance upon and in conformity with written
information furnished to the Company by such Investor expressly for use in
connection with such Registration Statement; and, subject to Section 6(c), such
Investor will reimburse any legal or other expenses reasonably incurred by an
Indemnified Party in connection with investigating or defending any such Claim;
provided, however, that the indemnity agreement contained in this Section 6(b)
and the agreement with respect to contribution contained in Section 7 shall not
apply to amounts paid in settlement of any Claim if such settlement is effected
without the prior written consent of such Investor, which consent shall not be
unreasonably withheld or delayed; provided, further, however, that an Investor
shall be liable under this Section 6(b) for only that amount of Indemnified
Damages as does not exceed the net proceeds to such Investor as a result of the
sale of Registrable Securities pursuant to such Registration Statement. Such
indemnity shall remain in full force and effect regardless of any investigation
made by or on behalf of such Indemnified Party and shall survive the transfer of
the Registrable Securities by the Investors pursuant to Section 9.
Notwithstanding anything to the contrary contained herein, the

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

indemnification agreement contained in this Section 6(b) with respect to any
preliminary prospectus shall not inure to the benefit of any Indemnified Party
if the untrue statement or omission of material fact contained in the
preliminary prospectus was corrected on a timely basis in the prospectus, as
then amended or supplemented.

                           c. Promptly after receipt by an Indemnified Person or
Indemnified Party under this Section 6 of notice of the commencement of any
action or proceeding (including any governmental action or proceeding) involving
a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in
respect thereof is to be made against any indemnifying party under this Section
6, deliver to the indemnifying party a written notice of the commencement
thereof, and the indemnifying party shall have the right to participate in, and,
to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume control of the defense thereof
with counsel mutually satisfactory to the indemnifying party and the Indemnified
Person or the Indemnified Party, as the case may be; provided, however, that an
Indemnified Person or Indemnified Party shall have the right to retain its own
counsel with the fees and expenses of not more than one counsel for such
Indemnified Person or Indemnified Party to be paid by the indemnifying party,
if, in the reasonable opinion of the Indemnified Person or the Indemnified
Party, as the case may be, the representation by such counsel of the Indemnified
Person or Indemnified Party and the indemnifying party would be inappropriate
due to actual or potential differing interests between such Indemnified Person
or Indemnified Party and any other party represented by such counsel in such
proceeding. In the case of an Indemnified Person, legal counsel referred to in
the immediately preceding sentence shall be selected by the Investors holding at
least a majority in interest of the Registrable Securities included in the
Registration Statement to which the Claim relates. The Indemnified Party or
Indemnified Person shall cooperate fully with the indemnifying party in
connection with any negotiation or defense of any such action or Claim by the
indemnifying party and shall furnish to the indemnifying party all information
reasonably available to the Indemnified Party or Indemnified Person which
relates to such action or Claim. The indemnifying party shall keep the
Indemnified Party or Indemnified Person fully apprized at all times as to the
status of the defense or any settlement negotiations with respect thereto. No
indemnifying party shall be liable for any settlement of any action, claim or
proceeding effected without its prior written consent, provided, however, that
the indemnifying party shall not unreasonably withhold, delay or condition its
consent. No indemnifying party shall, without the prior written consent of the
Indemnified Party or Indemnified Person, consent to entry of any judgment or
enter into any settlement or other compromise which does not include as an
unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party or Indemnified Person of a release from all liability in
respect to such Claim or litigation. Following indemnification as provided for
hereunder, the indemnifying party shall be subrogated to all rights of the
Indemnified Party or Indemnified Person with respect to all third parties, firms
or corporations relating to the matter for which indemnification has been made.
The failure to deliver written notice to the indemnifying party within a
reasonable time of the commencement of any such action shall not relieve such
indemnifying party of any liability to the Indemnified Person or Indemnified
Party under this Section 6, except to the extent that the indemnifying party is
prejudiced in its ability to defend such action.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                           d. The indemnification required by this Section 6
shall be made by periodic payments of the amount thereof during the course of
the investigation or defense, as and when bills are received or Indemnified
Damages are incurred.

                           e. The indemnity agreements contained herein shall be
in addition to (i) any cause of action or similar right of the Indemnified Party
or Indemnified Person against the indemnifying party or others, and (ii) any
liabilities the indemnifying party may be subject to pursuant to the law.

                  7. Contribution.

                  To the extent any indemnification by an indemnifying party is
prohibited or limited by law, the indemnifying party agrees to make the maximum
contribution with respect to any amounts for which it would otherwise be liable
under Section 6 to the fullest extent permitted by law; provided, however, that:
(i) no Person involved in the sale of Registrable Securities which Person is
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the 1933 Act) in connection with such sale shall be entitled to contribution
from any Person involved in such sale of Registrable Securities who was not
guilty of fraudulent misrepresentation; and (ii) contribution by any seller of
Registrable Securities shall be limited in amount to the net amount of proceeds
received by such seller from the sale of such Registrable Securities pursuant to
such Registration Statement.

                  8. Reports Under the 1934 Act.

                  With a view to making available to the Investors the benefits
of Rule 144 promulgated under the 1933 Act or any other similar rule or
regulation of the SEC that may at any time permit the Investors to sell
securities of the Company to the public without registration ("RULE 144"), the
Company agrees to:

                           a. make and keep public information available, as
those terms are understood and defined in Rule 144;

                           b. file with the SEC in a timely manner all reports
and other documents required of the Company under the 1933 Act and the 1934 Act
so long as the Company remains subject to such requirements and the filing of
such reports and other documents is required for the applicable provisions of
Rule 144; and

                           c. furnish to each Investor so long as such Investor
owns Registrable Securities, promptly upon request, (i) a written statement by
the Company, if true, that it has complied with the reporting requirements of
Rule 144, the 1933 Act and the 1934 Act, (ii) a copy of the most recent annual
or quarterly report of the Company and such other reports and documents so filed
by the Company, if not otherwise available on EDGAR, and (iii) such other
information as may be reasonably requested to permit the Investors to sell such
securities pursuant to Rule 144 without registration.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  9. Assignment of Registration Rights.

                  The rights under this Agreement shall be automatically
assignable by the Investors to any transferee of all or any portion of such
Investor's Registrable Securities if: (i) the Investor agrees in writing with
the transferee or assignee to assign such rights, and a copy of such agreement
is furnished to the Company within a reasonable time after such assignment, (ii)
the Company is, within a reasonable time after such transfer or assignment,
furnished with written notice of: (A) the name and address of such transferee or
assignee, and (B) the securities with respect to which such registration rights
are being transferred or assigned, (iii) immediately following such transfer or
assignment the further disposition of such securities by the transferee or
assignee is restricted under the 1933 Act and applicable state securities laws,
(iv) at or before the time the Company receives the written notice contemplated
by subclause (ii) of this sentence the transferee or assignee agrees in writing
with the Company to be bound by all of the provisions contained herein, and (v)
such transfer shall have been made in accordance with the applicable
requirements of the Securities Purchase Agreement.

                  10. Amendment of Registration Rights.

                  Provisions of this Agreement may be amended and the observance
thereof may be waived (either generally or in a particular instance and either
retroactively or prospectively), only with the written consent of the Company
and Investors who then hold at least a majority of the Registrable Securities.
Any amendment or waiver effected in accordance with this Section 10 shall be
binding upon each Investor and the Company. No such amendment shall be effective
unless it applies to all of the holders of the Registrable Securities. No
consideration shall be offered or paid to any Person to amend or consent to a
waiver or modification of any provision of any of this Agreement unless the same
consideration also is offered to all of the parties to this Agreement.

                  11. Miscellaneous.

                           a. A Person is deemed to be a holder of Registrable
Securities whenever such Person owns or is deemed to own of record such
Registrable Securities. If the Company receives conflicting instructions,
notices or elections from two or more Persons with respect to the same
Registrable Securities, the Company shall act upon the basis of instructions,
notice or election received from the record owner of such Registrable
Securities.

                           b. Any notices, consents, waivers or other
communications required or permitted to be given under the terms of this
Agreement must be in writing and will be deemed to have been delivered: (i) upon
receipt, when delivered personally, (ii) upon receipt, when sent by facsimile
(provided confirmation of transmission is mechanically or electronically
generated and kept on file by the sending party), or (iii) one Business Day
after deposit with a nationally recognized overnight delivery service, in each
case properly addressed to the party to receive the same, assuming written
confirmation from such overnight delivery service has been received. The
addresses and facsimile numbers for such communications shall be:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                           If to the Company:

                                    DUSA Pharmaceuticals, Inc.
                                    25 Upton Drive
                                    Wilmington, Massachusetts  01887
                                    Telephone: (978) 657-7500
                                    Facsimile: (978) 657-9193
                                    Attention: President and CEO

                           with a copy to:

                                    Reed Smith LLP
                                    Princeton Forrestal Village
                                    136 Main Street
                                    Princeton, New Jersey 08543
                                    Telephone: (609) 514-8543
                                    Facsimile: (609) 951-0824
                                    Attention: Nanette W. Mantell, Esq.

                           If to Legal Counsel:

                                    Schulte Roth & Zabel LLP
                                    919 Third Avenue
                                    New York, New York  10022
                                    Telephone: (212) 756-2000
                                    Facsimile: (212) 593-5955
                                    Attention: Eleazer Klein, Esq.

If to an Investor, to its address and facsimile number set forth on the Schedule
of Buyers attached hereto or as otherwise provided to the Company upon any
transfer pursuant to Section 9 of this Agreement, with copies to such Investor's
representatives as set forth on the Schedule of Buyers or otherwise provided to
the Company, or to such other address and/or facsimile number and/or to the
attention of such other Person as the recipient party has specified by written
notice given to each other party five (5) days prior to the effectiveness of
such change. Written confirmation of receipt: (A) given by the recipient of such
notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the sender's facsimile machine containing the time,
date, recipient facsimile number and an image of the first page of such
transmission, or (C) provided by a courier or overnight courier service shall be
rebuttable evidence of personal service, receipt by facsimile or receipt from a
nationally recognized overnight delivery service in accordance with subclause
(i), (ii) or (iii) above, respectively.

                           c. Failure of any party to exercise any right or
remedy under this Agreement or otherwise, or delay by a party in exercising such
right or remedy, shall not operate as a waiver thereof.

                           d. All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by
the internal laws of the State of New York, without giving effect to any choice
of law or conflict of law provision or rule (whether of the

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York. Each party
hereby irrevocably submits to the non- exclusive jurisdiction of the state and
federal courts sitting The City of New York, Borough of Manhattan, for the
adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is brought in an inconvenient forum or that the
venue of such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being
served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. If any provision of this
Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity
or unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement in that jurisdiction or the validity or
enforceability of any provision of this Agreement in any other jurisdiction.
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO
REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY.

                           e. This Agreement, the Securities Purchase Agreement
and the instruments referenced herein and therein constitute the entire
agreement among the parties hereto with respect to the subject matter hereof and
thereof. There are no restrictions, promises, warranties or undertakings, other
than those set forth or referred to herein and therein. This Agreement, the
Securities Purchase Agreement and the instruments referenced herein and therein
supersede all prior agreements and understandings among the parties hereto with
respect to the subject matter hereof and thereof.

                           f. Subject to the requirements of Section 9, this
Agreement shall inure to the benefit of and be binding upon the permitted
successors and assigns of each of the parties hereto.

                           g. The headings in this Agreement are for convenience
of reference only and shall not limit or otherwise affect the meaning hereof.

                           h. This Agreement may be executed in identical
counterparts, each of which shall be deemed an original but all of which shall
constitute one and the same agreement. This Agreement, once executed by a party,
may be delivered to the other party hereto by facsimile transmission of a copy
of this Agreement bearing the signature of the party so delivering this
Agreement.

                           i. Each party shall do and perform, or cause to be
done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
any other party may reasonably request in order to

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

carry out the intent and accomplish the purposes of this Agreement and the
consummation of the transactions contemplated hereby.

                           j. All consents and other determinations required to
be made by the Investors pursuant to this Agreement shall be made, unless
otherwise specified in this Agreement, by Investors holding at least a majority
of the Registrable Securities.

                           k. The language used in this Agreement will be deemed
to be the language chosen by the parties to express their mutual intent and no
rules of strict construction will be applied against any party.

                           l. This Agreement is intended for the benefit of the
parties hereto and their respective permitted successors and assigns, and is not
for the benefit of, nor may any provision hereof be enforced by, any other
Person.

                                   * * * * * *

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

COMPANY:

DUSA PHARMACEUTICALS, INC.

By: _______________________
    Name: D. Geoffrey Shulman
    Title: President and Chief Executive Officer

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

SMITHFIELD FIDUCIARY LLC

By: _______________________
    Name: Adam J. Chill
    Title: Authorized Signatory

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

MAINFIELD ENTERPRISES INC.

By: _______________________
    Name:
    Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

CRANSHIRE CAPITAL L.P.

By: _______________________
    Name: Mitchell P. Kopin
    Title: President-Downsview Capital, Inc., The General Partner

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

VERTICAL VENTURES, LLC

By: _______________________
    Name:
    Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

OMICRON MASTER TRUST

By: _______________________
    Name:
    Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

PORTSIDE GROWTH AND OPPORTUNITY FUND

By: _______________________
    Name:
    Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

SUNRISE EQUITY PARTNERS, LP

By: _______________________
    Name:
    Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

SUNRISE SECURITIES CORP.

By: _______________________
    Name:
    Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

LANGLEY PARTNERS, L.P.

By: _______________________
    Name: Jeffrey Thorp
    Title: Managing Member of Langley Capital, LLC, its General Partner

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  IN WITNESS WHEREOF, each Buyer and the Company have caused
their respective signature page to this Registration Rights Agreement to be duly
executed as of the date first written above.

BUYER:

___________________________
    PAUL SCHARFER

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT A

                               SCHEDULE OF BUYERS

<TABLE>
<CAPTION>
                                           BUYER ADDRESS                       BUYER'S REPRESENTATIVE'S ADDRESS
         BUYER                          AND FACSIMILE NUMBER                        AND FACSIMILE NUMBER
         -----                          --------------------                        --------------------
<S>                                  <C>                                       <C>
SMITHFIELD FIDUCIARY LLC             c/o Highbridge Capital Management, LLC       Schulte Roth & Zabel LLP
                                     9 West 57th Street, 27th Floor               919 Third Avenue
                                     New York, New York  10019                    New York, New York 10022
                                     Attention: Ari J. Storch                     Attn: Eleazer Klein, Esq.
                                                Adam J. Chill                     Facsimile: (212) 593-5955
                                     Facsimile: (212) 751-0755                    Telephone: (212) 756-2000
                                     Telephone: (212) 287-4720

MAINFIELD ENTERPRISES INC.           c/o Sage Capital Growth, Inc.
                                     660 Madison Avenue, 18th Floor
                                     New York, New York  10021
                                     Attention: Eldad Gal
                                     Facsimile: (212) 651-9010
                                     Telephone: (212) 651-9008

CRANSHIRE CAPITAL L.P.               c/o Downsview Capital, Inc.
                                     The General Partner
                                     666 Dundee Road, Suite 1901
                                     Northbrook, IL  60062
                                     Attention: Mitchell P. Kopin
                                     Facsimile: (847) 562-9031
                                     Telephone: (847) 562-9030

VERTICAL VENTURES, LLC               c/o Vertical Ventures, LLC
                                     900 Third Avenue, 26th Floor
                                     New York, New York  10022
                                     Facsimile No.: (646) 274-1728
                                     Telephone No.: (212) 974-3070
                                     Attention:  Joshua Silverman

OMICRON MASTER TRUST                 c/o Omicron Capital
                                     810 Seventh Avenue
                                     39th Floor
                                     New York, New York 10019
                                     Attention: Brian Daly
                                     Facsimile: (212) 803-5263
                                     Telephone: (212) 803-5269

PORTSIDE GROWTH AND OPPORTUNITY      c/o Ramius Capital Group, L.L.C.
FUND                                 666 Third Avenue, 26th Floor
                                     New York, New York 10006
                                     Attention: Jeffrey Solomon
                                                Jeffrey Smith
                                     Facsimile: (212) 845-7999
                                     Telephone : (212) 845-7917

SUNRISE EQUITY PARTNERS, LP          c/o Sunrise Securities Corp.
                                     641 Lexington Avenue, 25th Floor
                                     New York, NY 10022
                                     Attention: Marilyn Adler
                                     Facsimile: (212) 750-7277
                                     Telephone: (212) 421-1616
</TABLE>

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

<TABLE>
<S>                                  <C>
SUNRISE SECURITIES CORP.             c/o Sunrise Securities Corp.
                                     641 Lexington Avenue, 25th Floor
                                     New York, NY 10022
                                     Attention: Marcia Kucher
                                     Facsimile: (212) 750-7277
                                     Telephone: (212) 421-1616

LANGLEY PARTNERS, L.P.               c/o Langley Capital, LLC
                                     535 Madison Avenue, 7th Floor
                                     New York, NY 10022
                                     Attention: Jeffrey Thorp
                                     Facsimile: (212) 208-2971
                                     Telephone: (212) 850-7528

PAUL SCHARFER                        265 East 66th Street
                                     New York, NY 10021
                                     Facsimile: (212) 772-0255
                                     Telephone: (212) 772-0255
</TABLE>

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT B

                         FORM OF NOTICE OF EFFECTIVENESS
                            OF REGISTRATION STATEMENT

American Stock Transfer and Trust
Attn:  Donna Ansbro

                  Re: DUSA Pharmaceuticals, Inc.

Ladies and Gentlemen:

                  We are counsel to DUSA Pharmaceuticals, Inc., a New Jersey
corporation (the "COMPANY"), and have represented the Company in connection with
that certain Securities Purchase Agreement, dated as of February 27, 2004 (the
"SECURITIES PURCHASE AGREEMENT"), entered into by and among the Company and the
buyers named therein (collectively, the "HOLDERS") pursuant to which the Company
issued to the Holders its shares of the Company's Common Stock, no par value
(the "COMMON STOCK") and additional investment rights exercisable for shares of
Common Stock (the "ADDITIONAL INVESTMENT RIGHTS"). Pursuant to the Securities
Purchase Agreement, the Company also has entered into a Registration Rights
Agreement with the Holders (the "REGISTRATION RIGHTS AGREEMENT") pursuant to
which the Company agreed, among other things, to register the resale of the
Registrable Securities (as defined in the Registration Rights Agreement),
including the shares of Common Stock issuable upon exercise of the Additional
Investment Rights under the Securities Act of 1933, as amended (the "1933 ACT").
In connection with the Company's obligations under the Registration Rights
Agreement, on ____________ ___, 2004, the Company filed a Registration Statement
on Form S-3 (File No. 333-_____________) (the "REGISTRATION STATEMENT") with the
Securities and Exchange Commission (the "SEC") relating to the Registrable
Securities which names each of the Holders as a selling stockholder thereunder.

                  In connection with the foregoing, we advise you that a member
of the SEC's staff has advised us by telephone that the SEC has entered an order
declaring the Registration Statement effective under the 1933 Act at [ENTER TIME
OF EFFECTIVENESS] on [ENTER DATE OF EFFECTIVENESS] and we have no knowledge,
after telephonic inquiry of a member of the SEC's staff, that any stop order
suspending its effectiveness has been issued or that any proceedings for that
purpose are pending before, or threatened by, the SEC and the Registrable
Securities are available for resale under the 1933 Act pursuant to the
Registration Statement.

                  This letter shall serve as our standing notice to you that the
Common Stock are, as of this date, freely transferable by the Holders pursuant
to the Registration Statement. Unless you receive separate notice or
instructions from us following the date hereof and preceding a request by a
Holder for a legend-free certificate or reissue thereof, you need not require
further letters from us to effect any future legend-free issuance or reissuance
of shares of Common Stock to the Holders as contemplated by the Company's
Irrevocable Transfer Agent Instructions dated February 27, 2004. This letter
shall serve as our standing opinion with regard to this matter.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                              Very truly yours,

                                              [ISSUER'S COUNSEL]
                                              By: ______________________________

CC: [LIST NAMES OF HOLDERS]

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                     ANNEX I
                             SELLING SECURITYHOLDERS

         The shares of common stock being offered by the selling securityholders
were issued pursuant to a Securities Purchase Agreement, dated as of February
27, 2004, and are issuable upon exercise of additional investment rights, which
were also issued pursuant to the Securities Purchase Agreement. For additional
information regarding the issuance of these shares of common stock and the
additional investment rights, see "Private Placement of Common Shares and
Additional Investment Rights" above. We are registering the shares of common
stock in order to permit the selling securityholders to offer the shares for
resale from time to time. Except for the ownership of these shares of common
stock and the additional investment rights, the selling securityholders have not
had any material relationship with us within the past three years.

         The table below lists the selling securityholders and other information
regarding the beneficial ownership of the common stock by each of the selling
securityholders. The second column lists the number of shares of common stock
beneficially owned by each selling securityholder, based on its ownership of the
shares of common stock and the additional investment rights issued pursuant to
the February 2004 private placement, as of ________ [ ], 2004, assuming exercise
of all of the additional investment rights held by the selling securityholders
on that date, without regard to any limitations on exercise.

         The third column lists the shares of common stock being offered by this
prospectus by the selling securityholders.

         The fourth column assumes the sale of all of the shares of Common Stock
offered by the selling securityholders pursuant to this prospectus.

         Under the terms of the additional investment rights, a selling
securityholder may not exercise the additional investment rights, to the extent
such exercise would cause such selling securityholder, together with its
affiliates, to beneficially own a number of shares of common stock which would
exceed 9.99% of our then outstanding common stock following such exercise,
excluding for purposes of such determination shares of common stock issuable
upon exercise of the additional investment rights that have not been exercised.
The number of shares in the second column does not reflect this limitation. The
selling securityholders may sell all, some or none of their shares in this
offering. See "Plan of Distribution."

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

<TABLE>
<CAPTION>
                                                                    MAXIMUM NUMBER OF SHARES
                                          NUMBER OF SHARES OWNED     TO BE SOLD PURSUANT TO       NUMBER OF SHARES
NAME OF SELLING SECURITYHOLDER              PRIOR TO OFFERING)           THIS PROSPECTUS        OWNED AFTER OFFERING
------------------------------              ------------------           ---------------        --------------------
<S>                                       <C>                       <C>                         <C>
Smithfield Fiduciary LLC (1)                       [___]                      [___]                     [0]

Mainfield Enterprises Inc. (2)

Cranshire Capital L.P. (3)

Vertical Ventures, LLC (4)

Omicron Master Trust (5)

Portside Growth and Opportunity Fund (6)

Sunrise Equity Partners, LP (7)

Sunrise Securities Corp. (8)

Langley Partners, L.P. (9)

Paul Scharfer (10)                                 [___]                      [___]                     [0]
</TABLE>

                  (1) Highbridge Capital Management, LLC ("Highbridge") is the
trading manager of Smithfield Fiduciary LLC ("Smithfield") and consequently has
voting control and investment discretion over the shares of common stock held by
Smithfield. Glenn Dubin and Henry Swieca control Highbridge. Each of Highbridge
and Messrs. Dubin and Swieca disclaims beneficial ownership of the shares held
by Smithfield.

                  (2) Pursuant to an investment management agreement, Avi Vigder
has voting discretion and investment control over the shares held by Mainfield
Enterprises, Inc. Avi Vigder disclaims beneficial ownership of such shares.

                  (3) Mitchell P. Kopin is the president of Downsview Capital,
Inc., the general partner of Cranshire Capital, L.P., and has sole voting
control and investment discretion over securities held by Cranshire Capital,
L.P.

                  (4) Joshua Silverman, a partner of Vertical Ventures, LLC has
voting control and investment discretion over securities held by Vertical
Ventures, LLC. Mr. Silverman disclaims beneficial ownership of the shares held
by Vertical Ventures, LLC.

                  (5) Omicron Capital, L.P., a Delaware limited partnership
("Omicron Capital"), serves as investment manager to Omicron Master Trust, a
trust formed under the laws

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

of Bermuda ("Omicron"), Omicron Capital, Inc., a Delaware corporation ("OCI"),
serves as general partner of Omicron Capital, and Winchester Global Trust
Company Limited ("Winchester") serves as the trustee of Omicron. By reason of
such relationships, Omicron Capital and OCI may be deemed to share dispositive
power over the shares of our common stock owned by Omicron, and Winchester may
be deemed to share voting and dispositive power over the shares of our common
stock owned by Omicron. Omicron Capital, OCI and Winchester disclaim beneficial
ownership of such shares of our common stock. Omicron Capital has delegated
authority from the board of directors of Winchester regarding the portfolio
management decisions with respect to the shares of common stock owned by Omicron
and, as of April 21, 2003, Mr. Olivier H. Morali and Mr. Bruce T. Bernstein,
officers of OCI, have delegated authority from the board of directors of OCI
regarding the portfolio management decisions of Omicron Capital with respect to
the shares of common stock owned by Omicron. By reason of such delegated
authority, Messrs. Morali and Bernstein may be deemed to share dispositive power
over the shares of our common stock owned by Omicron. Messrs. Morali and
Bernstein disclaim beneficial ownership of such shares of our common stock and
neither of such persons has any legal right to maintain such delegated
authority. No other person has sole or shared voting or dispositive power with
respect to the shares of our common stock being offered by Omicron, as those
terms are used for purposes under Regulation 13D-G of the Securities Exchange
Act of 1934, as amended. Omicron and Winchester are not "affiliates" of one
another, as that term is used for purposes of the Securities Exchange Act of
1934, as amended, or of any other person named in this prospectus as a selling
stockholder. No person or "group" (as that term is used in Section 13(d) of the
Securities Exchange Act of 1934, as amended, or the SEC's Regulation 13D-G)
controls Omicron and Winchester.

                  (6) Ramius Capital Group, LLC ("Ramius Capital") is the
investment adviser of Portside Growth & Opportunity Fund ("Portside") and
consequently has voting control and investment discretion over securities held
by Portside. Ramius Capital disclaims beneficial ownership of the shares held by
Portside. Peter A. Cohen, Morgan B. Stark, Thomas W. Strauss and Jeffrey M.
Solomon are the sole managing members of C4S& Co., LLC, the sole managing member
of Ramius Capital. As a result, Messrs. Cohen, Stark, Strauss and Solomon may be
considered beneficial owners of any shares deemed to be beneficially owned by
Ramius Capital. Messrs. Cohen, Stark, Strauss and Solomon disclaim beneficial
ownership of these shares.

                  (7)

                  (8)

                  (9)

                  (10)

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                              PLAN OF DISTRIBUTION

         The selling securityholders may, from time to time, sell any or all of
their shares of common stock issued pursuant to the February 2004 private
placement or upon exercise of the additional investment rights on any stock
exchange, market or trading facility on which the shares are traded or in
private transactions. These sales may be at fixed or negotiated prices. The
selling securityholders may use any one or more of the following methods when
selling shares:

-        ordinary brokerage transactions and transactions in which the
         broker-dealer solicits purchasers;

-        block trades in which the broker-dealer will attempt to sell the shares
         as agent but may position and resell a portion of the block as
         principal to facilitate the transaction;

-        purchases by a broker-dealer as principal and resale by the
         broker-dealer for its account;

-        an exchange distribution in accordance with the rules of the applicable
         exchange;

-        privately negotiated transactions;

-        short sales;

-        broker-dealers may agree with the selling securityholders to sell a
         specified number of such shares at a stipulated price per share;

-        a combination of any such methods of sale; and

-        any other method permitted pursuant to applicable law.

         The selling securityholders may also sell shares under Rule 144 under
the Securities Act, if available, rather than under this prospectus.

         The selling securityholders may also engage in short sales against the
box, puts and calls and other transactions in our securities or derivatives of
our securities and may sell or deliver shares in connection with these trades.

         Broker-dealers engaged by the selling securityholders may arrange for
other brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the selling securityholders (or, if any
broker-dealer acts as agent for the purchaser of shares, from the purchaser) in
amounts to be negotiated. The selling securityholders do not expect these
commissions and discounts to exceed what is customary in the types of
transactions involved. Any profits on the resale of shares of common stock by a
broker-dealer acting as principal might be deemed to be underwriting discounts
or commissions under the Securities Act. Discounts, concessions, commissions and
similar selling expenses, if any, attributable to the sale of shares will be
borne by a selling securityholder. The selling securityholders may agree to
indemnify any agent, dealer or broker-dealer that participates in transactions
involving sales of the shares if liabilities are imposed on that person under
the Securities Act.

         The selling securityholders may from time to time pledge or grant a
security interest in some or all of the shares of common stock owned by them
and, if they default in the performance of their secured obligations, the
pledgees or secured parties may offer and sell the shares of common stock from
time to time under this prospectus after we have filed an amendment to this
prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act of 1933 amending the list of selling securityholders to

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

include the pledgee, transferee or other successors in interest as selling
securityholders under this prospectus.

         The selling securityholders also may transfer the shares of common
stock in other circumstances, in which case the transferees, pledgees or other
successors in interest will be the selling beneficial owners for purposes of
this prospectus and may sell the shares of common stock from time to time under
this prospectus after we have filed an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act of 1933 amending
the list of selling securityholders to include the pledgee, transferee or other
successors in interest as selling securityholders under this prospectus.

         The selling securityholders and any broker-dealers or agents that are
involved in selling the shares of common stock may be deemed to be
"underwriters" within the meaning of the Securities Act in connection with such
sales. In such event, any commissions received by such broker-dealers or agents
and any profit on the resale of the shares of common stock purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act.
The selling securityholders have advised us that they have acquired their
securities in the ordinary course of business and they have not entered into any
agreements, understandings or arrangements with any underwriters or
broker-dealers regarding the sale of their shares of common stock, nor is there
an underwriter or coordinating broker acting in connection with a proposed sale
of shares of common stock by any selling securityholder. If we are notified by
any selling securityholder that any material arrangement has been entered into
with a broker-dealer for the sale of shares of common stock, if required, we
will file a supplement to this prospectus. If the selling securityholders use
this prospectus for any sale of the shares of common stock, they will be subject
to the prospectus delivery requirements of the Securities Act.

         We are required to pay all fees and expenses incident to the
registration of the shares of common stock. We have agreed to indemnify the
selling securityholders against certain losses, claims, damages and liabilities,
including liabilities under the Securities Act.

         The anti-manipulation rules of Regulation M under the Securities
Exchange Act of 1934 may apply to sales of our common stock and activities of
the selling securityholders.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT D

                           TRANSFER AGENT INSTRUCTIONS

                           DUSA PHARMACEUTICALS, INC.

                                February 27, 2004

American Stock Transfer and Trust
59 Maiden Lane
New York, NY 10038
Attention: Donna Ansbro

Ladies and Gentlemen:

                  Reference is made to that certain Securities Purchase
Agreement, dated as of February 27, 2004 (the "AGREEMENT"), by and among DUSA
Pharmaceuticals, Inc., a New Jersey corporation (the "COMPANY"), and the
investors named on the Schedule of Buyers attached thereto (collectively, the
"HOLDERS"), pursuant to which the Company is issuing to the Holders shares (the
"Common Shares") of Common Stock of the Company, no par value (the "COMMON
STOCK"), and additional investment rights (the "ADDITIONAL INVESTMENT RIGHTS"),
which are exercisable into shares of Common Stock.

                  This letter shall serve as our irrevocable authorization and
direction to you (provided that you are the transfer agent of the Company at
such time):

                  (i) to issue shares of Common Stock upon transfer or resale of
the Common Shares; and

                  (ii) to issue shares of Common Stock upon the exercise of the
Additional Investment Rights (the "ADDITIONAL INVESTMENT RIGHT SHARES") to or
upon the order of a Holder from time to time upon delivery to you of a properly
completed and duly executed Exercise Notice, in the form attached hereto as
Exhibit I, which has been acknowledged by the Company as indicated by the
signature of a duly authorized officer of the Company thereon.

                  You acknowledge and agree that so long as you have previously
received (a) written confirmation from the Company outside legal counsel that
either (i) a registration statement covering resales of the Common Shares and
the Additional Investment Right Shares has been declared effective by the
Securities and Exchange Commission (the "SEC") under the Securities Act of 1933,
as amended (the "1933 ACT"), or (ii) sales of the Common Shares and the
Additional Investment Right Shares may be made in conformity with Rule 144 under
the 1933 Act and (b) if applicable, a copy of such registration statement, then
within two (2) business days of your receipt of the Exercise Notice, you shall
issue the certificates representing the Common Shares and the Additional
Investment Right Shares, and such certificates shall not bear any

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

legend restricting transfer of the Common Shares and the Additional Investment
Right Shares thereby and should not be subject to any stop-transfer restriction;
provided, however, that if such Common Shares and the Additional Investment
Right Shares are not registered for resale under the 1933 Act or able to be sold
under Rule 144, then, the certificates for such Common Shares and Additional
Investment Right Shares shall bear the following legend:

                           [NEITHER THE ISSUANCE AND SALE OF THE SECURITIES
                           REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES
                           INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE
                           BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE
                           HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF
                           1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
                           LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
                           SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF
                           (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
                           SECURITIES UNDER THE SECURITIES ACT OF 1933, AS
                           AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR (B)
                           AN OPINION OF COUNSEL, IN A FORM REASONABLY
                           ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT
                           REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT
                           TO RULE 144 OR RULE 144A UNDER SAID ACT.
                           NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE
                           PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
                           OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE
                           SECURITIES.

                  A form of written confirmation from the Company's outside
legal counsel that a registration statement covering resales of the Common
Shares and the Additional Investment Right Shares has been declared effective by
the SEC under the 1933 Act is attached hereto as Exhibit II.

                  Please be advised that the Holders are relying upon this
letter as an inducement to enter into the Agreement and, accordingly, each
Holder is a third party beneficiary to these instructions.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                  Please execute this letter in the space indicated to
acknowledge your agreement to act in accordance with these instructions. Should
you have any questions concerning this matter, please contact me at
416-363-5059.

                                   Very truly yours,

                                   DUSA PHARMACEUTICALS, INC

                                   By: ___________________________
                                       Name: D. Geoffrey Shulman
                                       Title: President and CEO

THE FOREGOING INSTRUCTIONS ARE
ACKNOWLEDGED AND AGREED TO

this 1st day of March 2004

AMERICAN STOCK TRANSFER AND TRUST

By: _______________________
      Name: _______________
      Title: ______________

Enclosures

cc:    Smithfield Fiduciary LLC
       Mainfield Enterprises Inc.
       Cranshire Capital L.P.
       Vertical Ventures, LLC
       Omicron Master Trust
       Portside Growth and Opportunity Fund
       Sunrise Equity Partners, LP
       Sunrise Securities Corp.
       Langley Partners, L.P.
       Paul Scharfer
       Eleazer N. Klein, Esq.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT I

                                 EXERCISE NOTICE

            TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS
                           ADDITIONAL INVESTMENT RIGHT

                           DUSA PHARMACEUTICALS, INC.

To:      DUSA Pharmaceuticals, Inc.

         The undersigned is the holder of Additional Investment Right No. _____
(the "ADDITIONAL INVESTMENT RIGHT") issued by DUSA Pharmaceuticals, Inc., a New
Jersey corporation (the "COMPANY"). Capitalized terms used herein and not
otherwise defined shall have the respective meanings set forth in the Additional
Investment Right.

         1. The Additional Investment Right is currently exercisable to purchase
a total of ____________ Additional Investment Right Shares.

         2. The undersigned holder hereby exercises its right to purchase
______________ Additional Investment Right Shares pursuant to the Additional
Investment Right.

         3. The holder shall pay the sum of $___________________ to the Company
in accordance with the terms of the Additional Investment Right.

         4. Pursuant to this exercise, the Company shall deliver to the holder
__________ Additional Investment Right Shares in accordance with the terms of
the Additional Investment Right.

         5. Following this exercise, the Additional Investment Right shall be
exercisable to purchase a total of ________________ Additional Investment Right
Shares.

         Please issue the Additional Investment Right Shares in the following
name and to the following address:

         Issue to: _____________________________________________________________
                   _____________________________________________________________
                   _____________________________________________________________

         Account Number: _______________________________________________________
                 (if electronic book entry transfer)

         DTC Participant Number: _______________________________________________
                 (if electronic book entry transfer)

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

Date: _______________ __, ______

________________________________
Name of Registered Holder

By:
    Name:
    Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                 ACKNOWLEDGMENT

         The Company hereby acknowledges this Exercise Notice and hereby directs
American Stock Transfer and Trust to issue the above indicated number of shares
of Common Stock in accordance with the Transfer Agent Instructions dated
February 27, 2004 from the Company and acknowledged and agreed to by American
Stock Transfer and Trust.

                                        DUSA PHARMACEUTICALS, INC.

                                        By: __________________________
                                            Name:
                                            Title:

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                   EXHIBIT II

                         FORM OF NOTICE OF EFFECTIVENESS
                            OF REGISTRATION STATEMENT

American Stock Transfer and Trust
Attn: Donna Ansbro

                  Re:      DUSA Pharmaceuticals, Inc.

Ladies and Gentlemen:

                  We are counsel to DUSA Pharmaceuticals, Inc., a New Jersey
corporation (the "COMPANY"), and have represented the Company in connection with
that certain Securities Purchase Agreement, dated as of February 27, 2004 (the
"SECURITIES PURCHASE AGREEMENT"), entered into by and among the Company and the
buyers named therein (collectively, the "HOLDERS") pursuant to which the Company
issued to the Holders its shares of the Company's Common Stock, no par value
(the "COMMON STOCK") and additional investment rights exercisable for shares of
Common Stock (the "ADDITIONAL INVESTMENT RIGHTS"). Pursuant to the Securities
Purchase Agreement, the Company also has entered into a Registration Rights
Agreement with the Holders (the "REGISTRATION RIGHTS AGREEMENT") pursuant to
which the Company agreed, among other things, to register the resale of the
Registrable Securities (as defined in the Registration Rights Agreement),
including the shares of Common Stock issuable upon exercise of the Additional
Investment Rights under the Securities Act of 1933, as amended (the "1933 ACT").
In connection with the Company's obligations under the Registration Rights
Agreement, on ____________ ___, 2004, the Company filed a Registration Statement
on Form S-3 (File No. 333-_____________) (the "REGISTRATION STATEMENT") with the
Securities and Exchange Commission (the "SEC") relating to the Registrable
Securities which names each of the Holders as a selling stockholder thereunder.

                  In connection with the foregoing, we advise you that a member
of the SEC's staff has advised us by telephone that the SEC has entered an order
declaring the Registration Statement effective under the 1933 Act at [ENTER TIME
OF EFFECTIVENESS] on [ENTER DATE OF EFFECTIVENESS] and we have no knowledge,
after telephonic inquiry of a member of the SEC's staff, that any stop order
suspending its effectiveness has been issued or that any proceedings for that
purpose are pending before, or threatened by, the SEC and the Registrable
Securities are available for resale under the 1933 Act pursuant to the
Registration Statement.

                  This letter shall serve as our standing notice to you that the
Common Stock are, as of this date, freely transferable by the Holders pursuant
to the Registration Statement. Unless you receive separate notice or
instructions from us following the date hereof and preceding a request by a
Holder for a legend-free certificate or reissue thereof, you need not require
further letters from us to effect any future legend-free issuance or reissuance
of shares of Common Stock to the Holders as contemplated by the Company's
Irrevocable Transfer Agent Instructions dated February 27, 2004. This letter
shall serve as our standing opinion with regard to this matter.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                            Very truly yours,

                                            [ISSUER'S COUNSEL]
                                            By: ________________________________

CC: [LIST NAMES OF HOLDERS]

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT E

         1.       The Company is a corporation duly organized, validly existing
and in good standing under the laws of the state of its incorporation and has
the requisite corporate power to own, lease and operate its properties and to
conduct its business as presently conducted.

         2.       The Company has the requisite corporate power and authority to
execute, deliver and perform its obligations under the Transaction Documents and
to issue the Securities in accordance with the terms thereof. The execution and
delivery of the Transaction Documents by the Company and the consummation by it
of the transactions contemplated thereby (including, without limitation, the
issuance and sale of the Securities) have been duly authorized by all necessary
corporate action and no further consent or authorization of the Company, its
Board of Directors or shareholders is required. Each of the Transaction
Documents has been duly executed and delivered and, assuming due and effective
authorization, execution and delivery by the Buyers, each of the Transaction
Documents constitutes valid and binding obligations of the Company enforceable
against the Company in accordance with their respective terms, except as such
enforceability may be limited by applicable bankruptcy, insolvency, or similar
laws relating to, or affecting generally the enforcement of creditors' rights
and remedies or by other equitable principles of general application.

         3.       The execution, delivery and performance of the Transaction
Documents by the Company and the consummation by the Company of the transactions
contemplated thereby, including, without limitation, the issuance of the
Securities, does not and will not result in a violation of: (i) the Company's
Certificate of Incorporation or By-Laws, (ii) any other agreement, note, lease,
mortgage, deed or other instrument to which the Company is a party or by which
the Company is bound or affected that has been filed as an exhibit to the SEC
Documents or (iii) any applicable law, rule or regulation of the United States,
the Principal Market or the State of New Jersey.

         4.       Subject to the accuracy as to factual matters of the Buyers'
representations in Section 2 of the Securities Purchase Agreement, the offer,
issuance and sale of the Securities pursuant to Regulation D in accordance with
the Securities Purchase Agreement and the Additional Investment Rights, as
applicable, will be exempt from registration under the 1933 Act. When so issued,
and delivered to, and paid for by, the Buyers pursuant to the Securities
Purchase Agreement and the Additional Investment Rights, as applicable, the
Common Shares and the Additional Investment Right Shares will be duly authorized
and validly issued, fully paid and nonassessable, and free of any all liens and
charges and anti-dilutive, preemptive or similar rights contained in the
Company's Certificate of Incorporation or By-Laws or any agreement, note, lease,
mortgage deed or other instrument to which the Company is a party or by which
the Company is bound that has been filed as an exhibit to the SEC Documents. The
Additional Investment Right Shares have been duly and validly authorized and
reserved for issuance by all proper corporate action.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

         5.       Subject to the accuracy as to factual matters of the Buyers'
representations in Section 2 of the Securities Purchase Agreement, no consent or
authorization of, filing with, notice to or registration with, any federal or
state governmental body, regulatory agency, self-regulatory organization or
stock exchange or market is required to be obtained by the Company to enter into
and perform its obligations under the Transaction Documents, except for: (i) the
filing of a Form D pursuant to Regulation D under the 1933 Act, (ii) the filing,
if required, of any notice with any state whose laws require such filing, (iii)
the qualification of the Securities, if required, under other applicable state
laws, (iv) the listing of the Common Shares and the Additional Investment Right
Shares, as appropriate, on the Principal Market, and (v) the filing of a
Registration Statement with the SEC.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT F

                            DUSA PHARMACEUTICALS INC.

                             SECRETARY'S CERTIFICATE

The undersigned hereby certifies that she is the duly elected, qualified and
acting Secretary of DUSA Pharmaceuticals Inc., a New Jersey corporation (the
"COMPANY"), and that as such she is authorized to execute and deliver this
certificate in the name and on behalf of the Company and in connection with the
Securities Purchase Agreement, dated as of February 27, 2004, by and among the
Company and the investors listed on the Schedule of Buyers attached thereto (the
"SECURITIES PURCHASE AGREEMENT"), and further certifies in her official
capacity, in the name and on behalf of the Company, the items set forth below.
Capitalized terms used but not otherwise defined herein shall have the meaning
set forth in the Securities Purchase Agreement.

(i)                        Attached hereto as Exhibit A is a true, correct and
         complete copy of the resolutions duly adopted by the Board of Directors
         of the Company at a meeting of the Board of Directors held on February
         26, 2004. Such resolutions have not in any way been amended, modified,
         revoked or rescinded, have been in full force and effect since their
         adoption to and including the date hereof and are now in full force and
         effect.

(ii)                       Attached hereto as Exhibit B is a true, correct and
         complete copy of the Certificate of Incorporation of the Company,
         together with any and all amendments thereto, and no action has been
         taken to further amend, modify or repeal such Certificate of
         Incorporation, the same being in full force and effect in the attached
         form as of the date hereof.

(iii)                      Attached hereto as Exhibit C is a true, correct and
         complete copy of the Bylaws of the Company and any and all amendments
         thereto, and no action has been taken to further amend, modify or
         repeal such Bylaws, the same being in full force and effect in the
         attached form as of the date hereof.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

(iv)                       Each person listed below has been duly elected or
         appointed to the position(s) indicated opposite his name and is duly
         authorized to sign the Securities Purchase Agreement and each of the
         Transaction Documents on behalf of the Company, and the signature
         appearing opposite such person's name below is such person's genuine
         signature.

         NAME                   POSITION                         SIGNATURE

         D. Geoffrey Shulman    President and Chief Executive
                                Officer                          _______________

IN WITNESS WHEREOF, the undersigned has hereunto set her hand as of this 1st day
of March, 2004.

                                                        ________________________
                                                        Nanette W. Mantell
                                                        Secretary

I, Dr. D. Geoffrey Shulman, as President and Chief Executive Officer of the
Company, hereby certify that Nanette W. Mantell is the duly elected, qualified
and acting Secretary of the Company and that the signature set forth above is
her true signature.

                                          ______________________________________
                                          D. Geoffrey Shulman, President and CEO

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT A

                                   RESOLUTIONS

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT B

                          CERTIFICATE OF INCORPORATION

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT C

                                     BYLAWS

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                                                       EXHIBIT G

                            DUSA PHARMACEUTICALS INC.
                              OFFICER'S CERTIFICATE

                  The undersigned, as President and Chief Executive Officer of
DUSA Pharmaceuticals Inc., a New Jersey corporation (the "COMPANY"), pursuant to
Section 7(vii) of the Securities Purchase Agreement, dated as of February 27,
2004, by and among the Company and the investors identified on the Schedule of
Buyers attached thereto (the "SECURITIES PURCHASE AGREEMENT"), hereby
represents, warrants and certifies to the Buyers as follows (capitalized terms
used but not otherwise defined herein shall have the meaning set forth in the
Securities Purchase Agreement):

                  1.       The representations and warranties made by the
                           Company as set forth in Section 3 of the Securities
                           Purchase Agreement are true and correct as of the
                           date hereof (except for representations and
                           warranties that speak as of a specific date).

                  2.       The Company has, in all material respects, performed,
                           satisfied or complied with all covenants, agreements
                           and conditions required by the Securities Purchase
                           Agreement to be performed, satisfied or complied with
                           by it at or prior to the date hereof.

                  IN WITNESS WHEREOF, the undersigned has executed this
certificate this 1st day of March, 2004.

                                        ______________________________
                                        D. Geoffrey Shulman,
                                        President and Chief Executive Officer

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                  SCHEDULE 3(a)
                   SUBSIDIARIES OF DUSA PHARMACEUTICALS, INC.

1. DUSA Pharmaceuticals New York, Inc.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                  SCHEDULE 3(k)
                           ABSENCE OF CERTAIN CHANGES

1.       In a Current Report on Form 8-K, filed with the Securities and Exchange
         Commission on February 2, 2004, the Company reported that it had
         recently been served with a complaint filed on December 4, 2003, in the
         State of Michigan Circuit Court for the County of Oakland alleging that
         DUSA's BLU-U(R) caused the plaintiff to suffer a seizure during the
         performance of her duties as an office assistant. The complaint names
         Berlex Laboratories, Inc. as another defendant.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                  SCHEDULE 3(q)
                                 CAPITALIZATION

1.       On September 27, 2002, the Company adopted a shareholder rights plan
         (the "Rights Plan") at a special meeting of the Board of Directors. The
         Rights Plan provides for the distribution of one right as a dividend
         for each outstanding share of common stock of the Company to holders of
         record as of October 10, 2002. Each right entitles the registered
         holder to purchase one one-thousandths of a share of preferred stock at
         an exercise price of $37.00 per right. The rights will be exercisable
         subsequent to the date that a person or group either has acquired,
         obtained the right to acquire, or commences or discloses an intention
         to commence a tender offer to acquire, 15% or more of the Company's
         outstanding common stock (or 20% of the outstanding common stock in the
         case of a shareholder or group who beneficially held in excess of 15%
         at the record date), or if a person or group is declared an Adverse
         Person, as such term is defined in the Rights Plan.

         The rights may be redeemed by the Company at a redemption price of one
         one-hundredth of a cent per right until ten days following the date the
         person or group acquires, or discloses an intention to acquire, 15% or
         20% or more, as the case may be, of the Company, or until such later
         date as may be determined by the Board. Under the Rights Plan, if a
         person or group acquires the threshold amount of common stock, all
         holders of rights (other than the acquiring shareholder) may, upon
         payment of the purchase price then in effect, purchase shares of common
         stock having a value of twice the purchase price. In the event that the
         Company is involved in a merger or other similar transaction where it
         is not the surviving corporation, all holders of rights (other than the
         acquiring shareholder) shall be entitled, upon payment of the purchase
         price then in effect, to purchase common stock of the surviving
         corporation having a value of twice the purchase price. The rights will
         expire on October 10, 2012, unless previously redeemed. The Board has
         adopted certain amendments to the Company's Certificate of
         Incorporation consistent with the terms of the Rights Plan. The Rights
         Plan could discourage, delay or prevent a person or group from
         acquiring 15% or more (or 20% or more in the case of certain parties)
         of our common stock, thereby limiting, perhaps, the ability of our
         shareholders to benefit from such a transaction.

2.       The Company executed a consulting agreement, effective June 15, 2001,
         with Therapeutics, Inc. pursuant to which Company is obligated to pay
         to Therapeutics fifty thousand dollars ($50,000) or that number of
         shares equivalent to fifty thousand dollars ($50,000) as a private
         placement in June of each year.

3.       Financing schedules in connection with the Citizens Bank Loan (See
         Schedule 3(r)(i)).

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                SCHEDULE 3(r)(i)
                        INDEBTEDNESS AND OTHER CONTRACTS

1.       In May 2002, DUSA entered into a secured term loan promissory note
         ("Note") with Citizens Bank of Massachusetts to fund the construction
         of its manufacturing facility and borrowed $1,900,000. The Note
         currently bears interest at a 360-day LIBOR-based rate of 2.755%
         through June 30, 2004. Based on the terms of the Note, at June 30th of
         each year DUSA can either continue to choose a LIBOR-based rate at that
         time, execute a one-time conversion to a fixed rate loan, or repay the
         loan balance. Approximately $3,000,000 of the Company's United States
         government securities are pledged as collateral to secure the loan. The
         terms of the Note require monthly principal and interest payments
         through its maturity in June 2009, unless the Company repays the loan
         balance at the annual renew.

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                  SCHEDULE 3(s)
                                   LITIGATION

1.       On page 10 of the Company's Quarterly Report on Form 10-Q, filed with
         the Securities and Exchange Commission on November 13, 2003, the
         Company disclosed that it received notice on April 12, 2002, that one
         of the patents licensed to the Company by PARTEQ Research & Development
         Innovations, the technology transfer arm of Queen's University at
         Kingston, Ontario was challenged by PhotoCure ASA. PhotoCure ASA has
         filed a lawsuit in Australia alleging that Australian Patent No.
         624985, which is one of the patents relating to the Company's
         5-aminolevulinic acid technology, is invalid. As a consequence of this
         action, Queen's University has assigned the Australian patent to the
         Company so that DUSA may participate directly in this litigation. The
         Company has filed a response setting forth its defenses, in addition to
         a related countersuit alleging that certain activities of PhotoCure and
         its marketing partner, Galderma S.A., infringe the patent. The case is
         ongoing and the Company is unable to predict the outcome at this time.
         The Company believes that the final hearing in the Federal Court of
         Australia will occur in 2004.

2.       In a Current Report on Form 8-K, filed with the Securities and Exchange
         Commission on February 2, 2004, the Company reported that it had
         recently been served with a complaint filed on December 4, 2003, in the
         State of Michigan Circuit Court for the County of Oakland alleging that
         DUSA's BLU-U(R) caused the plaintiff to suffer a seizure during the
         performance of her duties as an office assistant. The complaint names
         Berlex Laboratories, Inc. as another defendant.

3.       [c.i.].

<PAGE>

[ c.i. ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

                                  SCHEDULE 3(w)
                              INTELLECTUAL PROPERTY

1. [c.i.].

2. Trademark Actions:

<TABLE>
<CAPTION>
COUNTRY            MARK                           STATUS
<S>               <C>               <C>
Argentina         Kerastick         PENDING - OPPOSITION - seeking to end
                                    opposition.

Mexico            Levulan           OPPOSITION - pending.
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]